Genomics for Good
Illumina Corporate Social Responsibility Report CY’22

Message from the CEO

Introduction

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
2

CY’22 CSR Report

This Is the
GenomeEra
TM

At Illumina, we are driven
by the power of genomics
to positively impact theworld and shape a moresustainable and equitable
future for all.
Our fourth annual Corporate Social
Responsibility Report documents theevolution of our environmental, social,and governance (ESG) program fromJanuary 1 through December 31, 2022.
This report reflects the progress wehave made and looks to the futurewith our continued commitment todeepen our impact on human health byserving as a champion for patients, ourcommunities, our people, and our planet.
Learn more in About this Report →TABLE OF CONTENTS

Message from Leadership

Integrate Sustainability

3 Message from the CEO

40 Strategic Approach and Impact

Introduction

41 Climate Action
43 Sustainable Facilities

6 2022 CSR Highlights

46 Sustainable Products

7 Recognition

48 Sustainable Value Chain

8 About Illumina

50 Leveraging Genomics

9 Business Overview

52 Impact in Action

CSR Strategy and GovernanceNurture Our People

11 Q&A with Our CFO and CPAO

54 Strategic Approach and Impact

12 CSR Strategy: Creating Unique Impact

55 Our People

14 2030 Targets

57 Practice Diversity, Equity, and Inclusion

15 CSR Governance

60 Invest in Our People

16 Stakeholder Engagement and Materiality

64 Create a Culture of Care

Accelerate Access to Genomics

66 Impact in Action

18 Strategic Approach and Impact

Operate Responsibly

19 Drive Innovation and Affordability

68 Strategic Approach and Impact

22 Catalyze Genomic Startups

69 Corporate Governance

23 Democratize Genomics

70 Compliance

24 Enable Catalytic Philanthropy

72 Ethics and Integrity

26 Genomic Data Diversity

75 Data Security and Privacy

27 Expand Reach of Genomics

77 Responsible Supply Chain

31 Impact in Action

81 Public Policy

Empower Our Communities

Appendix

33 Strategic Approach and Impact

83 About This Report

34 Community Investment

86 Key Performance Indicators

35 Employee Engagement

100 Indices (GRI, SASB, TCFD, SDGs)

36 Equitable Access to STEM Education

105 Assurance Statements

38 Impact in Action

106 Disclosures

Message from the CEO

Introduction

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
3

CY’22 CSR Report

Message from the CEO
2023 marks Illumina’s 25th anniversary. For morethan two decades, we have been committed to
improving human health by unlocking the power ofthe genome. Yet today, the need is more urgent thanever to help build a healthier, more sustainable world
where all people can thrive.
Genomics has the ability to improve global healthcare, sustainability, and equity through better
diagnosis and treatment; better representationin genomic data; greater access to personalized
medicine; and a deeper understanding of the world.
This is the genome era, and the last few years
have shown the promise that exists around us.
Genomics enables the world to act quickly andmitigate the spread of infectious diseases.
The world’s first mRNA vaccine roll-out ignited awildfire of genomic innovation and breakthroughsthat will improve human health beyond the pandemic.
There will always be new pathogens, but whatmatters is our ability to identify and control theirspread. Effective global surveillance, backed bycollaboration and adoption, can prevent the next
pathogenic outbreak from becoming anotherglobal pandemic.
Genomics is transforming personalized
medicine and saving lives. The science is being
applied to every step of cancer care and reducing
the diagnostic odyssey for those suffering from rare
genetic diseases. Revolutionary therapies are hitting
the clinic and reinventing how we fight an expanding
number of conditions.

Genomic data has become the blueprint foreverything from diagnostics to precision
therapeutics. Each day, researchers are learning
more about genetic variants that will help unravel
the world’s most devastating diseases and publichealth challenges. Yet, genomic data is glaringly
imbalanced — underrepresenting the diversity of
global populations. Together with our partners, we
aim to increase the diversity of genomic data andhelp every patient access groundbreaking therapies.
Genomics is being brought to bear against theclimate crisis. We are already using genomics tounderstand which seeds will be most productive
or most resilient to drought and disease. CRISPR
gene-editing technology is starting to bolster thenatural ability of plants and soil microbes to both
capture and store atmospheric carbon. Genomics
will be an essential tool to fight food insecurity for
millions of people around the world.

This is the genome era, and the last
few years have shown the promise thatexists around us. Yet, the need is moreurgent than ever to help build a healthier,more sustainable world where all people
can thrive.
Continues on next page →Francis deSouza
Chief Executive Officer

Message from the CEO

Introduction

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
4

CY’22 CSR Report

Message from the CEO
Guided by our mission, we are taking bold,meaningful steps through our business strategy
to accelerate access to genomics, empower ourcommunities, integrate environmental sustainability,
nurture our people, and operate responsibly.
Accelerate Access to Genomics

transformative change across the American science,technology, engineering, math, and medicine(STEMM) ecosystem, with the aim of removing
systemic barriers and elevating STEMM equity.
I personally signed an open letter pressing
state governments and education leaders tomake computer science a foundational part of
K-12 curriculum.

We are delivering breakthrough innovations that
redefine the possibilities in genomics and accelerate
impactful health advances globally. We reduced thecost of next-generation sequencing (NGS) by morethan 99%, further democratizing the technology andhelping patients, communities, and whole populations
access the benefits of genomics. We introduced
several new innovations, including the NovaSeqTM
X – our most powerful and sustainable sequencing
system yet. We extended our philanthropic iHope
model, partnering with the March of Dimes BirthDefects Foundation of China. We continued ourphilanthropic support for the Pathogen Genomics
Initiative (PGI), providing critical public healthcapabilities in Africa and Southeast Asia. And wepartnered on population genomics projects including
Precision Health Research to launch the SG100K
Project, aiming to map the DNA of 100,000 people
in Singapore.

We know improving human health is directly tied
to creating a healthier planet, both through our own
operations and the impactful work of our partners.
We are one of the first companies in the world andthe first genomics company to receive verificationof our 2050 net-zero emissions targets by the
Science Based Targets initiative Corporate Net-Zero
Standard. We integrated environmental design into
our newest sequencing platform, the NovaSeqTM X,
resulting in 90% less packaging, 50% less plastic,
and a 61% reduction in climate change impact.
We also awarded our annual Agricultural Greater
Good Initiative Grant to Brazil's SENAI Innovation
Institute for Biosynthetics, where they are exploring
the genetic potential for carbon sequestration,
environmental services, and food security.

Empower Our Communities

Nurture Our People

The future of genomics depends on the curiosity,
ingenuity, and passion of today’s STEM students.
This year, Illumina joined the STEMM Opportunity
Alliance (SOA) in collaboration with the White House
Office of Science and Technology Policy to drive

An extraordinary mission requires extraordinary
people and leaders at every level. Illumina employees
are the engine of innovation and key to powering
genomics for good. To foster an inclusive culture
where innovation and creativity thrive, we practice*Compared to Nova Seq 6000 and based on US list price, assuming 120 Gb/genome.

Integrate Sustainability

diversity and equity in all that we do. For the
fourth consecutive year, we achieved a zero net
pay gap. We have increased the percentage offemale executives for the third consecutive year,
and our US workforce includes 52 percent minority
representation. We filed a record 193 new patents
and we continue to have two times the numberof female inventors compared to the US nationalrate. We launched a new employee resourcegroup supporting employees affected by visible orinvisible disability and neurodiversity. And I signed
the Disability:IN CEO Letter on Disability Inclusion
urging my peers to advance equality and inclusion.
Operating Responsibly
Our role as a genomics pioneer brings with it the
responsibility to enable innovation for good, ensuring
the technology we create and the data we collectare used safely, ethically, and responsibly. We have
expanded the remit of the Nominating/Corporate
Governance Committee to assist the Board inoverseeing the company’s material ESG matters,
except as specifically delegated to another Board
committee. We also achieved ISO 27701 certification
for Illumina’s six cloud based products for privacy
information management.

Guided by our mission, we are taking
bold, meaningful steps through our businessstrategy to accelerate access to genomics,
empower our communities, integrate
environmental sustainability, nurture ourpeople, and operate responsibly.

The Future of Genomics Starts Now
For 25 years, we have shown the world thepromise of genomics and the power of collaboration.
Working with our customers, partners, and genomics
advocates around the globe, we know what is
possible. Now is the time to push the boundaries
and extend the benefits of genomics to all. Thatmeans ensuring genomics data reflects the diversityof a global population. It means bringing genomics
into the clinic and extending its applications.
As we look to the future, it means reaffirming ourcommitment to be the best employer, the best
environmental steward, and the best corporate
citizen we can possibly be.
Many thanks to our customers, partners, andemployees around the world for helping advanceour lifesaving work, giving back to our communities,
supporting one another, and bringing our mission
to life.

Francis deSouza
Chief Executive Officer

Introduction

Message from the CEO
CY’22 CSR Report

2022 CSR Highlights

Recognition

About Us

CSR Strategy & GovernanceBusiness Overview

Introduction

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix5

Introduction

Message from the CEO
CY’22 CSR Report

2022 CSR Highlights

Recognition

About Us

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
6

Business Overview

2022 CSR Highlights

Accelerate Access to Genomics

Empower Our Communities

Integrate Sustainability

Nurture Our People

Operate Responsibly

1.2 billion lives covered$17.7 million total donations

Maintained a zero net pay gap$11 million in-kind donations
to support Pathogen Genomics
Initiative

50% employee participation ingiving and volunteer programs

First genomics company to havenet zero targets verified by SBTi

100% Illumina core facilities
participated in third-party audit
programs

30,000+ medical education
learners reached
74 new genomic startups fundedsince inception$200 genome introduced with
NovaSeqTM X launch
Launched iHope China$1 billion and 22% revenue
R&D investment> 1.2 million STEM learners
reached since 2019
20,662 volunteer hours donated
1,747 causes supported
Community investment in
46 countries

100% of global electricity
consumption came fromrenewable sources
100% of our strategic supplierscommitted to minimize theirenvironmental footprint
61% climate impact reduction
with NovaSeqTM X compared to
NovaSeqTM 6000

52% minority representationin the US workforce
45% global female workforce
5% increase in female executive
leadership representation in the last
three years
86% employee engagement index
New disability ERGs launched
62 hours average training per
employee

18% diverse supplier spend
Achieved Privacy Information
Management ISO 27701
certification
Expanded remit of theNominating/Corporate
Governance Committee
to assist the Board inoverseeing ESG matters

Introduction

Message from the CEO
CY’22 CSR Report

2022 CSR Highlights

Recognition

About Us

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
7

Business Overview

Recognition 2022
Workplace• Glassdoor Best Place to Work
• BioSpace Best Place to Work• Refinitiv Top 100 Global D&I Index• Just Capital Top 100 US Companies
Supporting Healthy Communities & Families• Just Capital Workforce Equity & Mobility• Wall Street Journal Top 250

Regional• SANDAG Green Commute Award San Diego• AmCham Cares CSR Singapore• MIT Tech Review 50 Smartest Companies in China• Water Efficiency Building (WEB) Singapore• Best Employer Straits Times Singapore• Workplace Safety Award Singapore

Leadership• Most Responsible CEO | Francis deSouza• Top Chief Human Resource Officer | Aimee Hoyt
• Savoy Most Influential Black Exec | Kathryne Reeves• Forbes 50 over 50 | Susan Tousi

1 | 1 | 3

Introduction

Message from the CEO
CY’22 CSR Report

2022 CSR Highlights

Recognition

About Us

CSR Strategy & Governance

AccessCommunity

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
8

Business Overview

About Illumina
Our Mission

Our Purpose

To improve human healthby unlocking the power ofthe genome.

Drive the positive progressof genomics to make it
useful for all.
Our Values

Innovation isin our DNA

We are relentlessin the creation ofgreat products

We collaborate
deeplyWe move fastand embracechangeWe are open

Driven by our mission, we are committed to making our technology more
affordable, accessible, and sustainable, realizing health equity
for billions around the world.
Illumina is a global genomics and human health company powering the future of personalized
medicine and beyond.
Innovating at the intersection of technology, biology, and health, we are reimagining what is
possible for human health and the health of our planet.

What if One Thing Could Change
Everything for the Better?
That’sGenomics.
What causes a cancer
cell to mutate?

How do we diagnose arare genetic disease?

How do you identify anovel virus like COVID-19
and create a vaccine?

How do we safeguard
the world’s food supply?

What effect does
climate change haveon biodiversity?

The answer to these and thousands of life’s most pressing questions
can be found in the world of genomics.

We provide the sequencing innovations that enable researchers and clinicians to discover,detect, diagnose, and treat diseases—from cancer to COVID-19, from protecting our natural
capital to securing a sustainable food supply.

A P P L I CAT I O N S

Oncology

As an engine of genomics innovation, we are enabling tomorrow's discoveries.

Reproductive Health

Genetic Disease

Research/Applied Genomics

Infectious Disease

Drug Discovery

Multi-Omics

Introduction

Message from the CEO
CY’22 CSR Report

2022 CSR Highlights

Recognition

About Us

Community

AccessCSR Strategy & Governance

Sustainability

PeopleOperate Responsibly
Responsibly

Appendix
9

Business Overview

Business Overview
Illumina at a Glance

10,200employees$1B

R&D
investment$4.55B

2022 revenue

22%

revenue R&D
investment

Financial Performance

1998

9,178

founding year

patents worldwide

23,000+55

cumulative
sequencing
installed basecustomer Net
Promoter Score

9,500+
customers

1

155

countries receive
our products

1%

$3.3B

5-

YE

AR

CA

GR

$4.5B

Revenue Details$4.55B

$3.5B
$3.2B

71% Consumables
Library prep and proprietary
sequencing kits such as flow
cells and reagents for oursequencing and microarray
instruments

$2.4B

2016

2017

2018

12% Service and Other
Warranties and maintenance contracts
for systems and services undertaken
in our labs, revenue from intellectual
property fees, in vitro diagnostic licensing,milestones, and informatics

REVENUE$2.8B

Where We Operate$4.55B

2019

2020

2021

17% Instruments
Sequencing systems that span
the full range of applications aswell as a microarray instrument
to support genotyping

2022

Sequencers
LOW-THROUGHPUT

Americas
Baltimore, MD, US 4
Foster City, CA, US 3, 4, 6
Hayward, CA, US 2, 4
Madison, WI, US 2, 4, 6
San Diego, CA, US 1, 2, 3, 4, 5, 6
São Paulo, Brazil 4

EMEA
Berlin, Germany4
Cambridge, UK2,4, 5, 6
Eindhoven, Netherlands4, 5Evry, France4
Istanbul, Turkey4
Mechelen, Belgium4
Moscow, Russia4
Rennes, France4
Steenoven, Netherlands4, 5
Tel Aviv, Israel4
Dubai, UAE4

Scope of this report reflects core Illumina.

Asia Pacific
Melbourne, Australia4
Osaka, Japan4
Seoul, South Korea4
Singapore2, 4, 5, 6
Tokyo, Japan4

Greater China
Beijing, China4
Shanghai, China2, 4
Taipei, China4

MiSeqTM 100

MiniSeqTM

MID-THROUGHPUT

iSeqTM 100

NextSeq 550

NextSeq
1000/2000

NovaSeqXTM Series

DIAGNOSTIC

MiSeqTM Dx

Headquarters, 2Manufacturing, 3Clinical,
4
Commercial, 5Distribution Center, 6R&D
1

NextSeq 500

HIGH-THROUGHPUT

NextSeqTM 550Dx

NovaSeqTM 6000Dx

NovaSeqTM 6000

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAO

Introduction

CSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

CSR Strategy& Governance

AccessCSR GovernanceCommunity

Sustainability

Stakeholder Engagement and Materiality

PeopleOperate Responsibly

Appendix10

Introduction

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAOCSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

AccessCSR GovernanceCommunity

Sustainability

PeopleOperate Responsibly

Appendix
11

Stakeholder Engagement and Materiality

Q&A With Our CFO
and CPAO
Q: When the new public affairs function wasestablished at Illumina, the ESG function
shifted from the office of the Chief Financial
Officer to the office of the Chief Public Affairs
Officer. Can you both tell us about that move?
A: John When Illumina created a new Public Affairs
department, it was a natural fit to bring together theinternal teams of government affairs, corporate social
responsibility, privacy, ethics, and patient advocacy sothese groups could work together more closely and takeadvantage of natural synergies. Coming from Microsoft,where I most recently led the UN Affairs group, theintersection of government affairs, the UN Sustainable
Development Goals, and our ESG efforts were interwoven,and we saw similar opportunities here at Illumina.

A: Joydeep I agree with John’s points, and while the ESG
team moved from Finance to Public Affairs, our sharedfocus on our investors and risk management is stronger
than ever. Our functions work very closely together, andwe expect that to deepen as various mandatory regulatory
reporting requirements evolve. We see ESG as a key
strategic driver to delivering value to our shareholders andstakeholders as we accelerate the adoption of sequencing
in existing markets and enable the most impactful, newopportunities for genomics.

Joydeep, you were recently appointed Chief
Financial Officer, expanding your role as
Chief Business Strategy and Corporate
Development Officer. How does Illumina’s
environmental, social, and governance (ESG)
approach fit into the overall financial andbusiness strategy of the company?

A: Joydeep Furthering our ESG strategy advances ourbusiness strategy and reinforces our mission to improve
human health. Stewardship of our fiduciary responsibility
includes a strong emphasis on managing risk, driving
performance, and ensuring business integrity. We connect
our ESG approach to existing finance governance, including
accountability, risk analysis, internal monitoring, reportingtransparency, and data assurance.
As CFO, I am looking for ways to ensure we are protecting
the long-term value of the company, and that includes
both financial and non-financial inputs related to risk
and opportunities. ESG provides a lens to evaluate thoserisks and opportunities, incorporating the voices of all our
stakeholders.
Investing in our ESG initiatives can drive growth, create
innovation, and contribute to our long-term success.

What are some updates on the ESG/CSR
governance approach at Illumina?
A: John There is a consensus that directors on boardsof public companies should be taking a greater role inoverseeing ESG programs and disclosures; however,there remains variation in how boards have chosen to
approach their oversight. Previously, the Board’s oversightof Illumina’s ESG program and the various themes under
the ESG umbrella were captured under existing committee
work. Last year, we expanded the remit of the Nominating/Corporate Governance Committee to assist the Boardin overseeing the company’s ESG matters, except as
specifically delegated to another Board committee. The
Compensation Committee continues to oversee and provide
input to management on diversity and inclusion matters, and
the Audit Committee continues to oversee cybersecurity.

Joydeep Goswami
Chief Financial Officer,
Chief Strategy & Corporate
Development Officer
John Frank
Chief Public Affairs Officer

This new structure will increase the clarity and level ofoversight of how we are managing the opportunities andIn addition, our commitment to climate action isdemonstrated in our NovaSeqTM X launch last September.

risks of our material ESG issues and signifies the importanceof ESG on the success of our business.

NovaSeqTM X significantly reduces waste and environmental
impact, reflecting Illumina’s commitment to using ourtechnology to support the health of people and the planet.
NovaSeqTM X features a 90% reduction in packaging waste
and weight and 50% reduction in plastic usage comparedto NovaSeqTM 6000. The enablement of ambienttemperature shipping of reagents will result in nearly 500
tons of dry ice savings per year, while significantly reducing
waste streams for our customers.

Given the importance of climate risk to theinvestment community and key stakeholders,
how is Illumina signaling to thesestakeholders your plans for climate action?
A: Joydeep As a science-based company, we wanted
to ground our environmental targets in a science-based
framework. We created a climate transition plan that istime-bound, with quantitative targets based on the best
climate science recommendations available and aligned
to the science-based target initiative (SBTi). We received
external validation from SBTi of our climate transition
plan, including our emission reduction targets and net
zero commitments, demonstrating to stakeholders ourcommitment to mitigate our climate impact and provide a
credible and accountable set of targets to help guide ourcompany toward a 1.5℃ climate scenario.

What do you see as the future for ESG/CSR
at Illumina?
A: John By engaging and empowering all our stakeholders,
including customers, business partners, employees, andcommunities, we will continue to build resilience, create
long-term value and support the science that advances
public health and the health of our planet.

Introduction

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAOCSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

AccessCSR GovernanceCommunity

Sustainability

PeopleOperate Responsibly

12

Stakeholder Engagement and Materiality

Connecting Our
CSR Strategy to
Our BusinessWith our mission to
improve human healthby unlocking the powerof the genome, we arecommitted to making
our products more
affordable, accessible,
and sustainable, realizing
health equity for billions
around the world.
As a purpose-driven company, wedeliver sustainable, long-term value
and impact by embedding our CSR
strategy in the business.
Our CSR strategy has been influenced
by materiality assessments andongoing stakeholder engagement. It
promotes the sustainable stewardshipof our business by managing ESG
risks, capitalizing on opportunities,
driving performance, and ensuringbusiness integrity.

r
r Ou
e
pow unities
m
E
mm
Co

o
st s
s
ce micc
A noe
G

Integrate
Sustainability

CS R V I S I O N

Nurtur
Peo e Ou
ple ruman health by serving
as a
ct on h
a
p
cha
o
,
u
r im
s
r
e
p
ti
i
e
n
o
u
u
p
mp
l
m
e
o
, and
com
n
r
io
e
u
o
o
u
p
,
r
e
s
p
t
lane n
n
e
De
i
t
t.
pa
for

PUR POSE

the positive progress of
Drive
s to make it useful for
omic
all.
gen

MISSION

Improve human health byunlocking the power of thehuman genome.

AppendixO
Re pe
sp rat
on e
si
bl
y

Introduction

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAOCSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

AccessCSR GovernanceCommunity

Sustainability

PeopleOperate Responsibly

Appendix
13

Stakeholder Engagement and Materiality

Creating Unique Impact
We prioritize action
on our most material
environmental, social,and governance (ESG)
issues, supported byrobust governance,transparency, andaccountability.
In this report we outline ourmanagement approach,targets, connection to the UN
Sustainable Development Goals,
and performance for each of ourmaterial ESG issues.
Through managing the risks andopportunities related to eachmaterial ESG issue, we executeon our purpose and deliver thegreatest positive impact to ourbusiness, our stakeholders, andthe planet.

Accelerate Accessto Genomics

Empower Our
Communities

Integrate
Sustainability

NurtureOur People

OperateResponsibly

We are committed to accelerating
access to genomics to realize
health equity for billions of people
around the world. We are driven
by our conviction that genomics
should be available to the many,
not the few.

We are committed to giving back,creating shared value throughour business, and seeking
opportunities to enable a more
equitable and sustainable future
for all.

We are committed to integrating
environmental stewardship into
the fabric of how we operate.
Human health and the health of
our environment are intertwined
and connected to creating ahealthy, sustainable future for all.

We are committed to engaging
extraordinary talent and helping
them thrive. By focusing on
diversity, equity, and inclusion,
investing in our people, andenabling a culture of care,
we magnify the value of thatcollaboration and build community.
Together our impact is amplified,and our potential is unlimited.

We are committed to conducting
ourselves with honesty, integrity,
and respect for all. As genomic
pioneers, we are enabling
innovation for good, ensuring thatthe technology we create and thedata we collect are used safely,
ethically, and responsibly.

UN SDGUN SDGUN SDGUN SDGUN SDG

Material Topics

Material Topics

Material Topics

Material Topics

Material Topics

Innovation →Community Investment →Climate Action →Diversity, Equity, and Inclusion →Data Privacy and Security →Pricing and Affordability →STEM Education →Sustainable Facilities →Human Capital Management →Corporate Governance →Sustainable Products →Employee Health, Safety, and Wellness →Ethics and Transparency →Democratize Genomics →Sustainable Supply Chain →In this report, we use the terms “material” and “materiality” to refer to topics that reflect Illumina’s meaningful environmental, social, and governance impact. The use of such terms shall not be deemed to constitute an admission as
to the materiality of any information in this report for purposes of applicable securities laws or any other laws of the United States, nor are we using them as they are used in the context of financial statements and financial reporting.

Product Safety and Quality →Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAO

Introduction

CSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

Community

AccessCSR Governance

Sustainability

PeopleOperate Responsibly

Appendix
14

Stakeholder Engagement and Materiality

Our 2030 Targets
Our Focus Areas

Objectives

Accelerate
Access to
Genomics

1. Drive innovation and affordability
2. C atalyze genomic startups to broaden the genomic ecosystem
3. Increase genomic data diversity
4. D emocratize genomics
5. Enable catalytic philanthropy
6. E
 xpand reach with payer coverage, genomic literacy,
and patient advocacy

Enable $100 genome
Support 50,000 patients through philanthropic iHope programming
Achieve 2 billion covered lives by 2026
Invest in 200+ genomic startups
Activate Pathogen Genomics Initiative donations enabling our$60 million commitments
Reach at least 25,000 medical education learners annually

Empower Our
Communities

1. P rovide meaningful and strategic community investment
2. E
 ngage our people to be agents of social change
3. D rive equitable access to STEM education

Reach 5 million STEM learners
Donate 100,000+ volunteer hours
Achieve 50% employee participation in giving and volunteering

Integrate
Sustainability

1. D rive climate action
2. Operate sustainable facilities
3. F oster a sustainable value chain
4. D evelop sustainable products
5. L everage genomics for a healthier planet

Deliver net zero emissions(Scope 1,2,3) by 2050
Reduce emissions by 46%(Scope 1,2)
Reduce emissions by 46%(Scope 3)
Achieve 100% renewableelectricity
Reach 90% landfill diversion
at core sites

1. P ractice diversity, equity, and inclusion
2. Invest in our people
3. C reate a culture of care

Increase gender representation in global leadership
Maintain zero net pay gap
Increase minority representation in executive leadership (US)Increase representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more in US workforce and leadership
Reduce recordable injury and illness rate

1. P
 ractice strong corporate governance
2. M aintain a culture of compliance
3. A ct with integrity in all that we do
4. F oster a responsible supply chain
5. Uphold high standards for data security and privacy
6. Participate in proactive public policy

Ensure 100% strategic suppliers committed to reducing theirenvironmental footprint
Achieve 20% spend with diverse suppliers (US)Achieve top industry ESG ratings

NurtureOur People

OperateResponsibly

2030 Targets

Achieved

Reach 10% reduction inwater intensity at core sites
Reduce packaging
by 75%
Invest $20 million inphilanthropic sustainability
initiatives
Have 100% of strategic
suppliers commit to minimizing
their environmental footprint

In Progress

UN SDG Target Alignment

Target 3.d: Improve early warning
systems for global health risks

Target 17.7: Promote sustainable
technologies to developing countries

Target 17.6: Knowledge sharing andcooperation for access to science,technology, and innovation

Target 17.16: Enhance the global
partnership for sustainable
development

Target 10.3: Ensure equal
opportunities and end discrimination

Target 5.b: Promote empowerment of
women through technology

Target 12.2: Sustainable
management and use ofnatural resources

Target 13.2: Integrate climatechange measures into policy
and planning

Target 12.5: Substantially reduce
waste generation

Target 10.3: Ensure equal opportunities and end discrimination

Target 9.2: Promote inclusive andsustainable industrialization
Target 10.3: Ensure equal
opportunities and end discrimination

Target 17.16: Enhance the global
partnership for sustainable
development

Introduction

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAOCSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

AccessCSR GovernanceCommunity

Sustainability

PeopleOperate Responsibly

Appendix
15

Stakeholder Engagement and Materiality

CSR Governance
CSR is integral to how we do business. Our
governance structure facilitates accountability,transparency, and continuous improvement.

CSR / ESG Executive Steering Committee• Comprised of senior leaders from across the organization and chairedby the Chief Public Affairs Officer, the ESG Executive Steering
Committee provides guidance on ESG strategic plans and practices,
approves major ESG programs, and monitors progress toward targets.

Board of Directors
We govern CSR at the highest level with oversight from the full Board of Directors (Board)
with support from the Nominating / Corporate Governance Committee.
• This strong leadership supports the
management of material environmental,social, and governance issues, including
climate action, diversity, equity, andinclusion, human rights, cybersecurity, andethical, responsible business practices• The full Board provides oversight andreceives updates on current performanceand future strategic plans at least annuallyor more frequently if material changes
occur• The Compensation Committee continues tooversee and provide input to management
on diversity and inclusion matters, and
the Audit Committee continues to oversee
cybersecurity• Select ESG targets are included in annual
corporate goals and influence executive
compensation through the management
performance scorecard. The compensationcommittee continues to oversee allcompensation matters• Members include Chief Medical Officer, General Counsel, Chief ofGlobal Operations, Chief People Officer, Chief Technology Officer,
Chief Marketing Officer, and Global Head of CSR/ESG.

Board ofDirectors
Nom/Gov
Board Committee
CEO & Executive Leadership
CSR / ESG Executive
Steering Committee

In addition to the full Board oversight, we have now expanded the remit of
the Nominating/Corporate Governance Committee to assist the Board inoverseeing the company’s material environmental, social, and governancematters (ESG), except as specifically delegated to another Board committee.

Learn more about our Board governance, member tenure,
independence, and diversity in Operate Responsibly →Giving Governance• The Illumina Corporate Citizenship Steering Committee has
oversight on philanthropic contributions from Illumina. Membership iscomprised of the CEO, CFO, General Counsel, Chief Medical Officer,
Chief People Officer, and VP of Treasury.
• The Illumina Corporate Foundation Board governs the philanthropy
associated with the Illumina Corporate Foundation, a separate entityand private foundation. The foundation board is comprised of Illumina
senior leaders including the CEO, CFO, General Counsel, Chief
Medical Officer, Chief People Officer, and VP Treasury.

Philanthropy Governing Board
CSR Functional GroupInternal Support Groups
Executive Diversity Council • EHS Steering Committee
Quality Council • Public Policy Committee • Sustainable Product Core Team
Supply Chain Sustainability and Responsibility Working Group
Supplier Diversity Governance Committee • Privacy Steering Committee

External Ethics Advisory Board
Employee Engagement Groups
Sustainability Green Teams • Illumina Cares Volunteer Champions • Employee Resource Groups

The CSR Functional Group is responsible for strategy development,
program implementation, and ESG reporting.

Our cross-functional working group teams engage to operationalize
and integrate CSR in each of their respective programs.

Our External Ethics Advisory Board provides guidance on a rangeof strategic issues, including recommendations on emerging ethics
matters, policies, and regulations that are relevant to the genomics
industry. Learn more in Operate Responsibly →We offer employees the ability to directly participate in our CSR
program through a variety of grassroots efforts. These teams provide
a wealth of ideas and support for activation at local levels all aimed
to link our CSR efforts back to our mission.

Introduction

Message from the CEO
CY’22 CSR Report

Q&A with Our CFO and CPAOCSR Strategy & Governance

CSR Strategy: Create Unique Impact

2030 Targets

AccessCSR GovernanceCommunity

PeopleSustainability

Operate Responsibly

Appendix
16

Stakeholder Engagement and Materiality

Stakeholder Engagement and Materiality
Our CSR strategy is continuously informed by engaging our stakeholders around our most material ESG issues.
Engaging Our Stakeholders
We are committed to operating with transparency and open communication to develop trusted relationships with all our stakeholders. We routinely
gather feedback on environmental, social, and governance (ESG) topics from our stakeholders and work to create an open dialogue. As part of ourongoing engagement, we have used a variety of ways to gather feedback and evolve our program, including customer surveys, employee surveys,
industry trade group participation, guidance from relevant frameworks, and external benchmarking.
Investors

Employees• ESG Investor Event – We convened our second annual ESG investor
event to share progress and field questions• Employee pulse surveys are sent out at least bi-annually
Learn more in People →• Investor Day – We hosted Investor Day for presentations by membersof Illumina’s executive team and a live Q&A session

Community Partners

Customers• Our Customer Experience team regularly surveys customers tounderstand how we can improve. We conduct biannual relationshipsurveys, leverage machine learning tools, and provide an open channel
for customer feedback from our field employees. These types of inputs
even helped inform our design for environment approach.
Learn more in Sustainability →EMPLOYEESCUSTOMERSSUPPLIERSINVESTORSDISTRIBUTORSWe engagewith a wide
range ofstakeholders.

NONPROFITS• Community investment grant recipients complete an impact reportfollowing completion of projects to help guide future opportunities
and provide feedback Learn more in Community →CHANNELPARTNERSCSR PEER GROUPSCOMMUNITY PARTNERS

Governments and Regulatory• Illumina connects with governments and organizations around theworld to engage and educate policymakers and key stakeholders
on issues that impact our mission and business

INDUSTRY LEADERSHEALTH CARE PROVIDERS

GOVERNMENTS & REGUL ATORY

Patients• We continue to advocate for the best clinical care for patients
across the globe, actively engaging with medical organizations andgovernments to ensure that the genetic disease community has not
only hope but also a voice
Reporting Frameworks and External Benchmarking

Materiality Assessment• Our materiality assessment guides our
CSR strategy by identifying the material1
issues that matter most to our businessand our stakeholders, and where weare uniquely positioned to create thegreatest positive impact• In 2021, we refreshed our 2018 baselinemateriality assessment. The updated
materiality assessment further
refined and validated our priorities
and focus areas
Learn more about our CSR Strategy →Our Most Material ESG Issues
Environment

SocialGovernance

Climate Action

Democratize Genomics

Innovation

Sustainable Facilities

Community Investment and Philanthropy

Pricing and Affordability

Sustainable Products

STEM Education

Data Privacy and Security

Sustainable Supply Chain

Diversity, Equity, and Inclusion

Corporate Governance

Human Capital Management

Ethics and Transparency

Employee Health, Safety, and Wellness

Product Safety and Quality

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Accelerate Accessto Genomics

Sustainability
Data Diversity

Reach

PeopleImpact in Action

Operate Responsibly

Appendix17

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction

CSR Strategy & Governance

Innovation and Affordability

Genomic Ecosystem

Access

Democratization

Strategic Approachand Impact
We are committed to accelerating access to genomics to realize
health equity for billions of people around the world. We are driven
by our conviction that genomics should be available to the many,
not the few.
Realizing the potential of the genome to exponentially improve the humancondition requires continued innovation and the democratization of genomics.
K E Y O B J ECT I V ES

1 Drive innovation and affordability
2 Catalyze genomic startups to broaden the genomic ecosystem
3 Democratize genomics
4 Increase genomic data diversity
5 Enable catalytic philanthropy
6 Expand reach with payer coverage, genomic literacy, and patient advocacy

UN SDGs

To successfully fulfill our mission to improve
human health, we must expand access to genomic
technology in medical care to improve outcomes,
regardless of social status, income, or geographic
location. We must continue to bridge the gaps toensure the individuals receiving genomic analysis
represents our global diversity.
Phil Febbo, MD
Chief Medical Officer

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Appendix
18

Impact in Action

2030 Target

2022 Progress

Achieve$100 genome$2001

Support 50,000 patients
through philanthropic iHope
programming

1,704
74

Invest in more than
200 genomic startups

Activate Pathogen Genomics
Initiative donations enabling
our $60 million commitments
by 2027$11M

Achieve 2 billion
covered lives by 2026

1.2B

Reach at least 25,000 medical
education learners annually> 30,000

2022 Highlights
Breakthrough NovaSeq™ X
series announced

22% revenue invested
in R&D

193 new patentapplications in 2022

9,178 total patents
issued worldwide~$200, based on US list price, assuming
120 Gb/genome; compared to NovaSeqTM 6000.
1

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Democratization

Drive Innovation
and Affordability

We have proven through focused and continuous innovation that
unlocking the power of the genome can exponentially improve
the human condition. As an engine of genomics innovation, we
understand that the larger we grow our network of partners, themore lives that can be impacted.
There is an urgency to our mission because we understand that today’s discoveries have the potential
to help tomorrow’s patients and address some of the world’s most pressing challenges. Everytechnological breakthrough that reduces cost, improves throughput, decreases turnaround time, or
improves ease of use helps us realize our potential, improving more lives and protecting our planet.

To drive innovation andaffordability we endeavor to:
Lower the cost of sequencing
and enhance the value beyond
cost per genome

Deliver breakthroughtechnology and workflows

Invest in strategic acquisitions
and collaborations

Catalyze genomic
startups

2030 TARGET

2022 PROGRESS

$100

$200

genomewith announcement oflaunch of NovaSeqTM X

AccessCommunity

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

Lower the Cost of Sequencing
and Enhance the Value Beyond
Cost Per Genome
Since 2001, the cost of DNA sequencing has
dropped more than 100,000x from $100 million
USD per human genome to ~ $2001 USD
with the NovaSeqTM X sequencers, putting
our dream of a $100 genome within reach.
Innovations are enhancing the value beyond
cost per genome and delivering the mostcomprehensive genomic view.
2001

$100M

2010

$10,000
HiSeqTM 2000

2014

$1000
HiSeqTM X

2020

$600
NovaSeqTM 6000 v 1.5
Reagent Kit

2022

$200
NovaSeqTM X

2030$100 genome

1~$200 / genome based on US list price,assuming 120 Gb/genome; compared to NovaSeqTM 6000.

PeopleImpact in Action

Operate Responsibly

Appendix
19

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

CSR Strategy & Governance

Innovation and Affordability

Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Appendix20

Impact in Action

Breakthrough Technology and Workflows
Innovating at the intersection of technology, biology, and health, Illumina is reimagining what is
possible for clinicians, transforming how they detect, diagnose, and treat cancer as well as otherrare, infectious, and genetic diseases. We aim to inspire our customers to dream big.

Illumina Complete Long Read
Technology

Our 2022 Product Innovations
TM

The NovaSeq X Series
At the end of 2022, we introduced the NovaSeqTM
X series, our most powerful and sustainable highthroughput next-generation sequencers. Breakthroughinnovations with new XLEAP-SBSTM chemistry deliver
revolutionary throughput, scale, sustainability, andaccuracy with transformative economics.
Learn more about the sustainability attributes
in Sustainability ->To address the small portion of the
genome that has historically beenchallenging to map due to highly
repetitive or highly homologous regionsof the genome, we developed a novel,
high-performance longread assay that
accelerates access to the remaining~5% of genic regions, creating our mostcomprehensive genomic view yet.

NovaSeqTM 6000 Dx
N OVA S E Q T M X S E R I E S H I G H L I G H T S
Throughput,
Accuracy, Efficiency

Economics

User Experience

Sustainability

2.5x higher output

60% reduction in cost/Gb*

Ergonomic innovations

90% reduction inpackaging weight
and waste

2x faster~$200 genome

Individually addressable flow celllanes are done onboard the system
automatically and automatedlossless data compression

50% reduction ofplastic mass

Reduced unpacking time andmaximized storage space withcompact cartridges and packaging

61% reduction inclimate change
impact(based on US list price,assuming 120 Gb/genome)

Up to 3x greater accuracy
with the XLEAP-SBS
chemistry

Lower disposal cost with morerecyclable plastics, no dry ice,no ice packs*~$200 (based on US list price, assuming 120 Gb/genome; compared to NovaSeqTM 6000.

The first FDA-registered and CE-marked
in vitro diagnostic (IVD) high-throughput
sequencer, delivering the highest
standards of compliance and driving
actionable insights for patient care.
This technology expands the breadthof applications and clinical testing incountries that require IVD products,
increasing access to clinical genomics
with scalable throughput while achieving
significant reductions in cost/Gb and total
cost of ownership. NovaSeqTM 6000 Dx isan open platform with Research Use Only
(RUO) and IVD modes and a dedicated
DRAGEN™ server, resulting in flexible,
high-quality, automated data processingthat will minimize the time and labor
required to complete projects.

99.87% accuracy score asmeasured by Precision FDA
Challenge v2
90% less DNA input than current
long read technology
Simple workflow with automatablesingle-day library preparation

First FDA-registered
and CE-marked
IVD high-throughput
sequencer

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Appendix21

Impact in Action

Invest in Strategic Acquisitions and Collaborations
At Illumina, we are not just at the forefront of a global genomics
movement, we are at the center of a transformation in global health.
The last few years have shown the world the promise of genomics andthe power of collaboration. Together we can achieve more. Enabling
innovation and driving affordability goes beyond delivering sequencers
and data. It includes delivering insights and accelerating the paradigm
shift toward genomic sequencing as a standard of care to improve
patient outcomes and drive down overall health care costs.

In addition to our internal innovation engine, we
leverage strategic acquisitions and collaborations tofurther support our mission, drive affordability, andaccelerate access to genomics for all so that thepotential of personalized medicine can be realized.
Joydeep Goswami
Chief Financial Officer, Chief Strategy& Corporate Development Officer

Illumina Launches a Research Test Co-developed with Merck to
Unlock Deeper Insights into the Tumor Genome
The research test builds upon Illumina’s commitment to broadly enable
comprehensive genomic profiling and enhance research critical torealizing precision medicine in oncology. Learn more
Illumina Launches Strategic Research Collaboration with
AstraZeneca to Accelerate Drug Target Discovery
The research collaboration aims to utilize artificial intelligence (AI)based genome interpretation and genomic analysis techniques alongwith industry expertise. Learn more
Illumina and GenoScreen Partner to Expand Access to Genomic
Testing for Multidrug-Resistant TBThis alliance will help advance the World Health Organization’s strategy
to end the global tuberculosis (TB) epidemic by 2035. It will also enableglobal access to a package combining Illumina sequencing products andthe GenoScreen Deeplex® Myc-TB assay, a targeted next-generation
sequencing (NGS) based test for rapid and extensive detection of antiTB drug resistance, to promptly inform treatment decision. Learn more
Illumina Acquires GRAIL, a Previous Spin-Off of Illumina, to Improve
Early Detection of Cancers (2021)
GRAIL is focused on lifesaving early detection of multiple cancers—all
through a simple blood test in a doctor’s office. GRAIL’s Galleri® blood
test can detect more than 50 types of cancer in asymptomatic patients.
Our acquisition of GRAIL will accelerate access and adoption of this lifesaving test worldwide.1
Illumina Acquires IDByDNA
This company is developing metagenomic technology for infectious
disease testing and pathogen surveillance. After an alliance for the past
two years, the acquisition brings in-house a respiratory pathogen panel
enrichment kit that identifies more than 280 pathogens, including SARSCoV-2, and more than 1,200 antimicrobial resistance alleles. It runs on
Illumina’s NextSeq 550 sequencing system and utilizes IDbyDNA’s Explify
analysis software.

Additional 2022 Acquisitions, Partnerships, and Collaborations• Illumina Enters Co-Development
Partnership with Somalogic• Illumina Collaborates with
National Cancer Center Japan• Boerhringer Ingelheim
Companion Diagnostic
Partnership• Illumina Partners with Centers
Across France to Advance
Precision Medicine Approach forPatients with Late-Stage Cancer• Illumina Partners with Agendia
to Expand Genomic Testing in
Breast Cancer• Illumina and Nashville
Biosciences Announce
Sequencing Agreement withAmgen

• Illumina and Deerfield
Management Partner to
Accelerate Drug Development• Illumina and GenoScreen
Partner to Expand Access to
Genomic Testing for MultidrugResistant Tuberculosis

Illumina Ventures
We further support the genomics startup community
through Illumina Ventures, an independently
managed firm founded in 2016. It is focused on
assisting startups that are pioneering genomic
applications and enabling precision medicine. We
provide funding and strategic counsel, as well as
access to the wealth of experience and expertiseof the world’s leading genomics solutions provider.
Learn more about Illumina Ventures.

Illumina Invested in Time Boost Capital I LP,a £30 million (US $36.8 million) genomics venture
fund from cornerstone investor LifeArc, other US andEuropean investors, Illumina, and Illumina Ventures.
The fund provides match funding to startups
graduating from Illumina Accelerator Cambridge withthe aim to advance breakthroughs in human health.

GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited the Illumina/GRAIL
transaction on 6 September 2022 under the EU Merger Regulation.
1

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Catalyze
Genomic Startups

Genomics startups are playing an increasingly important roleinternationally in the expansion of the genomic ecosystem. Illumina aims
to catalyze this growth by supporting Illumina for Startups and Illumina
Ventures. The dramatic innovations emerging are helping to drive down
costs and unlock new areas of biology and market use.

$1.1B

VC funding
secured47%
femalefounders

5

globallocations

93%

startups raised
additional capital

Operate Responsibly

22

Impact in Action

Illumina Accelerator,
Cambridge, UK

Illumina Accelerator,
San Francisco, US

Our Startup Engines

Illumina for Startups,
Singapore

Illumina for Startups,
Melbourne, Australia

SCOPE OF PROGRAMSNovel drug discoveries
to treat patients

Important agriculture andfood innovations to feed
more with less

Software and tools tofurther enable new insights

Impactful diagnostics todetect and prevent disease

New synthetic biology
approaches for a moresustainable future

Consumer-driven
applications to help us
better understand ourselves

Startup Spotlights
Broken String Biosciences

2030 TARGET

2022 PROGRESS

200+

74

genomics startups
supported

startups launched sinceprogram inception

Appendix

Sequoia Capital China Intelligent
Healthcare Genomics Incubator,
Powered by Illumina, Shanghai, China

Illumina for Startups
Illumina for Startups is focused on creating an innovation ecosystem for the
genomics industry by partnering with leading venture capital investors andentrepreneurs to create, launch, and grow genomics startups. Illumina for Startups
initiatives include Illumina Accelerator, founded in 2014, and Sequoia Capital ChinaIntelligent Healthcare Genomics Incubator, Powered by Illumina, founded in 2021.

Reach

PeopleThe llumina Accelerator
experience completelytransformed the way wethought about the future
development of ourgenomics startup.
Felix Dobbs, Ph.D.
Co-Founder & CEO, Broken
String Biosciences

Rethink Bio Private Limited,a synthetic biology
company from India, isfocused on harnessing thepotential of microalgae todevelop sustainable foodsolutions to benefit theplanet and people.

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

Democratize
Genomics
We are driven by our conviction thatgenomics should be available to the many,
not the few.
Realizing the potential of the genome requires
education, advocacy, access, and global datathat is representative of the diversity of ourpopulations.
Democratizing genomics and genomic sequencing
can enable families, communities, and whole
populations to harness the benefits of nextgeneration sequencing (NGS).

We are proud to support projects that:
Enable catalytic
philanthropy

Increase genomic data
diversity

Expand the reach of genomics with payer coverage,
genomic literacy, and patient advocacy

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleImpact in Action

Operate Responsibly

Appendix23

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

CSR Strategy & Governance

Innovation and Affordability

Genomic Ecosystem

Community

Access

Democratization

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Appendix

Impact in Action

Enable Catalytic Philanthropy
Bringing iHope™ to More Families

iHope Genetic HealthiHope China with March of Dimes

The Illumina iHope program will change the trajectory of genomic medicine worldwide,
helping patients who may have otherwise been invisible to diagnostic and preventative
service providers.

In 2021, we announced an expansion of theiHope program with the launch of the iHope
Genetic Health program under the auspices of
the nonprofit Genetic Alliance. The expanded
program is designed to provide cWGS to tensof thousands of underserved families acrossthe globe with at least half outside the US
and at least one third dedicated to patientsin Africa. In 2022, critical infrastructure andpartnerships were put in place. Learn more
about iHope Genetic Health.

Building upon the iHope model, in 2022 weannounced the launch of our iHope China, bringing
whole-genome sequencing to those in need with ourpartner, the March of Dimes Birth Defects Foundationof China. iHope China aims to provide free genetic
disease testing funding for 2,000+ families of raredisease patients across the country in the next three
years. Additionally, the program will provide genetic
disease identification and diagnosis training courses
for 100+ front-line clinicians in 20 hospitals andcontinue to empower the construction of genetic
disease specialty in China.

Families of children with undiagnosed
genetic diseases often face an uncertain andunpredictable future. Their diagnostic journeys
may take up to seven years in developed
countries, while in low- and middle-income(LMI) geographies, many families never know
the cause of their child’s suffering.
iHope is a philanthropic effort that provides
clinical whole-genome sequencing (cWGS)
to underserved families around the globe.
It was created in 2017, bringing together awide range of organizations aiming to shorten
the diagnostic journey and inspire hope.

Demonstrating the impact of the program
regardless of location, nearly 60% of the cases
received in 2022 came from seven iHope
program sites in LMI countries (Ghana, DR
Congo, Peru, and Mexico). Patients from iHope
sites in LMI countries who received a moleculardiagnosis had comparable rates of change
management to patients from high-income
countries. We are excited about the growth andexpansion that will bring iHope to more families
in the future. Learn more about iHope.

iHope Impact

1,704

40%

70%

28

3

patients impacted
since inception

patients receive
diagnosis aftercWGSchangemanagement
after cWGS1

iHope clinicalsites worldwide

new clinical sites
in Zimbabwe,
N. Macedonia,
and Singapore

2030 TARGET

2022 PROGRESS

50,000+

1,704

patients supported throughiHope programming

No child with a genetic
disease should suffer
unnecessarily. iHope points
to a future where every
patient receives a diagnosis
and true precision care.
Ryan Taft
VP, Scientific ResearchiHope™ Leadpatients supported
Derived from >1000 cohort 22.

1

24

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

PeopleSustainability
Data Diversity

Reach

Operate Responsibly

25

Impact in Action

Boost Pathogen Genomics Surveillance in Low- and Middle-Income Countries
Building pathogen genomics capabilities globallyprotects the health of everyone since a public healththreat in one location can quickly become a threat
everywhere. The UN Sustainable Development Goal
(SDG) 3 includes targets related to improving early
warning systems for global health risks. In addition,
SDG 17 promotes knowledge sharing and cooperation
for access to science, technology, and innovation.
We are proud to be part of the Pathogen Genomics
Initiative (PGI), a multi-sector collaboration with global
funders, industry, NGOs, and public health agencies.
In October of 2020, the Africa Pathogen Genomics
Initiative was launched with the aim to enhancedisease surveillance and public health throughintegrated, cross-continent laboratory networks
equipped with the tools, human resource capacityand data infrastructure to fully leverage criticalgenomic-sequencing technologies. The vision was tointegrate pathogen genomics and bioinformatics into
routine public health surveillance systems, outbreak
investigations, timely response to infectious disease
threats, responsible data sharing, and improved
disease control and prevention.
The partnership is designed to expand access tonext-generation genomic sequencing (NGS) tools andexpertise to strengthen public health surveillance andlaboratory networks across low- and middle-income
countries for COVID-19 and other epidemic threats
and endemic diseases such as AIDS, tuberculosis,
malaria, and cholera. Pathogen sequencing will also
contribute to research and development efforts for
new vaccines, diagnostics, and treatments for current
and emerging infectious diseases.
In 2019, only seven countries in Africa had nextgeneration sequencing capacity within their publichealth laboratories. By 2022, that number has grown
to 31, and Illumina donations have supported 20 ofthese countries. The new infrastructure was put toimmediate use in 2022 to manage the Ebola virus andMpox outbreaks, among others.

Illumina has committed $60 million over five years
with in-kind donations, including NGS platforms,
reagents, and training support to the initiative. The
initiative will bring us closer to the vision of an early
warning system to detect new epidemics and apply
genomics to benefit all.
COVID-19 pathogen surveillance is not the end of
the story. The UN Environment Program has warnedof the growing risk of zoonotic disease, infections thatspread between people and animals due to increased
urbanization and expansion of industrialized agriculture.
Building a global pathogen surveillance system that
supports a One Health approach and is both versatile
and adaptable is a vital part of managing these risks
and a core part of the PGI vision.
The Pathogen Genomics Initiative (PGI) is acollaboration between the Africa CDC Institute of
Pathogen Genomics, the U.S. Centers for Disease
Control and Prevention, the Bill and Melinda Gates
Foundation, Microsoft, Illumina, and other industry
partners. The initial Africa PGI commitment included$20 million and led to the expansion of a global
model. Illumina committed an additional $40 million
of product donations over five years to support the
global expansion and to other low-and middle-income
countries, starting in South Asia.
The PGI commitment will help create acomprehensive pathogen genomic network around theworld, building critical public health capabilities in areasof need.
The initiative will bring us closer to the vision of anearly warning system to improve global health risks
and apply genomics to benefit all.
An African proverb uttered in the halls of the African Union
captures the ethos of global partnerships and the spirit ofcollaboration: If you want to go fast, go alone. If you want togo far, go together.

TARGET

2022 PROGRESS$60 million committed$11 million

over five years

since program launch

Africa PGI Impact

Asia PGI Impact$9 million$2 million 4delivered

20

countries

Appendixdeliveredcountries

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Appendix

Impact in Action

Increase Genomic Data Diversity
Genomic Data That Reflects Everyone, Everywhere
Genomic data is the blueprint for everything fromidentifying new diseases to precision drug development.
That means the data sets must be representative toensure the positive impact of genomics is applicablefor all.
Genomics has been integrated into clinical practiceat a faster rate than almost any innovation in the historyof medicine, but inequities still exist. Implementation
has been almost entirely restricted to more developed
nations, and 87% of individuals included in genomic
studies of disease risk are of European ancestry.
To ensure that genomes can be interpreted in theappropriate context of global diversity, we aim toincrease the equitable representation of genomic data.
This allows for therapies and solutions to be attuned toa broader set of genomes, decreasing this bias in our
medicine for the future.
We are proud to support commercial and philanthropic
efforts to increase diversity in human genetics
and ensure that genomic representation is part ofequitable health care in the future.

Access to Genomics for Everyone
Ensure genomes can beinterpreted in the appropriate
context of global diversity
Increase diversity andequity of representationin genomic data

Close the gap in
under-resourced
communities

Ensure everyone has accessto lifesaving treatments tailoredto their individual health needs

Qatar Genome Program

The Qatar Genome Program (QGP) is using Illumina
technology to sequence individuals from the general
population of Qatar, advancing genetic studies in Araband Middle Eastern populations.

Egyptian Genome Project EGPThis year, the Scientific Research and Technology
Academy and Ministry of Defense celebrated the twoyear anniversary of the launch of the genome project inpartnership with Illumina to implement a reference
genome for Egyptians.

Singapore’s SG100K ProjectIn 2022, Precision Health Research (PRECISE), the leadentity implementing Singapore’s National Precision
Medicine strategy, partnered with Illumina to launched theSG100K Project. The three-year initative aims to aims to
map the DNA of a diverse group of 100,000 Singaporeans
who are of Chinese, Malay, and Indian ethnicity. In addition
to enabling population-based research in groups that havebeen historically underrepresented, PRECISE will use theinformation collected to identify the social, environmental,
lifestyle, and genetic factors that are associated withdiabetes, hypertension, cancer, and other importantdiseases in the multi-ethnic population of Singapore.

Human Heredity and Health in Africa

Illumina supports the Human Heredity and Health in Africa(H3Africa). The H3Africa assays use novel, genome-wide
content from individuals across African populations, built
on the MEGA Array backbone. These studies use genetic,
clinical, and epidemiologic methods to identify hereditaryand environmental contributions to health and disease,
empowering the ability to address African genomic
diversity that can improve the health of both African
peoples and the broader global population.

Genetic Research into Cancer Origins

The New York Genome Center’s (NYGC)
Polyethnic-1000 Project (P-1000) focuses on cancer
care inequities in underserved populations, with theobjective of democratizing and broadening access tothe power and potential of cancer therapies. Illumina
provided $2.4 million of in-kind product donations to
support this initiative and help to identify differences
between ethnicities that may account for disparities
in occurrence, response to treatment, and survival
for different cancer types. Using whole-genome
sequencing (WGS), the resulting data set will bemade public to the entire research community,
creating the largest and most diverse collection of
full-genome pairs available in oncology.

Native American Genomic Research

Native BioData Consortium (NBDC) is the first
nonprofit research institute led and staffed byindigenous scientists and tribal community
members in the US. Since its inception in 2018, theconsortium’s goal has been to ensure that Native
people can benefit from advances in genetics andhealth research.
In 2021, to empower the Native community’s
ability to respond to COVID-19 and future risks,
we supported the donation of a NextSeq 550,
consumables, and training to the Cheyenne River
Sioux Tribe. In addition to COVID-19 surveillance,
NBDC will be able to study other diseases that
disproportionately affect their population, such as
diabetes, cardiovascular disease, and colon cancer.

Alliance for Genomic Discovery (AGD)

Illumina and Nashville Biosciences, announced
a sequencing agreement with Amgen to wholegenome sequence 35,000 DNA samples primarily
made up of DNA from African Americans, currently
a community underrepresented in research for theclinical applications of genomics.

Australia’s OurDNA Initiative

Australia’s Centre for Population Genomics (CPG), a
collaboration between the Garvan Institute of Medical
Research and the Murdoch Children’s ResearchInstitute, has launched a new initiative to engage
diverse communities in genomic research. Supported
by a AU$10 million (US $6.26 million) grant fromthe Australian government, as well as contributions
from Illumina and other organizations, the Australian
Genetic Diversity Database project, called OurDNA,
will gather data to improve disease prediction,
diagnosis, and treatment in underserved communities.

26

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

AccessCSR Strategy & Governance

Innovation and Affordability

Genomic Ecosystem

Democratization

Community

Catalytic Philanthropy

PeopleSustainability
Data Diversity

Reach

Operate Responsibly

Appendix
27

Impact in Action

Expand Reach of Genomics with Payer Coverage,
Genomic Literacy, and Patient Advocacy
Increase Patient Coverage and Reimbursement

US Coverage Data (EOY 2022)

Enabling innovation and driving affordability goes beyond
delivering sequencers and data. It includes delivering
insights and accelerating the paradigm shift toward
genomic sequencing as a standard of care to improve
patient outcomes and drive down overall health care costs.
Through evidence generation, education, and community
outreach, Illumina is committed to advocating for healthcare coverage and accelerating the adoption of genomics
as a diagnostic tool.

Non-Invasive Prenatal Testing(NIPT)

Somatic Mutation Panels(Oncology)

Whole-Exome and Genome Sequencing(Genetic Disease)

Total Insured Lives 259.7 M

Total Insured Lives 317.3 M

Total Insured Lives 259.7 M

Evidence generation
for clinical utility

Expanded reimbursement
and payer engagement

Education of health careproviders and government
representatives

Increased adoption

Only High-Risk
Covered34.3 M
13%

All Pregnancies
Covered224.8 M87%

Not Covered
0.5 M
<1%

Not Covered
12.9 M
4%

Targeted &Expanded Panels
Covered273.3 M
86%

Only Targeted
Panels31.0 M
10%

Not Covered
30.4 M
12%

Only WES
Covered167.0 M
64%

Global Coverage Snapshot1
2030 TARGET

2022 PROGRESS

2 Billion

1.2 Billion

covered lives globallyby 20262022 PROGRESS

2022 PROGRESS

2022 PROGRESS

986M

536M

714M

↑149M YoY growth↑52M YoY growth↑62M YoY growthBased on coverage and reimbursement of NIPT, CGP in advanced cancer, or WES/WGS in genetic disease
Global coverage numbers represent our tracking of 19 countries globally (US, Canada, Belgium, Czech Rep, Denmark, France, Germany, Ireland,
Italy, Netherlands, Spain, Sweden, UK, Israel, Japan, S Korea, Australia, China).
1

WES & WGS Covered
62.3 M
24%

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

PeopleSustainability
Data Diversity

Reach

Operate Responsibly

Appendix
28

Impact in Action

Strategic Evidence Projects to Engage Health Systems Globally and Demonstrate Clinical Utility
Optum/UnitedHealth Group (US)The companies launched multiple
evidence-generation projects acrossrare disease, oncology, and cardiovasculardisease to accelerate the generation ofevidence needed to unlock the promiseof precise medicine.

Baby Lion (Germany) Hanover Medical
School will evaluate the use of WGS to show
the positive impact of earlier diagnosis andtreatment of infants suspected of having
a genetic disorder while in the neonatal
intensive care unit (NICU).

Baby Bambi (Israel) Illumina supported apilot program with Israel’s Ministry of Health,
led by the Genetics Institute of the Tel Aviv
Sourasky Medical Center, to implement theuse of whole-genome sequencing (WGS)
for rapid diagnosis in newborns in criticalconditions who are treated in NICUs. Clinicalresults have been reported back with adiagnostic yield coming close to 50%. Basedon the positive results of Baby Bambi, theMinistry of Health is expected to commission
a decision for reimbursement for rapid wholegenome sequencing (rWGS) in the NICU in
2023, providing the creation of a national
reimbursement for WGS as diagnostic tool in
hospitals across Israel.

800+
Providence (US) The company isperforming comprehensive genetic profiling(CGP) to demonstrate utility within an
integrated care system. The collaboration
has resulted in 10+ abstracts and there are
multiple peer-reviewed publications due out
in 2023.

Ballett (Belgium) The study will include
960 patients across Belgium from 12 cancer
centers and nine NGS labs using CGP todemonstrate utility within a nationalized
single-payer system.

Fudan Hospital (China) Children’s Hospitalof Fudan University in Shanghai is deliveringa 24-hour rapid WGS diagnosis solution to
NICU infant patients resulting in China’s firstexpert consensus and first research article
published for NICU rapid WGS application.

peer-reviewed papers instrategic clinical segments

2

263

studies and research collaborations
across the globe in pipeline

Illumina papers were highlighted in AJHG’s Genomic Medicine Year in Review
as part of the top 10 key advances in applying genomic information to clinicalcare reported in 2022

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleOperate Responsibly

Impact in Action

Champion Patients
Transforming patient outcomes epitomizes the heartof our mission. We partner with patients, families,
and organizations that represent communities to help
raise awareness, build hope, and create change.
In 2022, we have worked to amplify the diversityof patient voices by supporting projects that unite
single stories into collective evidence of the value ofgenomics in oncology and rare disease.

The Adolescent and Young Adults

Researchers at the Netherlands Cancer Institute(NKI) and the Dutch AYA foundation are working ona national large-scale genomics study. Within thatstudy, the teams are exploring how AYA patientsvalue and cope with the experience of having theirwhole genome sequenced (WGS). Output of thestudy aims to help inform the future of oncologicalpractice as WGS becomes more routine in the clinic
and to improve care for this population.

Know Your Biomarker

This campaign was launched by the Global Colon
Cancer Association to increase awareness aboutbiomarker testing and treatment decision making.
The campaign also features patient stories
highlighting the impact of biomarker testing on
outcomes for colorectal cancer patients.

Annual Rare Disease Awareness Campaign #IlluminatingRareDisease
Our employees are passionate about the rare disease community. They
understand the power of genomics to help end a patient’s diagnostic journeyand support their care management. Since 2008, Rare Disease Day events
have taken place around the world on the last day of February to raiseawareness about rare diseases and highlight their impact on patients’ lives.
Each year, our employees participate in a campaign and the Illumina Corporate
Foundation donates to the chosen charities for the year.

The Rare Barometer: The Journey to Diagnosis
for People Living with a Rare Disease
The Rare Barometer is EURORDIS’ signature survey
program that guides EURORDIS’ patient-driven
advocacy. The survey currently accesses theexperiences of over 15,000 people representing
over 1500 rare diseases in 80 countries across theworld. Survey results transform the experiences andopinions of individuals into collective data that isused to influence policymaking, foster informationexchanges, and raise awareness. In 2022, the survey
was designed to explore the individual and external
factors influencing the process of obtaining an
accurate diagnosis for rare disease.

We LOVE Rare in Zimbabwe

Recognizing the disparity of access to diagnosis invarious countries, Child and Youth Care (CYC), a
Zimbabwean-based private voluntary organization,
deployed a project to not only raise awareness but
to physically go out and ‘find’ children and young
people impacted by rare disease and to start tocreate the database of evidence needed to build thevalue case for prevalence and impact of rare diseasein Zimbabwe.

Rare Youth Intern ProgramThis initiative seeks to empower young people
affected by rare disease around the world with skills
and confidence to seek meaningful employment
and to empower the next generation of advocates.
This is Illumina’s second year supporting this
impactful program.

Illumina Patient Ambassadors

Illumina Patient Ambassadors are a coalition ofpatients and family members dedicated to increasingawareness of the importance of genetic testing.
Connecting families to a wider community of people
with similar experiences helps provide support andstrength during the search for a diagnosis and can
improve patient care and management. By sharing
personal stories about their disease journey, thegroup can educate and motivate an entire ecosystemof support.

Appendix29

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

Expand Genomic Literacy
To accelerate access to genomics, we need to accelerateawareness. Illumina is committed to increasing the awareness ofgenomics in health care and the advancement of precision medicine.
We aim to increase genomic literacy by supporting health care
professionals, government representatives, connecting genomic
professionals, and inspiring the next generation of scientists,
innovators, and researchers.
We are committed to expanding understanding and access togenomic testing through our outreach to community health systems.
In 2022, we partnered with the American Society for Preventive
Cardiology (ASPC) to create a podcast series which reachedover 26,000 learners by year-end. We continued support of theAmerican Society of Human Genetics (ASHG) online education
for genetics professionals, and we participated in Becker’s 10th
annual leadership roundtable on how internalizing genomics canhelp providers achieve key health care goals. Learn more

2030 TARGET

2022 PROGRESS

Expand independent medical
education (IME) partnerships withprofessional societies and the medical
community, providing education
across all clinical segments>30,000>95%

98%

25,000+30,000+supported medical education
programs increase in participant
knowledge and competence

health care professional learners
reached annually

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Reach

PeopleImpact in Action

Operate Responsibly

Appendix30

Illumina Genomics Forum (IGF)
In 2022, we hosted our inaugural Illumina
Genomics Forum (IGF), which convened
more than 800 visionaries, customers,
and leaders from translational and clinicalresearch organizations, government
institutes, and academia, as well as
hospital leadership, clinicians, payers, andpatient advocates. An additional 7,800
people joined virtually. As an engine ofgenomics innovation, we are reimagining
what’s possible, inspiring our customers todream big.
Explore additional Illumina events.

Illumina is honored to host thisunique gathering of the brightest
minds discussing solutions to some of
today’s biggest challenges, redefining
what’s possible together.
Francis deSouza
CEOlearners reachedthrough IME

increase in participant
knowledge andcompetence

health care professional
learners reachedFrancis deSouzaCEOIntroduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Innovation and Affordability

CSR Strategy & Governance
Genomic Ecosystem

Access

Democratization

Community

Catalytic Philanthropy

Sustainability
Data Diversity

Impact in Action

Reach

PeopleOperate Responsibly

Appendix
31

Impact in Action

Beating Stage IV Lung Cancer:
Biomarker Testing Changed Everything
Eight years ago, AJ Patel was diagnosed with advanced lung cancer. The
Southern California resident and father of three had tumor masses in both lungs.
AJ met a physician who recommended biomarker testing, an approach that uses
next-generation sequencing to determine an individual’s cancer-causing genes
and other markers. When the causal genetic alteration is identified throughtesting, a patient can be eligible for more personalized therapies or beneficial
clinical trials. For AJ, biomarker testing led to a targeted therapy plan—and it is
the reason he is still here today, telling his story. Learn more

Podcast series with
American Society
for Preventive
Cardiology reached>26,000
learners

Continued Efforts andInnovation in the Surveillanceof SARS-CoV-2 Variants
Illumina technology has been at theforefront of the pandemic since its
inception and continues to be used
across the outbreak continuum inover 200 countries around the globe.

Baby Fitz’s Lifesaving Diagnosis Through Whole-Genome Sequencing
In June 2019, Christina and Daniel Kettler
were barely home from the hospital with
their newborn son when they received anurgent phone call. They needed to rush back
immediately: A routine screening, called the heel
stick test, had revealed that Fitz, their firstborn
baby, had severe combined immunodeficiency(SCID). SCID is a rare condition also known as“bubble boy disease.” Fitz had no functioning
immune system. Further testing through rapid
whole-genome sequencing (rWGS) at Rady
Children’s Institute for Genomic Medicine in San
Diego, California (US), identified the specific kindof SCID Fitz had, known as Artemis, or ARTSCID. Fitz was able to receive gene therapy in
San Francisco—a process of extracting his stem
cells, injecting them with a corrected copy of the

SCID-causing gene, and infusing them back into
his body. The treatment succeeded in creatingfrom scratch an immune system that would
function properly and support Fitz. This year, Fitzcelebrates his third birthday as a happy, healthy,
and active toddler.
On April 25, to help raise awareness for National
DNA Day, Fitz threw the first pitch with Illumina’s
Chief Technology Officer, Alex Aravanis, during theApril 24 San Diego Padres baseball game at San
Diego’s Petco Park. Tens of thousands of baseballfans (and a contingent of proud Illumina employees)
came together to celebrate Fitz and the victory of
his health, and to raise awareness for genomics andits incredible potential to unlock information that
improves human health.
Learn More

Illumina Introduced New Pan-Cancer
Companion Diagnostic to Match
Patients with Rare Genetic Mutations
to Targeted Therapy
In 2022, we added a companion diagnostic (CDx) indication
to our CE-marked in vitro diagnostic TruSight™ Oncology(TSO) Comprehensive (EU) test. This single test kit assesses
multiple tumor genes and biomarkers to reveal the specificmolecular profile of a patient’s cancer. We continue to focus
on unlocking the potential of new biomarkers to identify
those most likely to benefit from precision medicines. This
CDx claim, developed in partnership with Bayer, is the firstof a series building upon our broad portfolio of oncology
partnerships with industry leaders to advance cancer
diagnostics and precision medicine. Learn moreMessage from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Community Investment

CSR Strategy & Governance
Employee Engagement

Empower Our
Communities

AccessEquitable Access to STEM Education

Community
Impact in Action

Sustainability

PeopleOperate Responsibly

Appendix32

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Community Investment

CSR Strategy & Governance
Employee Engagement

AccessEquitable Access to STEM Education

Community

Sustainability

PeopleAppendix
33

Impact in Action

Strategic Approachand Impact

2030 Target

2022 Progress

1.2M

Reach 5 millions
STEM learners

We are committed to giving back,creating shared value through ourbusiness, and seeking opportunities
to enable a more equitable andsustainable future for all.
Fostering a culture that empowers our
employees to give back is integral to our
mission. Guided by our CSR focus areas,
we deploy our skills, time, and resources tocreate a positive impact in our communities.

STEM learners1

Donate 100,000
volunteer hours

49,827

Achieve 50% employee
participation through Illumina
Cares programs

50%

hours1

employeeparticipation

2022 Highlights

K E Y O B J ECT I V ES

1 Provide meaningful andstrategic community
investment

46 countries community
investment~18 million total
donations

10% increase in employee
participation (giving andvolunteering) since 2019

1,747 causes
supported globally

Volunteering
GivingTotal participation

Employee participation ingiving and volunteer programs

2 Engage our people tobe agents of change

50%

3 Drive equitable accessto STEM education

UN SDGs

Operate Responsibly

40%

39%

29%

I continue to be inspired by the passion of
our employees to give back and create a path
for a more just and sustainable future.

20%

19%

24%

31%
26%

28%

10%
5%

Sharon Vidal
Head of Corporate
Social Responsibility

2019
Future Kings students visiting
Illumina Baltimore facility.

Since 2019 baseline

1

2020

2021

2022

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Community Investment

Employee Engagement

Community

AccessCSR Strategy & Governance

Equitable Access to STEM Education

Sustainability

PeopleOperate Responsibly

34

Impact in Action

Provide Meaningful and Strategic
Community Investment
We focus our community impact
strategy on investments that
support our CSR efforts forpatients, our communities, ourpeople, and our planet.

Community Investment Areas
Equitable Accessto Genomics

STEM Education
for All

APPROACH

Sustainability andEnvironmental Justice

APPROACH

Enable access to genomics forpatients in need and increase thediversity of genomic data.

How We Give Back

• iHope• Pathogen Genomics Initiative• Native BioData• NYGC Polyethnic Study• Red Cross Sickle Cell →• Illumina Genomic Discoveries• DNA Decoded• Genomics 101• SD STEM Diversity (SD2)• ENLACE SD and Mexico• Form the Future, UK• CHRF STEM, Bangladesh• Cold Spring Harbor, China• Junior Achievement• iConserve• Illumina Agricultural Greater

Learn morein Access →Learn morein Community →Learn morein Sustainability →Illumina
Corporate
Illumina Corporate
Foundation

SAMPLE PROGRAMMING

Employee Giving andVolunteering

Increase genomic literacy andsupport equitable access to
STEM opportunities.

APPROACH

We drive collective impact and leverage ourresources to help address local and global
needs with philanthropic activities andnonprofit partnerships.

SAMPLE PROGRAMMING

Invest in sustainability projects andefforts to create a just transition toa low carbon future.

SAMPLE PROGRAMMING

Good Initiative• STREAM• CSUEB Green Biome Institute• GRID Alternatives• The Solutions Project• World Wildlife Fund
• SEE Foundation, China

Local
ImpactAPPROACH

Engage in local efforts to address
the issues and challenges where
we live and work and support thecauses employees care most about.
SAMPLE PROGRAMMING• Disaster response →• Regional Community Grants →• Ukraine support →• Illumina Cares Ambassadors →Learn morein Community →Diversity, Equity, and Inclusion
Diversity, Equity, and Inclusion is the foundational lens across all our investments, ensuring we
consistently prioritize and promote equitable representation and support for vulnerable populations.
Learn more in People →AppendixIntroduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Community Investment

EngageOur People
to be Agentsof Change
We strive to create a purposedriven culture with opportunities
for employees to volunteer in theircommunity with the organizations
that matter most to them.

CSR Strategy & Governance
Employee Engagement

16

$25

$10

donation match

new hire seed
donation deposit

Equitable Access to STEM Education

Individual

PeopleSustainability

Operate Responsibly

Appendix
35

Impact in Action

FamilySan Diego Classroom– Keith Rego, SeniorDirector of Global EHS,
went to his child’sclassroom to shareabout his work and thepossibilities of DNA.

Team

China Wetlands – 48 Illumina Greater China
volunteers and their family members visitedthe Shanghai Chongming Dongtan Nature
Reserve for the second habitat cleanup event.
A total of 250 kg of used plastic bottles andStyrofoam were collected and turned into
recyclable goods.

International Coastal Cleanup –100+ Illumina employees, current
and future, cleaned up local
beaches. Across the region, over
4,000 volunteers cleaned 35,000
pounds of litter and debris.

Singapore Illumina Hair for Hope –27 Illumina Singapore employees shaved
their heads to raise funds and awarenessfor childhood cancer. More than 200
employees supported the event, whichraised nearly 38,000 SGD for Children’s
Cancer Foundation Singapore.

Cambridge County Day – Incelebration of the Queen’s Platinum
Jubilee, Illumina served as the leadsponsor of the Cambridge County
Day. We had our own Illumina marquee
dedicated to the story of DNA, whichbegan in the city in the 1950s.

Site
Pedal the Cause – The
St. Louis customer successteam made superhero capesfor the Pedal Kids Challengeride, supporting Pedal the
Cause, an organization thatprovides critical funding forcancer research.

RegionERG
Diversity in Life Science – Each ERG completes asocial impact project. iLatinX ERG members regularly
engage in community outreach where they mentor
students and expose them to STEM concepts andcareers and are active partners with programs suchas the Biocom California Institute’s Generation STEAM.

hours paid volunteer
time off (VTO)

Volunteer rewards
donation earned
for each hour ofvolunteer work

Community

We offer a variety of ways for employees to engage in giving back. Employees can volunteer as individuals, with theirfamilies, teams, local sites, regions, with employee resource groups and through corporate global engagements.

Employee Giving andVolunteer Benefits$500

AccessVolunteering Day – In conjunction with Singapore’s month-long National
Day Giving Campaign, 253 employees from Singapore, Australia, Japan,
Korea, India, and other APJ regions came together to give back in a single
day over five activities in the island city. Our employees provided STEM
learning opportunities to underprivileged children, contributed resource
support to at-risk seniors, and enhanced environmental sustainability.

Learn more in People →Company-wide
Rare Disease Day Campaign – For 2022 Rare
Disease Day, Illumina focused on SLC6A1 Connect
in the US, ASrid in Japan, NoRo in Romania, andRare Disease South Africa. Five families from eachorganization captured photos representing theeveryday world of people living with a rare disease.
Learn more in People →Giving “Twosday” – Illumina launcheda worldwide double match campaign tocommemorate Giving Tuesday. Our recent#GivingTWOsday22 campaign raised over
$230,000 with almost 800 employees
participating and impacted 580 charities in
29 countries.

Walk the World to End Cancer – Over 900 employees joined
a virtual step challenge, walking the world for oncology. We
featured international oncology charities for this special “Walkto End Cancer,” including the ASARGA Fighting Sarcoma,
KickCancer Curing Kids, Zero – The End of Prostate Cancer, Rare
Cancers Australia, and BEABA Cancer Education. Each charity
received a $5,000 donation for a campaign total of $25,000.

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Community Investment

CSR Strategy & Governance
Employee Engagement

Drive Equitable
Access to STEM
Education
We are committed to equitable access to STEM
education with the goal of empowering students
and enabling educators to inspire the next
generation of scientists, innovators, and trailblazers.
The future of our mission is reliant on nurturing and equipping the next
generation. Through direct programming, nonprofit partners, and engaging
our employees, we aim to enable educators to be advocates of genomics
and inspire learners to envision themselves as our future STEM leaders.

Our STEM Strategy
Working to build STEM and genomics into theeducation ecosystem where educators andstudents have access to resources.
AUDIENCE

TACTICSRESULTS

Educators

Provide direct
programming

Empowered tobe advocates ofgenomics

Work with nonprofit
partners

Students

Engage our
employees

Since 2019 baseline.

Community

Equitable Access to STEM Education

PeopleOperate Responsibly

Appendix
36

Impact in Action

Enable Educators

DNA Day Campaign: The Future is Bright

Inspiring the next generation of scientists, engineers, andinnovators, starts with our educators. With the expertise of
our employees and nonprofit partners, we develop tools andcurricula for educators to bring genomics into the classroom.
• Illumina Genomic Discoveries – In partnership with Biocom
Institute California, Illumina Genomic Discoveries wasdeveloped to create an educational community of practicewhere teachers can learn the world of genomics. The programprovides genomics-focused professional development, realworld curriculum, in-classroom activations, access to theIllumina Virtual Lab training, and industry connections.
• DNA Decoded – In partnership with Discovery Education,
DNA Decoded is designed to help educators explore curated
resources with their students. The resources and guides
provide educators with an overview of genomics, highlighting
real-world connections to genomics and instructional
resources sorted by applications.
• Virtual Field Trip – In 2022, DNA Decoded released the
Genomics: Decoding the Language of Life virtual field trip.
This free virtual learning experience transports educatorsand students around the world to our labs in San Diego, CA,
to meet our real-world experts harnessing the power of the
genome to improve lives and support the conservation of the
Earth’s natural resources.
Learn more and access our STEM resources.

Inspiredto envision
themselves as
future leaders

Sustainability

Educators

2030 TARGET

2022 PROGRESS

5 million

1.2 million+

STEM learners
reached globally
1

AccessSTEM learners
reached globally1

In honor of DNA Day, which is celebrated on April 25, we host “The
Future Is Bright,” a month-long genomic literacy initiative. Illumina
employees connect with students by hosting career panels, implementing genomics
curriculum, and leading hands-on experiments. Learn More2022 IMPACT:

90,000+130+1,500+

1,600+

53%

2,230

and schools

Title 1 schools whereextraction kits

6

low-income families

donatedlearners

community partners

countries

eventsof US classrooms were

make up at least 40%
of enrollment

employee volunteer hours

strawberry DNA

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Students

Inspire the Next
Generation
We’re committed to inspiring
the next generation of genomic
leaders and aim to nurture adiverse and inclusive STEM
workforce for the future. To dothis, we collaborate with a rangeof community partners andengage our employees to reachand empower students of all
backgrounds.

Introduction
Community Investment

Employee Engagement

Community

AccessCSR Strategy & Governance

Equitable Access to STEM Education

Sustainability

PeopleOperate Responsibly

Appendix
37

Impact in Action

Empowering Learners from Curiosity to Career
Through each stage of their educational journey, we empower students to envision themselves as future scientists, innovators, and trailblazers.
CareerCuriosity
PRIMARY EDUCATIONSECONDARY EDUCATION

Junior Achievement BizTown – In
2022, we opened a storefront in
Junior Achievement (JA) BizTown in
San Diego. Biztown, a mini-city, isJA’s experiential-based elementary
school capstone program. The
Illumina storefront mimics our labs with stations for students tobecome “scientists” and explore careers in the life science andbiotech industry. Learn More

San Diego Squared (SD2) – We areproud to be a founding funder of San
Diego Squared (SD2). The organization,
based in our HQ hometown, focuses on
creating diversity in STEM careers. In
2021, Illumina committed $500,000 overthree years to support the program. See
the recipients of the Illumina 2022 Scholarship Award and readmore about the launch of the organization.

Cambridge Science Center – Over the summer, we sponsored a
PopUpScience Roadshow with the Cambridge Science Center.
Students and their families explored space through hands-on
science exhibits and interactive science shows.

Future Kings – Future Kings delivers immersive STEM
programs to middle and high school boys from underserved
communities through a multi-year, hands-on curriculumand dedicated mentorship. Students also receive training
in science communication, entrepreneurship, and project
research. See their impact

Child Health Research Foundation –Illumina and the Illumina Corporate
Foundation provided a cash grant
and in-kind donations valued atover $300,000 to the Child HealthResearch Foundation (CHRF), a
Bangladeshi nonprofit that promotes public health and STEM
education. The grant will support CHRF’s Building Scientists
for Bangladesh program, which will introduce young women inunder-resourced communities around the country to scienceand provide hands-on genomic training for university students
and early career professionals. Learn More
Mobile Genomics Lab – Illumina and the Illumina Corporate
Foundation provided funding to the Carl R. Woese Institute for
Genomic Biology (IGB) at Illinois University to construct, staff,
and operate a mobile STEM lab. With the mobile lab, the team
can travel to economically and educationally disadvantaged
locations. Learn MoreGloucester Marine Genomics
Institute (GMGI) – Illumina provided
in-kind donations to support GMGI,
which addresses critical challenges
facing oceans, human health, andthe environment through innovative
scientific research and education. To advance education in thelocal community, GMGI created the Gloucester Biotechnology
Academy, which offers seven months of hands-on training anda three-month paid biotech internship. Learn More
Genspace – Genspace, a community biology lab in New York City,
provides STEAM education programs. In 2022, Illumina and theIllumina Corporate Foundation provided in-kind product donations
and a cash grant totaling over $100,000 to build capacity
for genomics research supporting students from historicallymarginalized backgrounds. Learn More

UNIVERSITY & BEYOND
Center for Marine Biotechnology
and Biomedicine at Scripps – Illumina
provided a transfer of equipment and aphilanthropic grant to Scripps Institutionof Oceanography at the Universityof California San Diego (UCSD) for
researchers at the Center for Marine Biotechnology and Biomedicine(CMBB). CMBB focuses on research at the intersection of ocean
sciences and human health. This support from Illumina will be usedin the development of an automation hub and become a training
tool for students as they prepare to enter the biotechnology andgenomics workforce. Illumina is dedicated to creating opportunities
to invite innovation and work collaboratively. We are thrilled to get
this automated technology into the hands of future scientists whowill drive the next era of discovery. With this equipment transfer, andsupporting $1 million grant, we hope to enable students and support
the acceleration of discoveries in marine biology that could improve
both human and planetary health. Learn More
ENLACE – ENLACE (Spanish for “link”) is a program at the UCSD thatuses science and engineering as a bridge for Mexican high school
and college students to build professional connections and personal
friendships. Illumina provided funding to sponsor 14 students to attend
in 2022 to participate in the mentorship program, enabling them towork in fields ranging from marine biology to the physical sciences andeven get a chance to contribute to published manuscripts. Learn More
Mira Costa Community College Biotech – Illumina provided in-kind
support to enable genomics lab at the community college level. The
community college offers a biotechnology program with associate,and bachelor’s degrees, and certificates grounded in hands-on,
contextualized coursework. By providing access to next-generation
sequencer technology, the program offers advanced specialized
coursework leading to success from the diverse community it serves.

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Community Investment

CSR Strategy & Governance
Employee Engagement

AccessEquitable Access to STEM Education

Community

Sustainability

$100K

$128K

for Pediatric Oncology

Ukrainian medical students

Corp, UN Refugee

Supported pediatricdisplaced to continue

Agency, Doctors

cancer patients displaced

studies at the University

Without Borders

from Ukraine to theof Cambridge

Employee donation

Princess Maxima Centre

University of Cambridge

Netherlands and every
US state

Red Cross, Intl Medical

and match program

$100K

$250K

Rare disease patientsof the Red Cross

displaced from Ukraine to

Humanitarian aid

other parts of EMEA

for Ukraine

EurordisInternational Committee

38

Sickle cell disease is the most common genetic blood
disease in the US. Most patients with sickle cell disease areof African descent and rely on blood given by people of thesame race/ethnicity. Illumina provided a philanthropic grant tosupport work dedicated to understanding how genetics affecthealth outcomes.

In 2022, we engaged
two new signatories$80K

Appendix

Illumina Is Proud to Support Sickle Cell
Initiative with American Red Cross
Southern California Region

Signaling Our
Commitment
to STEM for All

UKRAINE RESPONSE

Operate Responsibly

Impact in Action

Impact in Action

Supporting Ukraine

PeopleOur CEO signed the CEOs for
Computer Science open letterto the Governors and Education
Leaders of United States withCode.org and over 800 leaders.
The letter called on state
governments to update the K-12
curriculum in each state, forevery student, in every school
to have the opportunity to learn
computer science.
Illumina also joined the
STEMM Opportunity Alliance(SOA). In collaboration with
the White House Office of
Science and Technology
Policy, the alliance will be led
by American Association for
the Advancement of Scienceand the Doris Duke Charitable
Foundation to activate a national
vision to drive transformativechange across the American
science, technology,
engineering, math, andmedicine (STEMM) ecosystem
by expanding access andopportunities. The alliance aims
to eliminate systemic barriersand elevate equity in STEMM toa sustained, national priority.

Intern Skills-Based Volunteering

Collaborating with
Cambridge, UK
LaunchPad
The birthplace of DNA
sequencing, Cambridge is oneof the UK’s most science- andtechnology-intensive clusters
with a vibrant, growing economy
that draws an extensive rangeof STEM skills. Illumina isproud to be one of the local
STEM businesses playing apivotal role in helping teachers,
schoolchildren, and young
people to experience thevast array of available career
opportunities and support the
future growth of skills and jobs
in Greater Cambridge.

Each summer, Illumina interns put ourculture of giving back into action bycompleting a social impact projectwith a nonprofit charity partner.
This year, our interns donatedover 500 hours and collectively
completed 15 projects. For the firsttime, we expanded the programinternationally, including our UKbased interns as well.

Ascending One of the Most Challenging Mountain
Passes in Europe to Support Cancer Charity
To raise awareness and fundingfor cancer research, the Stelvio
for Life Foundation organizes anannual event up the Passo dello
Stelvio in North Italy.

The Stelvio for Life event supports
cancer research. The research
implementation is carried out by
the Center of Personalized Cancer
Treatment Foundation (CPCT
Foundation). In 2022, we had several
brave Illumina colleagues participate
in this impactful event. The
sponsorship provided by Illumina, andthe individual fundraising by individual
riders, will be used to support
research for DNA-based personalized
treatment of cancers through the
Stelvio for Life Charity.

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

CSR Strategy & Governance
Sustainable Facilities

Integrate
Sustainability

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleImpact in Action

Operate Responsibly

Appendix
39

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix40

Impact in Action

Strategic Approachand Impact

Achieve net-zero emissions(Scope 1,2, and 3) by 2050

In progress

We are committed to integrating environmental stewardship into
the fabric of how we operate.

Reduce emissions by 46% in our direct
operations (Scope 1, 2)

100%

Human health and the health of our environment are intertwined, connecting
our mission with our commitment to operate responsibly and sustainably.

Reduce emissions by 46% in our value chain(Scope 3)↑51%3

Decrease water intensity at core sites by 10%↑4%32030 Target

We recognize the importance of the environment in creating a healthy,
sustainable future for all. Our approach to environmental sustainability
prioritizes taking action on climate change and the implementation ofsustainable solutions in our facilities, products, and across our value chain.
As the world seeks innovative solutions to tackle climate challenges andprotect our natural capital, we recognize the incredible opportunity the fieldof genomics and our technology provides.
We view sustainability through the lens of continuous improvement, knowing
there will always be more opportunities for us to protect our planet and do
our part.
K E Y O B J ECT I V ES

1 Drive climate action
2 Operate sustainable facilities
3 Foster a sustainable value chain
4 Develop sustainable products
5 Leverage genomics for a healthier planet
UN SDGs

Our science-based, verified
climate action targets are an
important part of our overallbusiness strategy to minimize
risk associated with climatechange, build resilience, andidentify opportunities for longterm sustainable growth.

Kevin Pegels
Chief of Global Operations

2022 Progress↓9% YoY

Achieve 100% renewable electricity

100%

Divert 90% of waste from landfill at core sites

64%

Invest $20 million in sustainability andenvironmental justice initiatives$759K

Reach 100% of strategic suppliers to commit
to minimizing their environmental footprint

100%

Minimize packaging by 75%30%$1.5M Total

2022 Highlights
NovaSeqTM X launch
resulting in 61% reduction2
in climate impact comparedto NovaSeqTM 6000

Carbon neutral in direct
operations (Scope 1, 2) supporting
the SBTi beyond value chain
mitigation1 approach

100% renewable electricity

Verified SBTi Net-Zero andemission reduction targets

1SBTi Beyond Value Chain Mitigation.
Learn more on the sustainable product page.

2

Since 2019.

3

Climate Action

Sustainable Facilities

Drive Climate
ActionClimate change represents a threat to humanhealth, the environment, and the global economy.

• Business Ambition for 1.5 °C

PeopleOperate Responsibly

Appendix
41

Impact in Action

Our Path to a Science-Based Net-Zero
To ensure we hit critical milestones on our path to net-zero, we created short-, medium-,and long-term SBTi-verified targets aligned to the 1.5 °C climate action pathway.

Our Climate Action
Progress
SCOPE 1

100%
Net-Zero Target by

0 GHG

reduction

20

Reach net-zero GHG
emissions across Illumina’s direct
operations (Scope 1 ,2) and ourvalue chain (Scope 3) by 2050
from 2019 baseline levelsmReduction Targets
ion
s
is

↓90%

Reduce Scope 1, 2 absolute
GHG emissions 90%
by 2050 from 2019 baseline

Reduce absolute GHG emissions
from material Scope 3 categories
90% by 2050 from 2019baseline

Near-Term Emission R
ed
uc
ti

↓46%

Reduce Scope 1, 2 absolute
GHG emissions 46% by 2030
from 2019 baseline
Reduce absolute GHG emissions
from material Scope 3
categories 46% by 2030
from 2019 baseline

s
rget
Ta

We ensure that our efforts are aligned with the leading
practices and organizations addressing climate action:

Leveraging Genomics

SCOPE 2100%

reduction
SCOPE 351%

increase
SCOPE 1, 2

Carbon neutral*
I N V E S T in sustainability
and environmental justiceinitiatives

$1.5M

on

As a science-based organization, we aim to ground our climate action
targets in a science-based framework.
In 2022, we were among the first companies in the world and ourindustry, and the first genomics company to receive verification of our2050 net-zero emissions targets by the Science Based Targets initiative
Corporate Net-Zero Standard.
In 2021, our Scope 1, 2, and 3 emission targets were also externallyverified by SBTi and aligned to the Paris Agreement’s climate ambition
goal of keeping planetary warming to 1.5°C. We aimed to create an
approach that helps us demonstrate that our long-term net-zero climate
targets are credible, ambitious, and accountable.

Sustainable Value Chain

50

Among First in the World to Receive Approval of
Net-Zero Target verification from the Science Based
Targets Initiative (SBTi)

Sustainable Products

E

Strategic Approach and Impact

Sustainability

Long-Term

CY’22 CSR Report

Community

AccessCSR Strategy & GovernanceRe
nIntroduction

Message from the CEO

le Electricity
ab
w
e

↑100%

Increase annual sourcingof renewable electricity
to 100% by 2030 from2019 baseline*Scope 1 reductions include our beyond
SBTi mitigation, applying Green E certified
Carbon Offsets for our natural gas Scope 1.
*Scope 2 reductions include the
combination of on-site solar, purchased
renewable electricity, and renewableelectricity credits.

• Science Based Targets initiative (SBTi)• We Mean Business Coalition• United Nations Race to Zero

Climate Change Position Statement
CSR Policy• The Implementation of UN SDG 13: Climate Change• Task Force on Climate Disclosure (TCFD)

Learn more in Sustainability
Impact in Action→

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Impact in Action

Climate Risks and Opportunities
Climate Risk Management
Addressing climate change is critical to achieving a sustainable,
just, and resilient future for all.
As external conditions evolve, we continue to evaluate ourapproach, recognizing that both physical risks, such as extreme
weather, and transition risks, such as regulatory and technologicaldevelopments, may affect our operations. We have integrated
climate risk into our enterprise risk management program.
Identifying Climate Risks and Opportunities
To deepen our understanding of the potential risks andopportunities of climate change, we conducted an assessment
using the recommendations of the Task Force on Climaterelated Financial Disclosures (TCFD). We engaged with BSR(Business for Social Responsibility) to develop three 2030
climate scenarios linked to global warming by 2100, understandthe potential implications of climate change for our business,and identify opportunities to build resilience.
The climate scenario analysis was completed using threeplausible narrative future representations of our operating
environment respectively aligned to a well below 2°C, a 3°C,
and a 4°C level of warming. To map assumptions for eachtrajectory, we utilized standardized third-party climate modelingdata, such as the Shared Socioeconomic Pathways (SSPs)
and the Intergovernmental Panel on Climate Change (IPCC)
Representative Concentration Pathways (RCP).
Managing Climate Risks and Opportunities
To manage climate-related issues, we are incorporating climate
resilience across our operations and value chain with a risk
management structure, our EHS team management system,
business continuity program management, supply chain risk
reviews, and periodic audits of related processes. Addressing
risk at the site level is performed by our site emergency
management cross-functional group, which plans for andreacts to immediate and near-term physical risks caused byclimate change.

Natural Capital and Biodiversity
We review the environmental management systemframework annually as part of the global aspect and impacts
clause. Output from this data influences environmental
performance and GHG reduction objectives. Illumina also uses
our ISO14001 environmental management system as one of
the mechanisms to monitor and reduce our environmental
impacts from GHG emissions.
Climate Risks
The climate change elements that have most influenced ourstrategy are physical risks to operations, supply chain impact,
and reputation. These risks have been incorporated intobusiness continuity planning, future product development,
redundancy in supply chain where possible, and site selection
for future growth. We are actively reviewing opportunities
to further integrate climate into our processes and paths tofurther expand resilience.
We have implemented redundant planning and maintained
safety stock to provide resilience during severe weather
events. For financial planning, we include risk and opportunities
evaluated through our standard budget planning. Investment
in energy-reduction projects that require capital expenditures
are evaluated through the Capital Committee planning process.
Potential indirect costs associated with supply chain, futuretax, or increased operating costs from extreme weather
connect with these internal workstreams.
Challenges
We have committed to ambitious science-based climate
action targets including net-zero commitments that include
our value chain and absolute based reduction targets. Illumina
continues to experience strong growth and, with absolutebased reduction targets, we recognize the challenges that lay
ahead. In addition, varying levels of climate maturity within
our supply chain and renewable sources in some markets may
also provide challenges. We will continue to work through eachchallenge as we do our part on the path to net zero.

Nature underpins all economic activities and humanwell-being. It is the world’s most important asset. As
part of our approach to sustainable and responsible
business operations, we have reviewed potential risk andopportunities beyond our climate footprint as part of aholistic look at natural capital and biodiversity. Natural
capital assets are elements in nature that provide thegoods and services that the economy depends on. We
reviewed the links between our potential direct impacts
and dependencies on natural capital.
We will continue to monitor progress from the Task
Force on Nature-Related Financial Disclosures and the
new Global Biodiversity Framework. At Illumina, ourexisting environmental-related targets currently include
efforts that prioritize reducing the impact of our facilities,
supply chain, and product. We will continue to monitor
and assess the natural capital elements of ourenvironmental footprint.
As evidence of the intersection between biodiversity,
natural capital, and the economy becomes more defined,
we recognize there are opportunities for the application of
genomics and Illumina sequencing to protect and innovate
in future nature-positive economies. Our technology
is currently used in research to understand and guideconservation of species, to implement more sustainableagriculture and food security pathways, and as a tool for
innovation to create new synthetic materials that minimize
the use of natural resources or create alternatives tonatural capital withdrawals.

EXPLORE OUR CLIMATE OPPORTUNITIESOur approach to managing the physical and transition
risks and opportunities presented by climate change aligns
with the TCFD framework. Additional details on our climate
scenario insights are in the TCFD Index → and our2022 Climate CDP Response.

Appendix42

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

AccessCSR Strategy & Governance
Sustainable Facilities

Sustainable Products

Community

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix
43

Impact in Action

Operate Sustainable Facilities
2022 Initiatives

We approach reducing the environmental footprint of our facilities by focusing on green building design,
optimizing energy, reducing water and waste, and expanding the use of renewable electricity.

Greening Our Labs
We have partnered with My Green Lab® toimprove the sustainability of our laboratories
around the world. In
2022, we initiated theprocess of participatingin the My Green Lab® Certification Program aspart of our commitment to a net-zero future,with efforts continuing into 2023.

Emission Reduction
100%

We regularly evaluate energy-efficiency measures and renewable energy
projects to reduce our operational carbon emissions. Each of our sites
maintains a pipeline of energy projects to contribute to emission reductions.
59%

2030 TARGET

2022 PROGRESS

100%

100%

renewable electricity
achieved

46%

reduction in Scope 1
and 2 emissions

11.4

Through onsite generation, purchased
renewable electricity, and renewableenergy credits

9.8
5.8

100%

4.2

reduction in Scope 1 and 2
emissions1

0.6%

2%

2019 2020 2021

Renewable Electricity

Green Building Design LEED Certified Sites• San Diego, CA•

Singapore, SG• Foster City, CA•

Shanghai, China
New Singapore Manufacturing
Site Achieves Green Building
LEED Gold Certification
The new facility opened in 2022 andhas been awarded LEED Gold status,reflecting energy conservation, water
usage reduction efforts, and the use ofsustainable materials.

2022
12019 2020

2021

Emission Intensity

2022
2

Regenerative Thermal Oxidizer (RTO)
Decommission
At the end of 2022, we began decommissioning the RTO at our San Diego
headquarters. As our manufacturing process
evolved and hazardous pollutants decreased,
the local Air Pollution Control District deemed
the unit was no longer required. Every year,
the RTO burns an average of 109,000 thermsof natural gas at a cost of $103,000 and at anenvironmental impact of 580 metric tons of CO2
emissions. Full decommission is expected to becomplete in 2023.

SBTi Net-Zero Mitigation Hierarchy3
Illumina follows the recommended mitigation hierarchy with our net-zero commitments. SBTi recommends science-based targets
for the near- and long-term to address our value chain emissions and implement strategies to achieve these targets as a firstorder of priority and then to invest in mitigation outside the value chains. Under the recommendations of SBTi Net-Zero Standard,
companies should go beyond their near- and long-term science-based targets to further mitigate climate change by undertaking
actions or making investments that generate additional co-benefits for people and nature. To further facilitate beyond value chain
mitigation, Illumina has invested in Nature Based Green-e Certified Carbon Credits while on our journey to net zero. We haveapplied carbon offsets for our natural gas scope 1 as a temporary mitigation.
Onsite generation, purchased renewable electricity, renewable energy credits, and Green-e certified nature-based carbon credits.

1

Scope 1 and 2 emission intensity per million dollars revenue.

2

SBTi Beyond Value Chain Mitigation

3

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix
44

Impact in Action

Water Stewardship
We continuously seek opportunities to reduce
our water footprint by improving operational
efficiencies and assessing potential risks toprotect this vital natural resource. At our largest
locations and highest water risk location,
we employ a variety of water conservation
applications. We assess our water usage bycomparing the locations of our sites with thebaseline water stress risk ranking according to
the World Resource Institute and its Aqueduct
Atlas. For facilities that have been identified
as operating in water-stressed regions, we arecommitted to focusing additional efforts on water
management planning.

WATER RISK AT CORE SITE LOCATIONSSan Diego, CA
Madison, WI

Steenoven, NL

Foster City, CA

Singapore, SG

Cambridge, UK

Hayward, CA

WATER RISK ASSESSMENT BY SITE

Extremely High

Low-Medium

High

Low

Medium-High2022 Water Projects
Singapore Water Efficiency Building (WEB) Certification
Our Singapore site received a Water Efficiency Building
Certification (WEB), that recognizes businesses, industries, andreduction of monthly
buildings that adopt water-efficient measures in their premises
water consumption
and processes. By installing a total of 85 control flow restrictors,
water sensors, and water delay fittings, we’ve reduced the monthly water consumptionof the building by 5%, resulting in .29 million gallons of water saved annually.

5%

Re-Use Water Cooling Tower
Our San Diego headquarters completed a project which added
piping to divert drain water to a storage tank that feeds into HVAC
cooling towers. This project will conserve 2.2 million gallons ofwater annually.
Reclaimed Water Use
Our San Diego locations continue
to utilize reclaimed water forlandscaping, water features, andour cooling towers.

2.2M

gallons estimatedto be conserved

2030 TARGET

2022 PROGRESS

10%

4%

reduction inwater intensity
at core sites

increase in water intensity
at core sites from baseline

9%

reduction YoY
San Diego (i3, HQ, Distribution Center),Foster City, Hayward, Madison, UK IlluminaCentre, Netherlands, Singapore Woodlands.
1

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

Sustainable Facilities

Sustainable Products

Waste Management

Sustainable Value Chain

Plastics Shedding Pilot
In an effort to increase the circularity of our products, we conducteda pilot in 2022 to test the diversion of consumables waste to be
repurposed for other plastic applications through a third-party
partnership. Of the 6,540 pounds of plastic (PP and HDPE) that wediverted in the pilot, 5,232 pounds were recovered, resulting in a 20%
loss of material during the repalletization process. We plan to further
explore internal processes for the collection of plastics.

Leveraging Genomics

PeopleOperate Responsibly

Appendix
45

Impact in Action

Most preferable

AVOID OR REDUCE

REUSE

Hazardous Waste
Our hazardous waste management program is designed to minimize
impact and manage materials in the most environmentally responsible
manner. The process follows a hierarchy that specifies reclamation/
reuse, recycling, waste-to-energy recovery, fuel blending, wastewater
treatment, incineration, autoclave, and landfill when alternatives are notavailable.

Responsible eWaste Disposal
Through our waste management programs, we aim to reduce theenvironmental impact from electronic waste and ensure responsible
management at end of life. We partner with E-Steward, R2, and othercertified recyclers to refurbish, rebuild, and reuse devices to helporganizations around the world.

Sustainability

How We Tackle Waste

We take a hierarchical approach to waste management, where source
reduction is the most preferable option, and landfill is the least
preferable. We continue to prioritize innovative waste management
efforts as part of our 2030 landfill diversion target.

Producer Responsibility
We participate in required compliance schemes for producer
responsibility to ensure proper collection, management, and disposal.
This includes the recycling of packaging, batteries, and waste electricaland electronic equipment (WEEE). Under the EU’s Batteries andAccumulators Directive and Packaging Waste Directive and regulations
in several EU member states, we comply with requirements to financethe collection and recycling of batteries and packaging supplied with our
products at end of life.

Community

AccessCSR Strategy & Governance

RECYCLEINCINERATELANDFILL

Least preferable

iRecycle
An employee-led program in our Asia, Pacific, Japan (APJ) region, iRecycle
aims to minimize the environmental footprint associated with waste from thefield service engineer teams. During the pilot phase in Australia, Illumina service
teams sent product parts used in testing back to the office from field visits where
they are then disinfected and recycled. Since launching in 2022, an estimated5,000 kg of electrical waste has been repurposed, recycled, or disposed of in anenvironmentally friendly way annually through iRecycle. With the successful pilot,
the team plans to expand through the region for deeper impact.
RepairCollect

Ship

2030 TARGET

90%

landfill diversion at all core sites1

2022 PROGRESS64%

Recyclelandfill diversion

13%

improvement since 2019
San Diego, Foster City, Hayward, Madison,
UK Illumina Centre, Netherlands, Singapore.
1

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

PeopleSustainability

Leveraging Genomics

Operate Responsibly

Appendix

Impact in Action

Develop Sustainable Products
We develop innovations that reduce the environmental impactof our products, technologies, and solutions.

Sustainable End of Life
While we develop innovations
that serve our customers forlong into the future, our design
process extends to the end oflife of our products.

Designing for the Environment
We integrate the Design for the Environment (DfE) approach into the coreof our product development to find more opportunities to shift to a circular
economy, addressing the full lifecycle of materials and their end of life. We apply
environmental criteria to resource selection, design, energy use, data processing
efficiency, size, weight, stability, packaging, shelf life, temperature requirements,
end-of-life management, and more.

Sustainable Resources
We are committed to sourcing sustainable
materials, including reducing the amount of
petroleum-based plastic in new product designs.
We also believe that big science can equal green
science and actively work to replace the use ofchemicals of concern with greener alternatives.
Sustainable Production
Through our sustainable facilities, we aim to
make the manufacturing process less energy
intensive, minimize the use of toxic materials,
and recycle waste from the production process
where possible.
Learn more about our sustainable facilities→

We aim to:• Integrate Design for the Environment (DfE) in product development• Optimize sequencer power consumption and processing efficiency

Resources

End of Life

• Reduce amount of petroleum-based plastic in new product designs• Replace use of chemicals of concern wherever possible withgreener alternatives

Sustainable Distribution and Packaging
We work to make the transportation of our products
more efficient and sustainable. We invest in making
our packaging recyclable, returnable, and reusable.
Learn more about our sustainable value chain→• Seek additional opportunities to engage in circular economy

2030 TARGET

2022 PROGRESS

75%

30%

reduction of packaging
from 2019 baseline90%of our secondary andtertiary packaging will
be recyclable, reusable,or compostable

packaging reduction• Recyclable Insulated Containers: A move to

Sustainable
Production

Use• Returnable Insulated Containers: Insulated70%

secondary andtertiary recyclable,
reusable, orcompostable

plant-based paper-insulated containers offered a
100% curbside recyclable solution1

Sustainable Use
When designing our lifesaving innovations, we aim
to create products that areboth more powerful andmore energy efficient.

containers used for refrigerated and frozen invitro diagnostic (IVD) product shipments can be
returned to us for reuse• Reusable Bulk Sustainable Solutions: Insulated

Distribution& Packaging

pallet shippers for frozen and refrigerated products
are validated for multiple uses and returnable
for refurbishment and reuse. Supports internal
movement network and customer bulk order1

100% recyclable in the US and widely recyclable globally.

46

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

47

A life cycle assessment (LCA) evaluates theenvironmental impacts associated with aproduct over its life cycle, from raw material
extraction to production, use, and end of life
(from cradle to grave).
In 2022, we engaged a third party tocomplete a streamlined life cycle assessment
to further quantify the improved environmental
impact of the NovaSeqTM X kits. We evaluatedthe NovaSeqTM X 10B 300 cycle kit comparedto the NovaSeqTM 6000 S4 300 cycle kit andused the functional unit of a per gigabase (Gb)of genetic code.
Our findings demonstrated a 61%
reduction in climate change impact* with
the NovaSeqTM X kit. Armed with data on theholistic impact, we will use the information toaddress new opportunities in future design forenvironment applications and sustainability
product enhancements.

50%

less plastic mass
and volume

NO DRYICE OR ICE
PACKS

Ambient
temperature
reagent
shipping

Emissions per gigabase (Gb)weight and waste

Designedfor cartridge
disassembly andrecycling with notool required

Appendix

Life Cycle Assessment

Impact the World, Not the Environment
The NovaSeqTM X Series Systems announced at the end of 2022
were purposefully designed to reduce environmental impact. The
improved robustness and stability of XLEAP-SBS reagents allows
for shipping at ambient temperatures, and reagent consumableplastics are made from sugar-cane based biopolymers.
Sustainability was at the forefront of NovaSeqTM X design, with an
aim to move beyond incremental improvements and challenge thestatus quo to benefit our customers and the planet.

90%
less packaging

Operate Responsibly

Impact in Action

Meet the NovaSeqTM X Series

50%
less cartridge volume

PeoplePlant-based
bio-polymer
plastics

NovaSeqTMX

NovaSeqTM6000

NovaSeqTM 6000

NovaSeqTM X

0.09 kg CO2 e

0.04 kg CO2 e

FUNCTIONAL UNITS ASSESSED• NovaSeqTM X 10B 300 cycle kit vs.

NovaSeqTM 6000 S4 300 cycle kit• Sequencing + Primary analysis + Secondary

analysis• 1 gigabase (Gb) of genetic code

Data storage
optimized for
reduced storage andenergy requirementsin
61% reduction
climate impact*

Based on comparison of NovaSeqTM 6000 reagent kits to NovaSeqTM X reagent kits.

We radically redesigned and transformed the technology andchemistry with sustainability principles at the core.
Alex Aravanis MD, PhD
Chief Technology Officer,
Head of Research and Product Development• The project aligned with the methodologicalrequirements and guidelines of the ISO
standards ISO 14040 (2006a) and ISO 14044(2006b) on LCA and the GHG Protocol
Product Life Cycle Accounting and Report
Standard (WRI/WBCSD, 2011). However, as it
is a streamlined LCA study, it does not fulfill
all of the reporting requirements of thesestandards.

* Based on end market assessment NY, USIntroduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

AccessCSR Strategy & Governance
Sustainable Facilities

Sustainable Products

Community

Sustainable Value Chain

Leveraging Genomics

Foster a Sustainable Value Chain
As a global organization, we
recognize our environmental footprint
extends beyond our facility walls.
Scope 3 Emissions

2019 Baseline Scope 1, 2, 3
Scope 1

5%

Scope 28%

in Operations
0.6% Category 8: Upstream
Leased Assets
1.0% Category 12: End-of-Life
Treatment of Sold Products
3.0% Category 3: Fuel- andEnergy-Related Activities
3.0% Category 11: Use of Sold ProductBased on our first Scope 3 emission inventory assessment
completed in 2021, 87% of our global emissions are
attributable to elements in our value chain associated withour baseline year of 2019. We assessed all 15 Scope 3
categories and identified the most material contributors toour emission inventory. Categories that represented 7% ormore were defined as material and accounted for 92% of
our total Scope 3 footprint.

Business Travel
EmployeeCommuting87%↑4% since 2019↑406% year over year
Material
Categories
of Focus

Category 2: Capital Goods

23% Contribution↑108% since 2019↑4% year over year

• Purchased goods and services

19% Category 4:• Capital goods

UpstreamTransportation& Logistics• Investments• Business travel

Category 4:
Upstream Transportation& Logistics

24% Contribution↑86% since 2019↑25% year over year

• Employee commuting

31% Category 1:

For each category, we work with relevant functional groups on
projects to further drive down the value chain impact.

2030 TARGET

2022 PROGRESS

46%

51%

reduction in Scope 3 emissions

Category 7:
Employee Commuting

6% Contribution

Investments

Scope 3

↓100% since 2019↓0% year over year

Category 6: Business Travel

10% Category 15:

Capital Goods

0% Contribution↓17% since 2019↑97% year over year

8% Category 7:

17% Category 2:

Category 15: Investments

4% Contribution

8% Category 6:

Our most material Scope 3 categories
of focus include:• Upstream transportation and distribution

2022 Scope 31

0.1% Category 5: Waste Generated

Increase since 2019

Purchased
Goods &
Services

Category 1:
Purchased Goods & Services

37% Contribution↑81% since 2019↓5% year over year

We recognize the challenges associated with an absolute reduction
target in an environment where Illumina continues to grow year overyear. We remain committed to our net-zero path and have a number of
initiatives that will impact our trajectory as they implement and mature.
For full data on all Scope 3 categories, see Appendix.

1

Sustainability

PeopleOperate Responsibly

Appendix48

Impact in Action

Sample Reduction Efforts
Shifting from Air to Ocean
Transportation
Following a successful air-to-oceantransition of key inbound raw
materials from APAC to the US in
2019, we further strengthened ourcommitment in 2022 to leveragesignificant Scope 3 emissions
reductions via the usage of ocean
freight as a mode for our major
global freight lanes.
2022 Ocean Freight Pilot
In 2022, we successfully
qualified the intercompany
movement of manufactured
goods from Singapore to
the US via a pilot programof three ocean shipments.
With the success of thepilot, we now have theplatform for regular monthly
intercompany ocean
shipments throughout
2023. Our network strategy
from 2024 onward will see
the usage of ocean overair further develop on acontinuous growth plan.
Sustainable Investments Policy
We modified our investments policy
to eliminate investing in energy andutilities sector bonds unless theassociated issuance is identified
as a Green, Social or Sustainability(GSS) Bond. We were able to adjust
our approach without any expected
impact on our returns.

Sustainable Business Travel
At Illumina, we enable employees toeffectively avert travel for businessmeetings with a host of virtual
tools, reducing carbon emissions.
For our most traveled routes, weare curating preferred partnerships
with airlines where sustainableaviation fuel and increased aircraft
efficiency are options. We partnerwith an electric car consortium
called SWOOP that allows forelectric car transfers in our hightransfer routes of Chicago/Madisonand San Diego/Los Angeles.
Sustainable Suppliers
Through our strategic suppliers
scorecard program, we assess
environmental sustainability
commitments made by our
suppliers. Our goal is to empower
our suppliers to reduce theircollective carbon footprint andencourage transparent reportingon their progress.
Sustainable Shipping
The 2022 breakthrough innovationof NovaSeqTM X allows for ambient
shipping and elimination ofcold chain transportation. Firstshipments of NovaSeqTM X began
in 2023. Learn more→
Sustainable Employee Commute
We support employees with avariety of regional commute
options. Learn more→Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

AccessCSR Strategy & Governance
Sustainable Facilities

Sustainable Products

Community

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix49

Impact in Action

Sustainable Supply Chain
We consider it business-critical to work with suppliers and partners across our value chain
who share our commitment to the environment.
We engage with strategic suppliers and business partners on climate-related issues,
hold them to the same high standards of business conduct that we set for ourselves,
and require them to commit to reducing their own environmental footprint. Social impact
and environmental screening are included in our Request for Information (RFI) tools whenevaluating potential suppliers.
All new suppliers are required to acknowledge the Supplier Code of Conduct to complete
the onboarding process. Our Supplier Code of Conduct is consistent with commitments wemade both as a signatory of the United Nations Global Compact and as a member of the
Dow Jones Sustainability World Index.
We expect our suppliers to:• Comply with local regulations

and applicable US andinternational regulations• Uphold employee human rights andthe Illumina Human Rights Policy• Ensure a safe and healthy workplace• Demonstrate social andenvironmental responsibility• Conduct business in an

ethical manner• All new suppliers are required toacknowledge the Supplier Codeof Conduct to complete theonboarding process

Learn more about our supplierengagement efforts in the
Responsible Supply Chain section of
the Operate Responsibly chapter →Partnering with Amazon Web Services on
Shared Sustainability Commitments
The amount of genetic data generated fromnext-generation sequencing that we securely
store in the cloud has grown tremendously—from 1 petabyte to 100 petabytes in justeight years. We partnered with AWS andleveraged their Amazon Simple Storage
Service (Amazon S3)Intelligent-Tiering thatallows for automatedreduction in ourstorage cost savings
carbon emissions
by moving data whenaccess patterns change, associated withgenomic data
while still maintaining
storagedata security. It also

90%

improves sustainability
by storing less volatile data on technologies
designed for efficient long-term storage. Since
implementing this project in 2021, there has
been a 90% reduction in our carbon emissions
associated with genomic data storage on thecloud. Learn more

2030 TARGET

2022 PROGRESS

100%

100%1

of strategic suppliers commit tominimizing their environmental footprint

In 2022, we embedded the requirement in our Supplier Code of Conduct and require our strategic suppliers to accept this with issuance of any purchase order.

1

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleImpact in Action

Leveraging Genomics for a Healthier Planet
The positive power of genomics is
helping to identify, measure, andsolve some of the planet’s mostchallenging and pressing issues.
Today, our technology and the useof genomics are being leveraged
by scientists for studies around theworld on biodiversity, endangered
species protection, ecosystemconservation, sustainable agricultural
practices, climate change research,and innovation.

Conservation Genomics
Conservation genomics focuses on characterizing
the genetic diversity of endangered species andapplying molecular tools like Illumina sequencing
to support sustainable management of threatened
species and populations.

Agrigenomics
Agricultural genomics, or agrigenomics, has and willcontinue to drive sustainable productivity and offer
solutions to the mounting challenges of feeding a
growing global population. Using modern technology,
farmers, breeders, and researchers can easily
identify the genetic markers linked to desirable traits,
informing cultivation and breeding decisions.

Biodiversity and eDNA Sequencing
eDNA sequencing is a rapidly emerging method forstudying biodiversity and monitoring ecosystemchanges. As organisms shed DNA into theirenvironments, eDNA analysis can provide clues
about the species present without disrupting theecosystem. Potential applications of eDNA include
port monitoring, biodiversity surveys, ballast
water testing, soil testing, and more. Scientists are
utilizing our technology and environmental eDNA togain insights to develop innovative environmental
solutions. Learn more

Agrigenomics and the Agricultural
Greater Good Initiative
Greater Good Initiative
Launched in 2011 and awarded
annually, The Illumina Agricultural
Greater Good Initiative grant spurs
critically needed research thatwill increase the sustainability,
productivity, and nutritional densityof agriculturally important crop andlivestock species. Grant recipients
receive donations of Illumina products
to support their projects.
2022 Recipient: SENAI Innovation Institute for
Biosynthetics
The 2022 Agricultural Greater Good Initiative
recipient was SENAI Innovation Institute for
Biosynthetics, based in Rio de Janeiro, Brazil. The
institute focuses on seaweed cultivation to explore
the genetic potential for carbon sequestration andenvironmental services, and food security.
By leveraging the power of molecular genetics,
the institute studies the impact of environmental
change on macroalgae distribution and biodiversityand defines metabolic pathways relevant to carbon
fixation, bio stimulants, food industry, methane
reduction, environmental services, and more.
Seaweed aquaculture supports several of theUnited Nation Sustainable Development Goals as itenriches marine biodiversity, fights climate change,
promotes local economies, and helps to clean
seawater. Learn more

Operate Responsibly

Appendix50

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix
51

Impact in Action

Protecting Biodiversity
Marine Conservation
In 2022, Illumina and the Minderoo Foundation announced
a three-year, $28 million partnership to improve surveillanceof marine ecosystems using the power of high-throughput
sequencing with Illumina technology. Learn more

iConserve Initiatives
iConserve seeks to bring the community together to accelerate
wildlife conservation.
A new genomic atlas could help save endangered elephants
Data from this international partnership will assist biologists inprotecting the herds they study
The population of wild African elephants is in dangerous decline, but apartnership between Illumina’s iConserve program, the San Diego Zoo
Wildlife Alliance, and the universities of Copenhagen and Illinois are here to
help. Using a library of 400 DNA samples from elephants across Africa, theteam will use whole-genome sequencing to create a “genomic atlas” that canshow which groups are most in danger from ivory poaching, reproductive
scarcity, and conflict with humans. The partnership also aims to makesequencing tools available to biologists working in the field, empowering
local communities to make a real difference.
Learn more about this iConserve project here

Learn more about our other iConserve efforts:

Studying the Health of STREAMs
Pollution, drought, and climate change are taking theirtoll, making watershed monitoring more important
every year. Using eDNA and Illumina technology,
Sequencing the Rivers for Environmental Assessment
and Monitoring (STREAM) samples freshwater rivers
throughout Canada. STREAM partners with citizen
scientists, local groups, and Indigenous communities
that have strong interests in preserving their waterways to help
collect samples throughout the watersheds being studied. In turn, by
democratizing the data, the Indigenous communities are empoweredwith vital information. Many of them rely on fishing, and the organisms
STREAM monitors are literally fish food. Learn more
Profiling Endangered Plants
California State University, East Bay, located in thesame community as our Hayward manufacturinglocation, has launched the Green Biome Instituteusing genomics to profile California’s endangered
plants. The Institute aims to create molecular profilesof nearly 380 threatened or endangered plant species
to promote conservation and document their biology,
ecological interactions, and potential human benefits.
The Illumina Corporate Foundation provided the Institute with a$50,000 grant for the advancement of genomic literacy and STEM
education through hands-on genomics research for high school,
undergraduate, and graduate students, while contributing to theknowledge and preservation of California’s endangered flora.
Protecting Koalas

How Genomics Will
Support Gorilla
Conservation

Sequencing
to Savethe Lemurs

Bottlenose Dolphin
Genome Made Available
to Researchers

The University of Sydney’s Australasian Wildlife
Genomics Group is using genomics to battle
decreased genetic diversity threatening koalas.
Illumina whole-genome sequencing technology
provides insights to researchers to help protect the
species from climate change, disease, and other risks.
Learn more

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Climate Action

CSR Strategy & Governance
Sustainable Facilities

Sustainable Products

AccessCommunity

Sustainable Value Chain

Sustainability

Leveraging Genomics

PeopleOperate Responsibly

Appendix
52

Impact in Action

Impact in Action

The Solutions Project
To support Black Climate Week, anannual event hosted by The Solutions
Project designed to raise the profile ofBlack voices in climate action, Illumina
provided a $40,000 grant to honor the
groundbreaking climate solutions andenvironmental justice work being led byBlack and Indigenous communities andpeople of color.

WATCH

How the NovaSeq
6000 Is Empowering
Agrigenomics Acrossthe Globe

Let It Grow: A DNA Database for Plants

Honoring a Just Transition to a Carbon-Free Future
We’ve partnered with GRID
Alternatives, a nonprofit
organization providing accessto clean, affordable renewableenergy, transportation, andjobs to the communities mostoften harmed by systemic
oppression across the nation,
to help further advance climate
and environmental justice. The
Illumina Corporate Foundation
provided a $500,000 grant tosupport projects near eachof our main campus locations
to provide clean energy, solar
industry job training, and job
placement to low-income andtribal communities in San Diego,
the San Francisco Bay Area,
Washington, DC, and Wisconsin.

Our grant has enabled GRID to:
Reduce carbon emissions
by 6,568 tons—theequivalent of 24 million
pounds of coal
Save families in San Diegoand the Bay Area around$2.7 million throughthe lifetime of their solar
projects
Expand job training in San
Diego and Washington,training 93 people so far
Learn more

We are a contributing
member of the EarthBiogenome Project, a
massive undertaking thataims to sequence thegenomes of all species on
Earth to help uncover thesolutions for preserving
and restoring biodiversity.

Plant GARDEN, led by Japan’s Kazusa DNA ResearchInstitute, is an online database that collects plant
genomes. Unlike other similar databases, the intent is
to make the data available to everyone. The Illumina
DRAGEN™ Bio-IT Platform provided a new solution to
overcome many of the challenges the research team
were experiencing in compiling plant genomes. With
Plant GARDEN, researchers have been able to identify
new variants and study their expression and function ina variety of plant species. Learn more

Carbon Capture Through Hungry Bacterium

Sustainable
Commute Options
We offer a variety of regional
commuter benefits including
vanpool programs, free electric
shuttles to local transit, andover 250 free electric vehicle
charging stations globally.

Illumina customer, LanzaTech can transform greenhouse gas into ethanol
and other useful chemicals. Their goal is to turn carbon emissions into
valuable material commodities. LanzaTech, a biotech company based in
Illinois, has the goal of turning carbon emissions into valuable material
commodities. LanzaTech found that an anaerobic bacterium called
Clostridium autoethanogenum possesses an ancient pathway that could
ferment both CO and CO2, effectively converting it into ethanol under
the right conditions. Illumina’s sequencing technology helped LanzaTech
identify and modify the microbial genes responsible for making acetone.
LanzaTech’s have produced over 50 million gallons of ethanol fromindustrial emissions, which is the equivalent of keeping over 200,000 tonsof carbon from entering the atmosphere. Learn moreMessage from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

NurtureOur People

AccessInvest in Our People

Community
Create a Culture of Care

Sustainability

PeopleOperate Responsibly

Appendix
53

Impact in Action

EMEA Human Resources TeamMessage from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

Strategic Approachand Impact
We are committed to creating a workplace
centered on innovation and care, aworkplace that values the unique talentsof the individual, brings forward the bestof the collective, and delivers on Illumina’s
mission at a global scale.
An extraordinary mission requires extraordinary
people at every level. By nurturing
an inclusive and caring culture we magnify thevalue of collaboration and building a community.
Together our impact is amplified and ourpotential is unlimited.

AccessInvest in Our People

Community
Create a Culture of Care

PeopleSustainability

Operate Responsibly

54

Impact in Action

2030 Target

2022 Progress

Increase gender representation in
global leadership1

41%

Increase representation of Black, Native,
Pacific Islander, Hispanic or Latino
communities, 2 or more in our US leadership1

13%

Increase representation of Black, Native,
Pacific Islander, Hispanic or Latino
communities, 2 or more in our US workforce

18%

↑2%4

↑1%4

↑9%4

Maintained

Maintain zero net pay gap

K E Y O B J ECT I V ES

↑3%4

30%

Increase minority representationin executive leadership (US)2,3

4th consecutive year

Reduce recordable injury and illness rate

1 Practice diversity, equity, and inclusion
2 Invest in our people
3 Create a culture of care

Appendix.23↓from .564

2022 Highlights
45% female workforce
representation

Inclusion is core to our purpose.
It is essential to the work we do, thecommunities we serve, the partners wechoose, and the teams we build.
UN SDGs

Aimee Hoyt
Chief People Officer

Launched new disability ERGs
52% minority representationin US workforce
80 Net Promoter Score on
Executive DEI Training Program

5% increase in female
executive leadership in last
three years
85% average satisfaction ratefrom leaders on professional
development programming
Launched new mental healthbenefit program (US)Leadership: Manager, equivalent, and above.
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.
3
Executive Leadership: Director, equivalent, and above.
4
Since 2019 baseline.
12Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

Our People
Everyone at Illumina is driven by the powerof genomics to positively impact theworld. We seek opportunities. We embracechallenges. We work tirelessly to movegenomics and humanity forward.

Practice Diversity, Equity, and Inclusion

Community

AccessCSR Strategy & Governance

Invest in Our People

6,342 AMR

Create a Culture of Care

1,459 EMEA

Sustainability

PeopleOperate Responsibly

Appendix
55

Impact in Action

Gender Representation (Global)

2,456 APAC

54%
Male

45%
Female1%

Other/
Undisclosed

Employee Age Distribution (Global)

19%

Under 30

66%
30-50

15%
Over 50

Additional Identities (US)10,257

Total global employees (FTE)

3%

LGBTQ

3%

Veterans

4%

Persons with
Disabilities

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Our People

Practice Diversity, Equity, and Inclusion

Community

AccessCSR Strategy & Governance

Invest in Our People

Create a Culture of Care

Sustainability

PeopleOperate Responsibly

Appendix
56

Impact in Action

Workforce Diversity
and Representation Data
Gender Representation Trends (Global)

2019

2020

2021

2022

Women in management roles in revenue-generating function

35%

36%

42%

42%

Revenue-generating roles held by women

41%

36%

48%

48%

Women in STEM-related roles (as % of total STEM positions)

37%

37%

39%

39%

IT workforce that are women

24%

23%

24%

24%

Engineering workforce that are women

37%

36%

29%

29%

Gender Representation by Level (Global)
Support toEntry Professional
Intermediate to
Senior Professional
Supervisor to
Associate Director
Director & Sr. Director
VP
SVP/C-Suite
Board of Directors

0%Male
2030 TARGET

2022 PROGRESS

Increase gender representation in global leadership2

41% | ↑2%1

Increase representation of Black, Native, Pacific Islander,
Hispanic or Latino communities, 2 or more in our US leadership2

13% | ↑3%1

50%
Female100%

Other/Undisclosed

Minority Representation By Level (US)Minority Representationin Workforce (US)Support toEntry Professional
Intermediate to
Senior Professional44%

Self-identified
as whiteManager to
Associate Director

Increase representation of Black, Native, Pacific Islander,
Hispanic or Latino communities, 2 or more in our US workforce
Increase minority representation in executive
leadership3,4 (US)

Since 2019 baseline.
2Leadership: Manager, equivalent, and above.
1

18% | ↑1%1

Director and Above

0%30% | ↑9%1

3Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.
4
Executive Leadership: Director, equivalent, and above.

50%

4%

100%

White/Caucasian

Hispanic/Latino

Native, Hawaiian/Other Pacific IslanderBlack/African American

American Indian/Native Alaskan

2 or More

Asian

Not Disclosed

Declined
to state

52%

Minority
representation3

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

Practice Diversity,
Equity, and Inclusion
We relentlessly practice diversity and inclusion in all
we do to advance equity and belonging.

AccessInvest in Our People

Community
Create a Culture of Care

Board of Directors
Compensation
Committee
Dedicated Vice
President, Head of DEI

Executive Diversity
Council

CSR/ESG Executive
Steering Committee

DEI Functional
Group

Diversity Council
Working Groups

CSR/ESG FunctionalGroup

Employee Resource Groups (ERGs)

As part of our commitment to DEI, we are the proud signatories of:• UN Women Empowerment Principles• UN Global Compact• CEO Action for Diversity and Inclusion • Disability:IN CEO Signatory

Appendix
57

Impact in Action

DEI Beyond Our Workforce

We strive to foster a diverse and inclusive
culture in which all employees feel valued andappreciated. This kind of environment helps people
engage at their best, knowing they have an equal
opportunity to grow and succeed based on theirperformance, fueled by their individual differences.

Our DEI strategy goes beyond just our internal workforce, people, andculture. It is integrated across our business and is foundational to eachof our CSR focus areas.

Acquire andDevelop
Diverse TalentCommunicate
withTransparency

Our DEI Governance
The following groups are in place to support DEI governance.

Operate Responsibly

Our DEI Strategy

Our DEI program is anchored in the philosophy of practice.
We invite everyone to start where they are and continue towork, appreciating that there is always more to learn.

Dr. Lisa Toppin
Global Head of Diversity, Equity, and Inclusion

PeopleSustainability

Build Inclusive
Leadership

Enhance
Equitable
Processes

Key Programs• DEI Ambassador Program • 'Bright Minds' Executive
DEI Training• Strengths Training• Global Smart Program• ERG Program• HR Team DEI Training• Self-serve DEI Learning

CSR Focus Area

DEI Intersection

Accelerate Accessto Genomics

Increase the diversityof genomic data

Read more in Access→Empower our
Communities

Empower diverse learners
to be future STEM leaders

Read more in
Communities→

Integrate
Sustainability

Invest in environmental
justice initiatives

Read more in
Sustainability →Nurture our People

Practice DEI in all we doRead more in People→

Operate Responsibly

Target spend withdiverse suppliers

Read more in Operate
Responsibly→

I knew when I joined Illumina the company held an intentional belief
that diverse perspectives are needed to drive innovation. What I didn't
know at the time was how much that company belief would impact myown journey to better understanding diversity dynamics and becoming
a stronger DEI champion. After participating in the DEI Ambassadors
Program, I find myself motivated to find new ways to lead change andconsider the areas I can have the most impact. I've been asked to lookinward to see the outside world more accurately.
Jennifer Pellegrini
Sr. Staff Brand Manager

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

Practice Diversity, Equity, and Inclusion

Community

AccessCSR Strategy & Governance

Invest in Our People

Create a Culture of Care

Sustainability

PeopleOperate Responsibly

Appendix
58

Impact in Action

Employee Resource Groups (ERGs)
ERGs as Career Development and theCornerstone of Our DEI Engagement
They deepen our respectful, inclusive culture by engaging
employees and providing an opportunity to connect,celebrate, and learn with peers and allies. The ERGs arealso a key lever to identify, develop, and retain talent.

Our ERG Program Philosophy
Each ERG at Illumina is structured around four contribution
pillars: community service, career development,
education, and business impact to ensure programming
supports ERG member needs and aligns with Illumina
values. This focused work educates our teams about thevalue of difference and uses the power of diversity todrive innovative problem-solving for our business. To readmore about the ERG contributions to our philanthropic
efforts, see the People Impact in Action section, theAccess chapter, and the Community chapter.

Leading the social impact project for my ERG connected
me with an organization that I became passionate about
and ultimately led to an invitation to join their Board of
Directors. The ERG created an opportunity for community
service and professional development.
Alexa Tralla
Sr. PCP Program Manager

I appreciate Illumina for raising awarenessthrough ERG iPRIDE events that our company
values our employees based on their abilities.
Seki Norihiro
Sr. EHS Specialist

2022 ERG HIGHLIGHTS

Employee Resource Groups (ERGs) Program Pillars

5,400+

participants engaged
COMMUNITY SERVICECAREER DEVELOPMENTEDUCATION

BUSINESS IMPACT

Support our communities
by engaging with nonprofits
where we live and work

Focus on building the
careers and skills of diverse
employees into future
leaders

Create more understanding
and deeper collaboration

Enhance innovation withdiverse teams identifying
and solving businesschallenges

Our Employee Resource Groups17

ERG chapters globally

2 New Disability ERGs
Introduced

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

Invest in Our People

Pay Equity
We monitor our pay equity status and market competitiveness onan annual basis.1 For a fourth consecutive year, we are proud toconfirm a zero net gap in pay.2
Our pay practices are designed to compensate employees
based on factors such as job performance, expertise, andexperience relevant to individual geography. Everyone should be
paid equitably, regardless of gender, race, age, ethnicity, sexual
orientation, national origin, or any attribute that does not relate totheir job and contribution.
Expanding Pay Transparency
As part of our commitment to pay equity and equitableprocesses, open communication, and leadership accountability,
we are providing salary range transparency on all US job postingseffective Jan. 1, 2023. To ensure fairness and consistency, we
will also be providing all employees with access to the salaryrange for their current position in 2023 via our HR people system.

2030 TARGET

2022 PROGRESS

Maintain a zeronet pay gap

Maintained for 4th
consecutive year

Equal Opportunity and Nondiscrimination Policies
We support the elimination of discriminatory practices with respect to employment. We arecommitted to fair and respectful treatment of all employees, promoting equal opportunityand diversity in the workplace and in all aspects of our business. Our policies prohibit
discrimination based on race, color, age, gender, sexual orientation, marital status, gender
identity and expression, ethnicity, religion, physical or mental disability, medical condition,
genetic information, veteran status, national origin, or any protected class.

Equal pay refers to paying a woman and man equally for the same or similar work.
Zero net gap in pay means no statistically significant difference in pay for the same or similar work, regardless of gender, ethnicity, or race.

1

2

AccessCommunity
Create a Culture of Care

Sustainability
Impact in Action

PeopleOperate Responsibly

Appendix59

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

Community

AccessInvest in Our People

Create a Culture of Care

PeopleSustainability

Operate Responsibly

Appendix60

Impact in Action

Invest in Our People
Development is the catalyst for how we achieve
success and become more than we ever thoughtpossible—as individuals, as teams, and as anorganization. We aim to create the opportunities andenvironment to unlock the full potential of our people.
We are committed to engaging extraordinary talent and helping them thrive.
To ensure that our employees enjoy long and fulfilling careers at Illumina, we:Invest inour talent

Provide high-impact
development opportunities

Reward employees
meaningfully

Development Happens Every Day
At Illumina, everyone can achieve and become more than they thoughtpossible. Regardless of work arrangements or location, opportunities exist
for continuous learning and growth. Development at Illumina is an intentional,
everyday activity that prepares employees for success in their work now andfor opportunities in the future. It is available to all, accessible in many formats,and contributes to a meaningful career experience at Illumina.
Guided and Supported at Every Step

Individuals own their development and are empowered
to grow their strengths, learn beyond their discipline, andpursue their own personal and professional growth path

Development

Leaders guide and support
development by helping to define thepath, providing access to resources,and growing individuals throughcoaching

Illumina invests in experiences, tools, andprograms that help people achieve their
aspirations and create a culture of development

Every day, we engage in conversations that shape
our expectations, relationships, and outcomes. We
approach work with curiosity and passion, and,supporting a mission that truly matters, you will growin ways you never imagined.”
Karen Wetherholt
Global Head of Talent41%

executive roles* filled with internal candidates

49%

roles filled with internal candidates

28%

new hires referred by Illumina employees

62

average hours of annual training per employee
Directors and above*

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

AccessInvest in Our People

Development Programs, Resources, and Solutions
We support Illumina employees from early career through seniorleadership with a variety of programs, tools, and solutions.

Employee Development
Talent Discussions and Succession – Achieving our mission requires constantly
developing the right talent. Talent assessments and succession planning allow us to get
the right people and programs in the right places to ensure we are supporting the visionof Illumina for today and tomorrow.
Team Enablement – Highly effective teams invest in harnessing the strengths of theindividual and bringing forward the best of the group. Team enablement provides teams
with self-guided resources that create team cohesion and a strong foundation for
future success.
Performance Enablement – Great performance requires an ongoing dialogue of
how individuals are doing and where we’re headed. Shifting from annual reviews,
our performance enablement creates a quarterly proactive connection opportunity
for individuals and their leaders to align on priorities, discuss development, and use
coaching and feedback—all in support of individuals’ achievement and growth.

Community
Create a Culture of Care

PeopleSustainability

Operate Responsibly

Appendix
61

Impact in Action

Listening to Our People
Illumina improves by deeply understanding our people. Employee listening, including iPulse, allows us to capture ourpeople’s successes, needs, and overall experiences in a timely way to take action and improve the employee experience.
We ask our employees to complete regular iPulse surveys. In 2022, we conducted one assessment.

95%

86%

81%

90%

81%

86%

are proud to work for Illumina

feel their manager supports efforts
to balance work and personal life

83%

believe Illumina really cares about
their well-being

engagement index

have confidence in the continued
growth and success of Illumina

83%

feel they belong at Illumina

trust & confidence index

would recommend Illumina as agreat place to work

87%

feel it is safe to be vulnerable

Learning and Leadership Development – From early career to senior leadership, Illumina
employees have unlimited opportunities to grow in the ways they never imagined.
Learning and leadership development supports individuals at all stages in their careerswith the tools, resources, and programs to be successful at every step.

Quarterly career development
and performance conversations

100%

Quarterly
promotion cycles

employees are provided opportunities for regularperformance and career development reviews

Resources• External speaker series

Learning and development resources are curated sothat employees can explore, share, plan, and act toget on the path that is the best fit for them.

• Open career panel discussions• TEK Talks (technical education knowledge)• Anytime, informal feedback tools as well as
formal assessments• Workday learning, LinkedIn Learning, and other on-demandlearning resources• Tuition assistance/financial assistance forjob-related education• 360-degree and 180-degree assessments, Valence, and Strengths
for Teams are available for individual and team feedback.

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

Community

AccessInvest in Our People

PeopleSustainability

Create a Culture of Care

Power Hours – A leadership development programfor frontline leaders, run by subject matter experts,
to develop the skills and knowledge required to lead
teams effectively
Discussion and Lean In Circles – Our businessleaders host discussions on important topics suchas “Moving into Management” and “Managing Your
Career.” We also support Lean in Circles through our
Women at Illumina (WIN) ERG
Mentoring Programs – The Horizons ERG hosts
Jedi-Padawan buddy programs, connecting early
career professionals with seasoned employees, and
the Women in Illumina (WIN) ERG offers a mentor
program called iMentor
Culture of Coaching – Our Coaching Learning Pathhighlights a variety of options to help leaders learn,
practice, and build their coaching skills
Leaders in Action – Leaders helping leaders growtheir skills and expand their impact

Illumina Inventors by the Numbers

Ignite – This leadership series brings external thought
leaders on leadership topics to provide ongoing andregular development
Elevate for Executive Leaders – Over a several
week journey, Directors and Sr. Directors engage
with peers around the globe in a cutting-edge social
and interactive learning experience. Leaders learn
from other executives through activities and guided
discussions, share expertise, and deepen insights
with a dedicated executive coachStrengths-Based Training Program – Using theClifton Strengths Finder Assessment tool, theprogram is designed to build self awareness ofstrengths and an appreciation for what colleagues
contribute, helping drive DEI through our work.
Bright Minds Executive DEI Training - A program
designed for Executives to learn how they can leadchange in every aspect of our talent life cycle engine.

Thrive New Leader Orientation – Targeted to newly
hired and promoted leaders at Illumina, this centerson our global new leaders and provides insight into
leading at Illumina and our leadership philosophy

422

Total
inventors

26%

US inventors
are women

28%

Femaleinventors

192

39%

First-timeinventors

34%

UK inventors
are women

US inventors
are minorities

30%

Singapore inventors
are women

2xIllumina female inventors
compared to the national rateof women receiving patents

In 2022, Illumina employees filed a record 193 newpatent applications. Illumina has a total of 9,178
patents worldwide.

• Over 1,000 participants in Strengths-Based
Training Program• 70% of leaders attend at least one development
program each year with an average satisfaction
rate of over 85%• Leaders have access to over 18,000 on-demandlearning courses

Recognizing Success
We have designed several
programs to recognize
employees’ outstandingachievements, including:• Innovation Award – Recognizes
this core element of our culture
and success by annuallycelebrating our pioneeringscientists for their extraordinary
contributions• Inventor Award – Recognizes
employee inventors whoannually contribute to ourpatent applications• Values Award – Presented
to individuals and teams
nominated by their peers for
exemplifying our values

Appendix
62

Impact in Action

Leadership Development at Illumina
Leaders actively prepare for the future through a variety of formal development offerings.

Operate ResponsiblyMessage from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

Practice Diversity, Equity, and Inclusion

Attracting Extraordinary Talent
Illumina's talent acquisition strategy plays a critical role in supporting
our mission. We integrate our DEI principles in our recruiting efforts tofind top talent who share our values, and have diverse backgrounds
and unique skill sets to join us and help deliver on the transformative
power of genomics.

Intern, Graduate, and Early-in-Career TalentInternGraduate

Early in Career

Employee

Alumni

Nurturing and investing in future talent is critical to Illumina’s growthstrategy. Robust engagement with key universities provides anopportunity for us to create long-term relationships with students,
graduates, professors, and university faculty. We create meaningful
student experiences through special events, professional development
workshops, technical talks, and campus ambassador programs. Our
hybrid approach meets students where they are by offering both virtualand in-person sessions across all time zones.

Intern Cohort

22%

Conversion
Rate (US)64%

Minorities(US)

CSR Strategy & Governance54%

AMR Women

57%

EMEA Women

AccessInvest in Our People

Community
Create a Culture of Care

Attracting Diverse Future Talent
As a global organization, the perspectives from diverse
backgrounds and experiences are core to our talentstrategy. Supporting and engaging with underrepresented
student groups continues to be a key priority as we invest
in the future. Examples of student organizations include
school chapters of Society of Women Engineers, National
Society of Black Engineers, and Society of Professional
Hispanic Engineers, among others. In 2022, we met over
500 students in the US through key diverse student
organizations through in-person events, campus visits, andvirtual sessions.

Internship Program
We know that students and graduates are innovators,
creators, and the future of Illumina. Annually we welcome
an extraordinary group of interns, work experience
students, and apprentices around the globe. These
dedicated students learn, grow, and become morethan they ever thoughtpossible as fully integrated
members of the team. Our
programs provide endless
opportunities for impactful
work, professional
development, andvolunteer projects. Interns
are empowered to practiceleadership, observe thedirect impact of their work,overcome challenges, andnavigate new situations.
Learn more about our employee engagement and internskills based volunteer program here.

Sustainability

PeopleOperate Responsibly

Impact in Action

Illumina Alumni Network
We aim to broaden the genomic
ecosystem and create a community
to forge the future of genomics
together. When joining Illumina, you
become part of the Illumina family.
If your journey takes you away fromthe company, we stay connected
through the Alumni Network. With
over 7,000 alumni representing 600+
companies across the globe, we
recognize the potential of our alumni
to advance thought leadershipand fill talent pipelines within
the biotechnology community.
Launched in 2021, the alumni
network provides former employees
an opportunity to make connections
with fellow alumni, sharing industry
trends, thought leadership andextending the network of genomics
influencers.

Appendix63

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

AccessInvest in Our People

Community
Create a Culture of Care

Sustainability

PeopleOperate Responsibly

Appendix64

Impact in Action

Create a Culture of Care

Building extraordinary teams and breakthrough innovations starts with caring
for our employees and putting their welfare at the heart of all we do.

Fostering Wellness Inside and Out

Additional Perks and Benefits• Medical, dental, and vision coverage

We offer a wide range of benefits as innovative as our work, including healthcare, access to genomics
sequencing, and family planning. Our goal is to enable all employees to take advantage of the benefits that are
most meaningful to them and their loved ones.

• Pre-tax spending accounts• Site amenities, including car washing, dry cleaning,mobile salons, food service, mindfulness, and selfimprovement courses

Employee Benefits

Cancer Early Detection Testing (US)• Business travel medical insurance

We offer a world-class portfolio of benefits andwell-being programs, and we extend these benefits
to employees, spouses, domestic partners, anddependent children.
Every day, our technology is being used to improve
human health—enabling advancements that were notpossible just a few years ago. Our employees receive
access to these new technologies, such as workplace
genomics, reproductive health programs, and cancer
testing to help better inform their health care decisions.
Our employee benefits, which vary by country andregion, recognize the tremendous value our people
bring to the business with an array of meaningfulprograms.

The GalleriTM multi-cancer early detection test is available
at no cost to eligible US employees and their dependents
as part of our Workplace Genomics Program.

Workplace Genomics Program*Through our partner, Genome Medical, we provide
access to genetic experts who can provide
consultations, guidance, and facilitate testing for
employees and their families. In addition, we offer
financial support for cancer tests, reproductive healthtests, and clinical whole-genome sequencing (cWGS)
for rare and undiagnosed diseases.

Supporting Growing Families*• Wellness rooms for nursing, meditation, and prayer• Ergonomic workstations, abundant natural light,
and opportunities to work outdoors• Commuter support• Cafeterias offering sustainable, healthy food
options, including vegetarian choices• In vitro fertilization• Cancer support and expert advisory review
through Access Hope

• Non-invasive prenatal testingThrough our partner, Progyny, we offer a comprehensive fertility benefit program to eligible US-based
employees that provides coverage for fertility
preservation, providing equitable access to care forour diverse employees, including those pursuingnontraditional paths to parenthood.

• Global well-being activities

Health Solutions (US)• Expert guidance for diagnosis, treatment, or finding
the best physician through Included Health (US)• Digital musculoskeletal (MSK) physical therapy caresolution through Hinge Health• Comprehensive mental health program for
employees, dependents and all household
members through Lyra

Providing Time to Recharge

Investing for the Future• Flexible time off• Employee stock purchase program• Two days of paid volunteer time off• Retirement savings plans• Minimum 10 days of holiday paid time off• Pensions (EMEA)• Compassion and Care Time Off• Donation matching program• Special interest clubs• Genetic counseling• Pre-implantation genetic testing• Employee referral program• Gym access or membership

Employees, their spouses, and domestic partners
may be eligible for the company-sponsored
reproductive health program either throughinsurance or financial support:• Company-wide shutdowns in July and December*Some services only available in the US.

• Employee assistance program (EAP)• Life and accident insurance• Disability insurance• Independent financial advice• Tuition assistance• Broadband allowance (hybrid + remote employees)

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Our People

Practice Diversity, Equity, and Inclusion

Community

AccessCSR Strategy & Governance

Invest in Our People

Create a Culture of Care

Sustainability

PeopleOperate Responsibly

Appendix
65

Impact in Action

Workplace Health and Safety
We are committed to a safe and healthy work
environment for all our employees, contractors, andthe communities in which we operate. Through a riskbased approach, our policies outline a process for theassessment, evaluation, elimination, and mitigationof EHS risks while adding value and efficiency across
our operations globally.

Prevention and Preparedness

Global EHS Management System

Environmental, Health, and Safety Trends

We continue to develop global processes underinternational voluntary standards for environmental
and occupational health and safety management
systems. Our Singapore site attained recertification
to ISO 14001 and ISO 45001 and obtained a
Workplace Safety Health Innovation Award.
We embrace our mission through the establishment,
implementation, and maintenance of an integrated
EHS management system. Read more in ourEHS policy.

EHS Programs

EHS’s Global IIPP describes basic processes our employees can take tomaintain a safe and compliant workplace. Our Emergency Action teams
work together to create awareness and lead regular preparedness drills andactivities. This precautionary approach2 is embedded in our risk assessments,
our environmental aspects/impacts, our EHS Policy, product stewardship, andthe engagement of our people.

.74
.53

.52

.43
.23

.34

.34
.18

.22

.17

2019 2020 2021 2022

2019 2020 2021 2022

2019 2020 2021 2022

Lost Time Illness Rate

Days Away, Restricted,
Or Transferred (DART)

2022 Safety Performance• Completion of EHS Regulatory Assessments at allcore sites1

Prevention reports• Standardization of a global process for Hazardous
Material Management including EHS review forhazardous material procurement and a chemical
inventory conducted at all core sites1.18

Recordable Injury& Illness Rate

Our vision is for every Illumina employee to be anenvironmental, health, and safety leader. This year
we championed a series of safety projects andinitiatives that drive continuous improvement andprogram maturity.

• Implementation of an updated Ergonomic
Risk Reduction program to further enable our
employees to identify and address ergonomic risk
factors to drive mitigation actions

.12

2,010

215

EHS risk assessmentscompleted globally

324

Ergonomic evaluations
completed>45,000.23

40%

Hours of EHS-related
training

Recordable injury
and illness rate

Reduction in days away,
restricted, or transferred rate*

Reduction reflects year over year comparison between 2021 and 2022*

Learn More
EHS Policy

14001 Certificate

45001 Certificate

Injury and Illness Prevention Program (IIPP)

Core Sites – San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, Netherlands, and Singapore Woodlands.

1

The UN Global Compact Principle 7 and The UN Global Compact Principle 15 state in order to protect the environment, the precautionary approach shall be applied.

2

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Our People

CSR Strategy & Governance

Practice Diversity, Equity, and Inclusion

AccessInvest in Our People

Impact in Action

Community
Create a Culture of Care

Sustainability

PeopleAs part of the ERG program
pillars, each group completes
a community service social
impact project. In 2022, theinitiatives included STEM
outreach to underrepresented
communities, creating carepackages and notes for teenswith gender dysphoria, career
mentoring for transitionaing
veterans, and many more.
The ERGs put our cultureof giving back into action
connecting our mission,
their ERG focus, andcommunity service.

66

Impact in Action

To support an inclusive place for all, we host sessions linked to current events inorder to foster conversations that promote healing, learning, and the deepeningof connections amongst our community. This year, one of the most impactful
sessions was "Woman, Life, Freedom" and the impact of recent events on our
Iranian community. Employees shared their experiences, showed support for thecommunity, and were provided resources to learn more about the rich and bravehistory of the Iranian Women.

Singapore Workplace Safety
Health Innovation Award
Illumina Singapore was recognized with
an award on innovation in workplace
health and safety. The project included
developing automation to support
assembly and manufacturing of heavyequipment. Reducing risk, eliminating
lifting hazards, and improving
efficiencies and safety earned external
acknowledgment from the Workplace
Safety and Health Council and theMinistry of Manpower (MOM).

Illumina Ranked One of
50 Smartest Companies in
China by MIT Technology Review

To promote self care for our employees and their loved ones, weoffered a $500 Health and Lifestyle Allowance to all employees
globally. To foster connection, we held a #HealthySelfie campaign
to have employees share how this is positively impacting theirhealthy lifestyle.

Appendix

Care and Connection Sessions

ERG Community
Impact Project

Healthy Selfie Campaign

Operate Responsibly

Through consistentinnovation in
next-generation
sequencing (NGS)
technologies, andrelentless efforts tocombat COVID-19
worldwide, Illumina distinguished itself from othermulti-national companies in the Technology Review
Top 50 Award in China.

Nurturing a Culture of Carewith Employee Wellness
Throughout the year, opportunities for wellness
activities are offered to employees, including global
5K walks and runs, Wellness Wednesdays, Wellness
Fairs, and virtual walk the world for charity events
through our wellness fitness platform.
Our EMEA HR Team expanded these efforts with afocus on mental health and well-being efforts, suchas the mental health advocates program, mental
health awareness session for leaders, sponsoring
the annual well-being day, and partnering with a UKcharity offering employee wellness session.

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

CSR Strategy & GovernanceCompliance

OperateResponsibly

Ethics and Integrity

AccessCommunity

Data Security and Privacy

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix67

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

CSR Strategy & GovernanceCompliance

Ethics and Integrity

Strategic Approachand Impact
We are committed to conducting ourselves with honesty,
integrity, and respect for all.
Doing the right thing is core to who we are. Our role as a genomics
pioneer brings with it the responsibility to enable innovation for
good, ensuring that the technology we create and the data wecollect are used safely, ethically, and responsibly.
K E Y O B J ECT I V ES

1 Practice strong corporate governance
2 Maintain a culture of compliance
3 Act with integrity in all that we do
4 Uphold high standards for data security and privacy
5 Foster a responsible supply chain
6 Participate in proactive public policy

AccessCommunity

Data Security and Privacy

Sustainability

Responsible Supply Chain

Operate Responsibly

Appendix
68

Public Policy

2030 Target

2022 Progress

Achieve 20% spend with diverse suppliers (US)18%

100% strategic suppliers committed toreducing their environmental footprint

100%

Achieve top industry ESG ratings

Ongoing

Position Illumina as the most trusted
company in genomic privacy and ethics

Ongoing

2022 Highlights

For us, doing the right thing is more thanjust compliance. It is having a deep senseof integrity and honoring the trust placedin us by employees, patients, customers,
shareholders, and communities.
UN SDGs

Gwen Chapman
Chief Compliance Officer

People33% Board members are women

33% Board members represent
racial/ethnic diversity$269 million (US)diverse supplier spend

100% Illumina core facilities
participated in third-party
audit programs1

Achieved ISO 27701 for Privacy
Information Management
on Illumina's six cloud-based
products

Industry Leader in multiple
ESG rating and ranking
indices including DJSI,
Sustainalytics, and CDP

Completed first Human
Rights Impact Assessment

72 approvals from58 regulatory agencies

Core facilities defined as San Diego, Bay Area, Madison, Cambridge, UK, and Singapore.

1Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

CSR Strategy & GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

Practice Strong
Corporate GovernancePeopleSustainability

Responsible Supply Chain

Operate Responsibly

Appendix69

Public Policy

Board of Directors

By exercising strong corporate governance, we aim to inspire
confidence in the work we do and in our company’s future.
Board of Directors

Board ESG Governance

Our Board of Directors is a diverse group of leaders
who champion scientific innovation. The Board’s aim
is to ensure the company is equipped with the tools
it needs to accelerate the power of genomics. The
Board has adopted Corporate Governance Guidelines
which are founded on a commitment to building
shareholder value, with an emphasis on responsible
governance. These guidelines, together with theCode of Conduct and Board Committee Charters,
provide the framework for corporate governanceat Illumina.

The full Board provides ESG oversight, and this past
year we expanded the remit of the Nominating/Corporate Governance Committee to assist theBoard in overseeing the Company’s material
environmental, social, and governance matters (ESG),
except as specifically delegated to another Board
committee. The Compensation Committee continues
to oversee and provide input to management on
diversity and inclusion matters, and the Audit
Committee continues to oversee cybersecurity.
Learn more in Governance →Our Board has established four standing committees.
Learn more in each committee charter:

Diverse and Independent Board

Audit Committee
Compensation Committee
Nominating/Corporate Governance Committee
Science and Technology Committee

As stipulated in our Corporate Governance
Guidelines, our company seeks to achieve a mixof Board members that represents a diversity ofbackground and experience, including with respect
to age, gender, international background, race, andspecialized experience.
Our Corporate Governance Guidelines also requirethat independent directors constitute at least amajority of the Board. In order to be independent
directors of the Company, directors must meet thecriteria for director independence established by the
Nasdaq Stock Market.

John W. Thompson (Chair)Francis deSouza

Frances Arnold, PhD

Caroline Dorsa

Robert S. Epstein, MD

Scott Gottlieb, MD

Gary S. Guthart, PhD

Philip Schiller

Sue Siegel

Board Profile

89%

Independent
directors

33%

Femalerepresentation

33%

Minority
representation

More details about the Board can be found in our Proxy and on our corporate website.

6.6 Years
Average Board
tenureIntroduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

Maintain a
Culture ofCompliance
We take pride in conducting ourbusiness with honesty, transparency,
and in accordance with legal
standards and ethical principles.
Our culture of compliance and ethics starts at theBoard level and is incorporated into every level of ourbusiness. Our policies guide employees on how toapply a culture of compliance to their daily work.

Illumina Code of Conduct
The Illumina Code of Conduct promotes honest andethical conduct, compliance with applicable laws
and regulations, and protection of our businessinterests. The code applies to all Illumina employees,
consultants, temporary workers, officers, andmembers of the Board of Directors, regardless oflocation, seniority level, business unit, function, or
region. Key topics of our Code of Conduct include
fraud prevention, bribery and corruption, antidiscrimination, anti-harassment, human rights,
diversity and inclusion, employee safety, corporatesocial responsibility, marketing and sales claims, andgovernment interactions and political activity.
CODE OF CONDUCT

12 languages

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Community

Data Security and Privacy

Training
We provide annual training on our Code of Conduct
and Anti-Bribery and Anti-Corruption Policies for all
employees globally and more focused training onother Illumina compliance-related policies.
All employees receive training when onboarded
and are annually certified through our enterpriselearning management system. On an annual basis,all employees are assigned Code of Conduct training
through our enterprise learning management system
and are required to electronically acknowledge thatthey have read, understood, and will abide by our
Code of Conduct.

TRAINING

100% of employees* are assigned training annually
98% completed the web-based training
and certified they have read and understand thecode in 2022
*Including FTEs, contractors, consultants, and interns

Expanded Oversight for Clinical Environments
At Illumina, we are at the forefront of the evolutionof genomics from pure research to in vitro
diagnostic (IVD) medical devices. With thisevolution, we operate in the ever-changing, highly
regulated IVD market and often interact withhealth care professionals and government officials,
representatives, and agencies that regulate themarkets in which we do business. Illumina iscommitted to high standards of ethical businessconduct, including compliance with all applicableanti-bribery/corruption and anti-kickback laws, aswell as relevant medical device industry codes.

PeopleSustainability

Responsible Supply Chain

Operate Responsibly

Appendix
70

Public Policy

Compliance Committee
Illumina’s Compliance Committee is a standing
committee responsible for ensuring that thecompany continues to conduct its operations andactivities ethically, with the highest level of integrity,and in compliance with all legal and regulatory
requirements. The Compliance Committee oversees
the development, maintenance, and monitoring of
global, legally-sound, practical, and sustainable
programs (collectively the Compliance Program)intended to satisfy the company’s legal complianceobligations and to foster a culture of compliancewith laws, regulations, industry standards, andcompany policies.

Ethics and Compliance Reporting
We are committed to fostering a culture in which
employees feel comfortable raising compliance andethics concerns without fear of retaliation. We promote
an open-door policy that encourages our employees
to raise concerns to their managers, HR, and theCompliance Department directly. We have establisheda third-party Compliance and Fraud Prevention Hotline
and website that Illumina employees and others may
use to report concerns anonymously.
Illumina takes the obligation to investigate reports
of potential violations of law, non-compliance with
Illumina’s Code of Conduct and corporate policies,
and unethical conduct very seriously. The company
is committed to impartially investigating all suchreports where warranted and in remediating any such
violations in a fair and consistent manner. Illumina
takes all reasonable steps permissible to protect
reporting or cooperating parties from retaliation.

Illumina’s Compliance and Fraud Prevention Hotline
is available to both employees and third-party
partners, 24/7 by phone or online.

K E Y P O L I C I ES

Code of Conduct
Compliance Program Framework
Anti-Corruption/Anti-Bribery
Anti-Competitive Behavior
Interactions With Healthcare Professionals
Compliance Information
Ethics Information
Ethics Advisory Board Charter
Ethics Advisory Board Members

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

CSR Strategy & GovernanceCorporate GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

Anti-Bribery/Corruption

Risk Management

We prohibit bribery and corruption in any form. We
comply with applicable anti-corruption laws in the
countries in which we conduct business, includinglaws that prohibit bribery of government officials
and employees of commercial organizations. Illumina
personnel and our sales channel partners worldwide
are prohibited from directly or indirectly offering,promising, paying, giving, or authorizing the givingof any financial or other advantage, or anything ofvalue, to any other person or organization in order toexert improper influence over the recipient, induce
the recipient to violate his or her duties, secure an
improper advantage for the company, or improperly
reward the recipient for past conduct. We require
our business partners (e.g., channel partners, andconsultants) to maintain the same standards whenacting on our behalf.

Illumina has adopted a company-wide approach, through various
mechanisms, to assess and manage risks. We endeavor to ensurethat all employees adhere to our ethics and compliance protocols. Our
Enterprise Risk Management (ERM) framework has been established
to anticipate, assess, monitor, manage, and report on risks that could
impede our business and identify emerging issues and opportunities.
We have implemented a corporate, global, Business Continuity
Planning (BCP) program to reduce risk exposure and mitigate negative
events to business operations. The ISO 22301:2019 standard is used
as a business continuity framework for this program. Additionally, theInternal Audit Department independently and objectively assesses risk
and reports insights to the Audit Committee of the Board of Directors
on a quarterly cadence.

Anti-Competitive Behavior
We work to compete and succeed in a fair andhonest marketplace. We do not engage in unethical,
unfair, or illegal communications with competitors.
We always deal fairly with customers, suppliers,
competitors, and employees. We do not takeunfair advantage of anyone through manipulation,
concealment, abuse of privileged information,
misrepresentation, or any other unfair-dealing
practice. We do not enter into formal or informal
agreements with competitors to engage in any
anti-competitive behavior, including setting prices
or dividing up customers, suppliers, or markets. We
comply with all laws related to competition, antitrust,and the gathering of competitive information. In orderto promote fair and honest competition, we minimize
contacts with competitors and always avoid sensitive
subjects, including those relating to competition
between the company and others.

Our risk assessments consider various quantitative and qualitative
inputs, including:Business and Finance

Product Quality

Operational

Employee

Legal and Regulatory

Environmental, Health, and Safety

Brand and Reputation

Climate (physical and transition)

Learn more about our risk factors in our 10K.

Climate Resilience
At Illumina, we believe addressing climate change is one of the
key topics to achieving a sustainable, just, and resilient future
for all. We are committed to climate action and the integration ofclimate resilience planning into our risk management program. See
Sustainability → for additional information and the Appendix → foradditional details on our Task Force on Climate-related Financial
Disclosures (TCFD) index.

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix71Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

CSR Strategy & GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

PeopleSustainability

Responsible Supply Chain

Public Policy

Act with Integrity

We are committed to reflecting the very best of our people, practices, and purpose.
Integrity and fairness are central to how we operate in the workplace and the marketplace.
Ethical Business and Use of Genomics
Ethics Advisory Board

Ethical Use of Genomic Technologies

Ethical Artificial Intelligence Principles

We seek guidance from our Ethics Advisory Board on a
range of strategic issues, including recommendations
on emerging ethics matters, policies, and regulations
that are relevant to the genomics industry. We meet with
the Ethics Advisory Board on a quarterly basis. Work
includes providing strategic advice to Illumina about:

Illumina is steadfast in our commitment that genomic
technologies should be used to benefit humanity,
and we will only work with partners who further thismission. Our Human Rights Policy and customer
agreements outline our expectations regarding
ethical business conduct, the use of our technology,
and the steps we can take in the event of a possible
violation. We have expanded and enhanced ouroversight and accountability processes to monitor
and enforce these commitments and prevent sales
that could result in misuse or human rights concerns
before they happen. Illumina is committed toinvestigating potential reports of product misuse
and will not hesitate to cease sales to business
partners in the event of a confirmed ethics orhuman rights concern.

Illumina is dedicated to improving human health byunlocking the power of the genome. Our mission
drives everything we do, including the technology
we develop. Illumina creates and uses artificial
intelligence (AI) systems to power industry-leading
sequencing quality, fuel data insights, improveunderstanding of genomic variation in relation to
health and disease, and advance genomic science.
We define AI systems to include machine learning,
deep learning, and predictive modeling. Illumina iscommitted to developing and using AI according toapplicable laws and the following guiding principles:

Emerging policies andregulations relevant to
the genomics industry
and the company’s
interests

Ethical issues
arising from
specific technology
or products

K E Y I N I T I AT I V ES

• Ethics Advisory Board
Clement Adebamowo,
BM, ChB, ScD, FWACS, FACS

Leslie Biesecker, MD

Glenn Cohen, JD• Human Rights
Oversight andAccountability
Framework• Human Rights
Response Playbook
for Product Misuse

Freda Lewis-Hall, MD,
DFAPA, MFPM

Nita Farahany, JD,
PhD

Charmaine Royal,
MS, PhD• Human Rights Impact
Assessment• Illumina Connected
Analytics Impact
Assessments (includes
ethical AI, privacy, andhuman rights analysis)• International Best
Practices for Genomic
Data Sharing• Genomic Ethics
Documentary Series• Transparency• Values-driven design• Diversity,
nondiscrimination,and fairness• Accountability

Learn More
Privacy Policy
Privacy Principles
Privacy Transparency Report
Responsible Stem Cell Use Position Statement
Animal Testing Position Statement
Ethical Artificial Intelligence Principles

Operate Responsibly

Appendix72

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

Ethical Marketing
The claims we make about our products must be
truthful and accurate. All information we provide
to our customers about our products, including
those that are involved in providing health careservices, must be consistent with the applicablelabel and consistent with local legal and regulatory
requirements.
Our Responsibilities• Represent our products and services fairly,
truthfully, and accurately. Promote them only for
their approved uses
• Do not create by statement or omission any
misleading impressions in any advertising,marketing or sales materials, or in any presentations• Do not overstate the efficacy of our products,
downplay or minimize the risks associated with
our products, or make false or illegal claims aboutor comparisons to the products or services of acompetitor

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Community

Data Security and Privacy

Affordability and Pricing
Transparency
Illumina is committed to offering prices that enablebroad access to genomic technology. We maintaina responsible approach to pricing our products. We
negotiate and partner with health care systems,
payers, and research institutions to provide
availability of our products at a fair net price.
To support our customers and increase access,Illumina has:
• Launched the NovaSeqTM X, a new productionscale sequencer that will push the limits of what is
possible with genomic medicine, enabling faster,
more powerful, and more sustainable sequencing• Partnered with GenoScreen to expand capabilities
for countries impacted by tuberculosis to more
effectively detect and combat multidrug-resistant
TB (MDR-TB). This will help advance the World
Health Organization’s (WHO) strategy to end theglobal TB epidemic by 2035

• All advertising and promotional materials must
adhere to our advertising and promotional materials
guidelines and policies• Continued to expand the open offer program, which
ensures a level playing field in the clinical oncology
NGS market• Do not use messages or marketing materials thathave not been properly reviewed and approved
following company policy and procedure

Illumina sets and adjusts list prices based on
several factors, including but not limited to costs,
inflation, and market dynamics. Prices are available
to customers through their account managers or
online on myIllumina.com. Prices are also visible tocustomers on their invoices and billing statements.
As in past years, Illumina’s price increases were ator below inflationary indices, while absorbing manyof the temporary cost increases driven by global
supply chain issues. For example, in the US in 2022,
the Illumina annual price change was below the US
Consumer Price Index (CPI).
Illumina pricing reflects its value proposition andenables the company to continue to innovate for ourcustomers and accelerate access to genomics for all.

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix73

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

CSR Strategy & GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

Upholding Human Rights
for All Stakeholders
We are committed to respecting human rights andtreating every stakeholder with dignity and respect.
We acknowledge and respect the fundamental
principles contained in the International Bill of Rights(i.e., United Nations Universal Declaration of Human
Rights, International Covenant on Civil and Political
Rights, and International Covenant on Economic,
Social, and Cultural Rights), the International Labor
Organization’s Declaration on Fundamental Principles
and Rights at Work, and the United Nations Guiding
Principles on Business and Human Rights. As amember of the United Nations Global Compact,
Illumina is committed to integrating these principles
into our strategy, our culture, our operations, and ourrelationships with business partners
Key Pledges of Our Human Rights Policy• Ethical business conduct• Supplier Code of Conduct• Right to exercise freedom of association• Fair wages and working hours• Protection of privacy• Safe workplace• Elimination of child and forced labor• Equal opportunity

Human Rights Impact Assessment
In 2021, we initiated a humanrights impact assessment inalignment with the UN Guiding
Principles. The assessment
continued into 2022 as weevaluated internal policies,
external disclosures, and worked
to map actual and potential
salient human rights impacts.
In 2022, we continued theevaluation with the goal ofidentifying Illumina's salient
human rights impacts, Illumina's
current practices for protecting
and promoting these rights,
and ways in which Illumina cancontinue to build on its humanrights practices.
We reviewed the International
Bill of Human Rights, theInternational Labor Organization's
Declaration on Fundamental
Principles and Rights at Work,and the United Nations Guiding
Principles on Business andHuman Rights.

Read the full Human Rights Policy here
K E Y P O L I C I ES

Human Rights Policy
Human Rights Policy—Japanese
Conflict-Free Minerals Policy
California Transparency in Supply Chains Act, UK Modern Slavery Act,
& Australian Modern Slavery Act Disclosure Statement 2022

We identified four salient humanrights impacts:• Right to equality and nondiscrimination• Right to privacy• Right of everyone to the highest
attainable standard of healthand to enjoy the benefits ofscientific progress and its
applications
We engaged with internal
stakeholders across Illumina's
departments to understand how
Illumina impacts these salient
human rights and to identify
opportunities for growth relevant
to each area.
We will continue to work acrossthe business to continuously
improve and support existing
efforts.

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix74

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Data Security and Privacy

Uphold High Standards
for Data Security and Privacy
As we expand access to genomics
around the world, we must also
respect and properly secure theresulting data.
Genomics data is powering positive progressaround the world. We are committed to developing,
upholding, and promoting high standards for genomic
data privacy. We develop, implement, and review
privacy-related policies, practices, and contractual
language and ensure the integration of privacy as apriority throughout the company. Our Privacy Policy
defines the way we use, maintain, protect, disclose,
and transfer personal information.

Our Privacy Principles
Our Privacy Policy defines how we may use, maintain, protect,disclose, or transfer certain types of personal information in
the provision of our products and services. How we handle
personal information is aligned to our four fundamental privacy
guiding principles:• Transparency• Ethical Use• Responsible Stewardship• Accountability

Key Initiatives in 2022
• The cross-functional Privacy Core Team and Privacy Steering
Committee brought together leaders from across thebusiness to advance Illumina's privacy program• Submitted EU Binding Corporate Rules application (controller
and processor) as a privacy program maturity effort regarding
cross-border data transfers within the group• Achieved ISO 27701 certification for Illumina’s six cloud-based
products for Privacy Information Management• Revised Illumina’s privacy and employee privacy policies toalign with California’s Privacy Rights Act and evolving global
privacy regulations
Learn More
Privacy Policy
Privacy Principles
Privacy Transparency Report

Community

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix75

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate GovernanceCompliance

Ethics and Integrity

Cybersecurity Framework

Community

AccessCSR Strategy & Governance

Data Security and Privacy

Responsible Supply Chain

Strong cybersecurity measures are a necessary component of modern
IT systems. Maintaining a safe and trustworthy platform for our customers
and the communities we serve is fundamental to our business.

Program Governance76• NIST Cybersecurity
Framework• California Consumer Privacy
Act (CCPA)CY B E R S EC U R I T Y
AWA R E N ES S M O N T H• ISO 27001• Health Insurance Portability
and Accountability Act(HIPAA)

Each October, we recognize
Cybersecurity AwarenessMonth (CSAM), which provides
heightened awareness regarding
cybersecurity events, threats,
attacks, and best practices that
all employees can follow to help
keep Illumina and its data safe
from cyber threats.

• ISO 13485• General Data Protection
Regulation (GDPR)

Carissa Rolins
Chief Information Officer

2

Appendix

Public Policy• Clinical Laboratory
Improvement Amendments(CLIA)

Learn More
Cybersecurity Illumina Security Resources and Best Practices

1

Operate Responsibly

K E Y R E F E R E N C ES

Our technologies and services inherently involve handling large amountsof genomic and health data that must be protected, making cybersecurity
integral to achieving our company’s mission.

The Five Pillars of Our Cybersecurity Commitment

Partnerships

3

4

Secure Product Design
and Placement

Risk Analysis andSecurity Testing• Products and systems secured andmaintained throughout life cycle• Continuously assess cybersecurity
risk• Risk mitigation at earliest stages of
product design and placement• Perform internal and external
security testing for all cloud software
products• Led by Chief Information Security
Officer (CISO)• Healthcare Information Sharing andAnalysis Center (H-ISAC)• CISO reports at least quarterly to theBoard of Directors’ Audit Committee• Domestic Security Alliance Council(DSAC)• Annual assessment against
National Institute of Standards andTechnology (NIST) Cybersecurity
Framework• Information 2 Systems Security
Association International (ISSA)• Employees and contractors trained
annually• Society for Information Management
San Diego (SIM)• Cloud-based products aligned withISO 27001• Chief Information Security Officer
Roundtable• Privacy by design• InfraGard• Strict data access controls• Third-party work requires
cybersecurity risk assessment prior
to engagement

PeopleSustainability• Security design requirements• Strong encryption standards• Regularly put cloud software
products through static analysis• Incident response plan and teamin place to handle cyber-related
disruption with business continuity
and contingency plans• Internal vulnerability analysis
conducted• Internal tests deployed to represent
simulated hacker attacks

2,486

employees participated in
our Cybersecurity Awareness Month activities

10%

increase in total
participation. Uniqueparticipants increased
35% YOY

5

Data Protection• Data protected in compliance withapplicable laws and cybersecurity
best practices• Data privacy and data protectionalign with standards set by GDPR,
CCPA, HIPAA, other regulations, and
our Privacy Policy• CLIA laboratories ensure data quality
and security with CLIA and regular
HIPAA framework assessments• Backup capabilities encrypt andstore data in immutable formats fordata confidentiality and integrity• Amazon Web Services (AWS) hosts
the Illumina BaseSpace Suite withadditional security features

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Community

Data Security and Privacy

Sustainability

Responsible Supply Chain

PeopleOperate Responsibly

77

Public Policy

Foster a Responsible Supply Chain
Our suppliers are critical to our mission. Together, we magnify the positive
impact to the customers we serve and the communities where we operate.
Supply Chain Overview
Illumina’s global supply chain consists of suppliers,sub-contractors, channel partners, manufacturing
sites, distribution centers, and customers. We
consider it business-critical to work with suppliers
who share our commitment to integrity and who
support an ethical and compliant culture. We view
our suppliers as partners in our effort to work
toward a more equitable and sustainable future
for all.
We hold our suppliers to the same standardsof business conduct that we set for ourselves.
We require them to comply with the standardsof behavior outlined in our Supplier Code of
Conduct and exhibit social responsibility andenvironmental stewardship.
The Supplier Code of Conduct is consistent withcommitments we made both as a signatory of theUnited Nations Global Compact and as a memberof the Dow Jones Sustainability World Index.
We expect our suppliers to:• Comply with local regulations and applicable US
and international regulations• Uphold their employees’ human rights and theIllumina Human Rights Policy• Ensure a safe and healthy workplace• Demonstrate social and environmental
responsibility• Conduct business in an ethical mannerSocial impact and environmental screening are
included in our Request for Information (RFI) tools
when evaluating potential suppliers.
All new suppliers are required to acknowledge
the Supplier Code of Conduct to complete theonboarding process.
In 2022, we embedded the requirement for suppliers
to commit to reducing their environmental footprintin our Supplier Code of Conduct and require ourstrategic suppliers to accept this with issuance ofany purchase order.

Our suppliers range from off-the-shelf packaging
material to highly sophisticated reagents. We define
our supplier base by categories, segments, andclassification. The categories include direct andindirect, with subcategories such as a segmentclassified as Strategic Suppliers. Classifications ofsuppliers depend on the product or service they
provide, such as finished medical devices, spec,
off the shelf, and services. We source components,
software, equipment, and services from over 75
countries across the world.

AppendixO U R S U P P LY C H A I N

3,323

suppliers acrossthe supply chain>$1B

estimated payments
to suppliers$694M
direct supplier
spend

919

active diverse
suppliers$269M

diverse supplier
spend

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate GovernanceTransparency in Supply Chains and UK
Modern Slavery Act
Illumina is committed to conducting its businesslawfully and with integrity. We work to continuallystrengthen our practices to ensure no humantrafficking, slavery, or forced or compulsory labor
occurs in any part of our supply chains and global
operations. We also seek to ensure that our global
business partners do not use modern slavery in anyof its forms in providing goods or services. In 2022,
we updated our California Transparency in Supply
Chains Act and UK Modern Slavery Act disclosurestatements to include disclosures for the AustralianModern Slavery Act 2018. Additional information isavailable in our California Transparency in Supply
Chains Act, UK Modern Slavery Act, and theAustralian Modern Slavery Act disclosure statements.

Conflict-Free Minerals
Illumina supports international efforts to ensure
no conflict minerals directly or indirectly benefit
armed groups in the Democratic Republic ofCongo or adjoining countries. To this end, Illumina
expects all suppliers to commit to the Responsible
Business Alliance (RBA) Code of Conduct. Throughour Conflict-Free Minerals Policy we expect all
our suppliers to establish their own due diligenceprogram to ensure supply chains are free of conflictminerals and make those due diligence measuresavailable to us upon request. Illumina routinely
evaluates its suppliers to ensure they are adhering toour expectations and values.

CSR Strategy & GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

PeopleSustainability

Responsible Supply Chain

Public Policy

Verification and Due Process

Channel Partners

We only build relationships with business partners
that share our commitment to fulfilling all legal andethical obligations. We never knowingly conductbusiness with business partners that employ
underage individuals, employ forced labor, or use
corporal punishment to discipline employees,
regardless of whether such practices are permitted
by law.
We perform due diligence on new business
partners to verify that they meet our standards.
This process involves conducting initial risk
assessments when onboarding new suppliers andconducting periodic assessments of performance.
In addition, for supply chain areas of higher risk, wetake steps to enhance our risk mitigation strategies.
Prior to engaging in business with any supplier, we
utilize tools that provide up-to-date sanction lists
from governments around the world that identify
companies and individuals involved in criminal
activities such as money laundering, financing
paramilitary groups, etc. In addition, we utilize
tools to continuously monitor our supplier base forpotential risk elements such as financial stability,
leadership changes, global news, and others.
We encourage all employees and business
partners to report potential violations or concerns
through a variety of formal channels, including
our legal team and/or our Compliance and Fraud
Prevention Reporting website or hotline.

Our products are available around the globe througha robust channel partner network. Our partners not
only offer critical access to our products throughout
the world but also provide the same level of sales,
marketing, service, and support that we offer tocustomers directly. The Illumina Channel Partner
Code of Conduct requires that channel partners
match the Illumina commitment to business integrity,
ethical conduct in the marketplace, adherence to allapplicable laws, and the fundamental elements ofhuman rights. Illumina is a member of the Advanced
Medical Technology Association (AdvaMed) and
MedTech Europe. Channel Partners are required toadhere to the applicable provisions of the AdvaMed
Code of Ethics and MedTech Europe Code of EthicalBusiness Practice.

Supplier Sustainability
In 2022, we assessed 100% of our supply chain aspart of our Scope 3 emission data collection.
Learn more about Supplier Sustainability →Learn More
Channel Partner Code of Conduct
California Transparency in Supply Chains Act &UK Modern Slavery Act Disclosure Statement
Conflict-Free Minerals Policy

Operate Responsibly

Appendix78

Introduction

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Corporate Governance

CSR Strategy & GovernanceCompliance

Ethics and Integrity

AccessCommunity

Data Security and Privacy

Sustainability

Responsible Supply Chain

PeopleOperate Responsibly

Appendix79

Public Policy

Supplier Diversity
Our supplier diversity efforts aim to cultivate a supplierbase that reflects the diversity of our communities,
customers, employees, and the local economies where
we operate.
We recognize that a diverse supplier base provides acompetitive business advantage by harnessing suppliers’
unique experiences and creative solutions. Our program,overseen by a Supplier Diversity Governance Committee,
promotes partnership opportunities for suppliers in the
US that are at least 51% owned, managed, and controlled
by a qualifying diverse group.

25% of total diverse
supplier spend attributed
to woman-owned
businesses

Active diverse
suppliers
2019: 400
2022: 919

35% of total diverse
supplier spend attributed
to minority-owned
businesses

Diverse supplierspend (US)2019: $190M
2022: $269M

These include, but are not limited to:• Woman-owned• Minority-owned• Veteran-owned• Disabled person-owned• LGBTQ-owned• Socially andeconomicallydisadvantagedowned businesses• Certified small
businesses

Globally, we encourage the use of local businesses
wherever possible to support the economies where our
employees work and live. Our program is expanding toinclude woman-owned businesses in APAC and small
businesses in Great Britain.
As part of our operational controls to embed supplier
diversity in our supplier management, we require a
mandatory internal training certification on supplier
diversity for our procurement sourcing managers throughour learning management system (LMS). In 2023, weplan to include diversity screening in our Request for
Information and Request for Proposal process further
strengthening the operational controls to support
diverse suppliers.
Learn More
Supplier Code of Conduct
Supplier Diversity Program

2030 TARGET

2022 PROGRESS

20%

18%

spend with diverse
suppliers (US)spend

Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Data Security and Privacy

Product Quality

Supplier Quality Vision and Values

Illumina is dedicated to being the leading provider ofintegrated solutions that advance the understandingof genetics and health. We achieve this through our
focus on the customer experience, our commitment tocontinual improvement, maintaining the effectivenessof our quality management system, and complying
with regulatory requirements.
During 2022, we issued zero medical device
product recalls that were reported to the FDA.
There was one medical device voluntary recall
that was not required to be reported to the FDA.
There were five voluntary medical device recalls/
field actions that were reported to non-US national
regulatory authorities and removed from the market
or corrected.

To ensure the quality of our products, we have toensure the quality of the components that we source.
That is the rationale behind the Illumina Supplier
Quality Vision, which is to construct and foster aleading supplier base that ensures safe and quality
products every time.
The supplier quality management life cycle
incorporates the following phases:

Quality Management Systems
The following locations are certified to the ISO
13485 Standard, which specifically covers thequality of medical devices:• Foster City, CA• San Diego, CA• Initial risk assessments• Audits• Qualification• Monitoring

Working with our suppliers, we focus on the customer
experience, continual improvement, effectivenessof our quality management system, and compliance.
All Illumina Direct Tier 1 suppliers are subject toonboarding and qualification per Illumina Purchasing
Controls. All products have traceability, and inventory
is tracked via our inventory management system,
SAP. Products may contain bar code, lot numbers,
and/or unique identifiers.

Supplier Quality Management Cycle• The Netherlands

A quality management system is a critical aspect atevery stage of the product life cycle to ensure thatpolicies and objectives are in place and productquality standards are of the highest caliber.

• Singapore• Supplier selection & evaluation• Cambridge, UK• Supplier qualification• Hayward, CA• Madison, WI• Supplier monitoring• Component qualification

100%

Illumina core facilities1 participated in thirdparty audit programs
Core facilities defined as San Diego, Bay Area, Madison,
Cambridge, UK, and Singapore.
1

Learn More
Supplier Quality Manual
Quality Policy Statement

Community

Sustainability

Responsible Supply Chain

PeoplePublic Policy

Operate Responsibly

Appendix80Message from the CEO
CY’22 CSR Report

Strategic Approach and Impact

Introduction
Corporate Governance

AccessCSR Strategy & GovernanceCompliance

Ethics and Integrity

Community

Data Security and Privacy

PeopleSustainability

Responsible Supply Chain

Public Policy

Make Responsible
Public Policy Decisions
Proactive engagement with public policy stakeholders enables
sharing accurate and reliable information about genomics andadvocating for policies that promote broad access.
Illumina participates in the political and public policy
process with governments and organizations aroundthe world to engage and educate policymakers andkey stakeholders on issues that impact our mission
and business.
Our interactions with policymakers must alignwith our core values, ethical responsibilities, andlegal obligations. The Illumina Nominating/Corporate
Governance Committee of our Board of Directors
oversees our political policies and contribution
practices. The Committee maintains responsibility
for ensuring all Illumina political activities promote
ethical and transparent engagement, advance thecompany’s mission, and comply with applicable laws
and reporting requirements. On an annual basis, we
provide an update on our public policy priorities,
political contributions, lobbying expenditures, andinformation about significant memberships. Our
Global Government Affairs team is responsible foradvocacy activities. Illumina does not have a Political
Action Committee but does retain outside strategic
advisors who support our global engagementwith policymakers and key stakeholders. These
advisors may also provide expertise on policy andspecific regional issues.

Illumina complies with all applicable laws andrequirements in connection with our global politicaland public policy activities. These laws generally
require reporting on lobbying activities and compliancewith applicable gift laws.
Reports filed on behalf of Illumina are publicly available
in the following government-hosted databases:
Office of the Clerk, US House of Representatives
Secretary of the Senate, US Senate
Lobbying Disclosure, California Secretary of State
Transparency Register, European Commission

Trade Associations and Memberships
Illumina participates in various trade associations forcollaboration and the exchange of ideas. We pay annual
dues to a number of trade and industry associations,some of which use a portion of membership dues for
nondeductible state and federal lobbying and politicalexpenditures. We disclose memberships in tradeassociations for which we contributed over $5,000 in
the immediately preceding year, as well as the total
amount of such dues.
For trade association payments in excess of$50,000, we also disclose the portion of
payments that are nondeductible under Section
162(e)(1)(B) of the Internal Revenue Code, suchas payments to organizations designated as
501(c)(4) and 501(c)(6).

Texas Ethics Commission

Learn More
Political Contribution Policy

Advocating for public policies that ensure and enablebroad access to genomic technologies is a priority.
In 2022, we focused engagement with public policy
stakeholders around:

Political Contributions Spend Report, Trade
Association and Significant Membership Report →• Advancement of precision medicine• Adoption and reimbursement for genetic testing• Adoption and reimbursement for NIPT
• Adoption and funding for genomic infectious disease
surveillance• Promoting STEM opportunities

As Illumina’s impact on clinical healthcare
grows, government and industry stakeholders
expect that we will engage with them on
how genomics can better serve patients,
individually and at global scale.

John Frank
Chief Public Affairs Officer

Operate Responsibly

Appendix81

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Appendix

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleDisclosures

Operate Responsibly

Appendix82Introduction

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

Community

AccessSASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix

Disclosures

About this Report
Our report has been designed to provide a comprehensive and integrated view of ourcommitments, progress, and activities related to our corporate social responsibility
program and most material environmental, social, and governance (ESG) themes.

Signatory Participation

Boundaries and Exclusions• UN Race to Zero

The boundary of this report includes only core Illumina activities.
In 2021, Illumina acquired GRAIL. GRAIL must be held and operated separately
and independently from Illumina pursuant to the interim measures ordered by
the European Commission, which prohibited the Illumina/GRAIL transaction on 6
September 2022 under the EU Merger Regulation. Data contained in this report
does not reflect any GRAIL operations, financial results, or ESG data.

• United Nations Global Compact (UNGC)• We Mean Business Coalition 1.5º

285 Recognition
86 Key Performance Indicators• STEMM Opportunity Alliance

86 About Illumina• CEOs for Computer Science

86 Accelerate Access to Genomics

Reporting Frameworks• In accordance with the GRI standards

January 1, 2022, to December 31, 2022, unless otherwise indicated.

• Task Force on Climate-related Financial Disclosures (TCFD)

105 Assurance Statements• Bloomberg Gender Equality Index

106 Disclosures• ISO 26000 as reference to provide guidance for integrationof social responsibility

Re-statements

Relevant Memberships• Business for Social Responsibility (BSR)• World Economic Forum• Association of Corporate Citizenship Professionals (ACCP)• Scope 1, 2, and 3 GHG emissions data

• Water data

• Energy data

• Human capital data

• Chief Executives for Corporate Purpose (CECP)• CSR Board.Org

Contact
We welcome your feedback at csr@illumina.com• World 50

Learn More

• Sustainable Packaging Coalition

Illumina CSR and ESG microsite• My Green Labs

Illumina ESG Reporting Hub

To access Illumina’s public facing CDP submission Learn More.

1

In 2023, the UNGC has updated the Communication on Progress reporting to an online portal. To access Illumina's participant page Learn More.

2

104 TCFD Index• CDP1US Dollars

Limited assurance has been provided in accordance with ISAE 3000
and ISAE 3410 on the following topics:

97 Operate Responsibly

103 SASB Index• HRC Corporate Equality Index

Assurance

90 Nuture Our People• UN Global Compact

Currency References

We conduct ongoing data review to ensure accuracy and consistency.
Any material data changes would be identified.

87 Integrate Sustainability

100 GRI Index• Dow Jones Sustainability Index

Based on the materiality assessment refreshed in 2021.

86 Empower Our Communities• UN Sustainable Development Goals• UN Universal Declaration of Human Rights

Materiality

84 2030 Targets• UN Women Empowerment Principles• Sustainability Accounting Standards Board (SASB)

2019, unless otherwise indicated.

83 About This Report• CEO Action for Diversity & Inclusion

Reporting Period

Baseline Year

ESG Appendix Contents

83Introduction

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

Community

AccessSASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix84

Disclosures

Our 2030 Targets
Our Focus Areas

Accelerate
Access to
Genomics

Objectives

2030 Targets

1. Drive innovation and affordability
2. C atalyze genomic startups to broaden the genomic ecosystem
3. Increase genomic data diversity
4. D emocratize genomics
5. Enable catalytic philanthropy
6. E
 xpand reach with payer coverage, genomic literacy,
and patient advocacy

Enable $100 genome
Support 50,000 patients through philanthropic iHope programming
Achieve 2 billion covered lives by 2026
Invest in 200+ genomic startups
Activate Pathogen Genomics Initiative donations enabling our$60 million commitments
Reach at least 25,000 medical education learners annually

Empower Our
Communities

1. P rovide meaningful and strategic community investment
2. E
 ngage our people to be agents of social change
3. D rive equitable access to STEM education

Reach 5 million STEM learners
Donate 100,000+ volunteer hours
Achieve 50% employee participation in giving and volunteering

Integrate
Sustainability

1. D rive climate action
2. O perate sustainable facilities
3. F oster a sustainable value chain
4. D evelop sustainable products
5. L everage genomics for a healthier planet

Deliver net zero emissions(Scope 1,2,3) by 2050
Reduce emissions by 46%(Scope 1,2)
Reduce emissions by 46%(Scope 3)
Achieve 100% renewableelectricity
Reach 90% landfill diversion
at core sites

1. P ractice diversity, equity, and inclusion
2. Invest in our people
3. C reate a culture of care

Increase gender representation in global leadership
Maintain zero net pay gap
Increase minority representation in executive leadership (US)Increase representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more in US workforce and leadership
Reduce recordable injury and illness rate

1. P
 ractice strong corporate governance
2. M aintain a culture of compliance
3. A ct with integrity in all that we do
4. F oster a responsible supply chain
5. Uphold high standards for data security and privacy
6. Participate in proactive public policy

Ensure 100% strategic suppliers committed to reducing theirenvironmental footprint
Achieve 20% spend with diverse suppliers (US)Achieve top industry ESG ratings

NurtureOur People

OperateResponsibly

Achieved

Reach 10% reduction inwater intensity at core sites
Reduce packaging
by 75%
Invest $20 million inphilanthropic sustainability
initiatives
Have 100% of strategic
suppliers commit to minimizing
their environmental footprint

In Progress

UN SDG Target Alignment

Target 3.d: Improve early warning
systems for global health risks

Target 17.7: Promote sustainable
technologies to developing countries

Target 17.6: Knowledge sharing andcooperation for access to science,technology, and innovation

Target 17.16: Enhance the global
partnership for sustainable
development

Target 10.3: Ensure equal
opportunities and end discrimination

Target 5.b: Promote empowerment of
women through technology

Target 12.2: Sustainable
management and use ofnatural resources

Target 13.2: Integrate climatechange measures into policy
and planning

Target 12.5: Substantially reduce
waste generation

Target 10.3: Ensure equal opportunities and end discrimination

Target 9.2: Promote inclusive andsustainable industrialization
Target 10.3: Ensure equal
opportunities and end discrimination

Target 17.16: Enhance the global
partnership for sustainable
development

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix85

Disclosures

Recognition 2022
Workplace• Glassdoor Best Place to Work
• BioSpace Best Place to Work• Refinitiv Top 100 Global D&I Index• Just Capital Top 100 US Companies
Supporting Healthy Communities & Families• Just Capital Workforce Equity & Mobility• Wall Street Journal Top 250

Regional• SANDAG Green Commute Award San Diego• AmCham Cares CSR Singapore• MIT Tech Review 50 Smartest Companies in China• Water Efficiency Building (WEB) Singapore• Best Employer Straits Times Singapore• Workplace Safety Award Singapore

Leadership• Most Responsible CEO | Francis deSouza• Top Chief Human Resource Officer | Aimee Hoyt
• Savoy Most Influential Black Exec | Kathryne Reeves• Forbes 50 over 50 | Susan Tousi

1|1|3

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix86

Disclosures

Key Performance Indicator Summary
Introduction
GeneralName of organization
Location of headquarters
Number of global locations
Nature of ownership and legal form

Empower Our Communities
2022
Illumina, Inc.
San Diego, California, US
33

2019

2020

2021

2022

Illumina, Inc. + Illumina Corporate Foundation + employee giving$1,185,088$13,829,496$14,966,331$18,239,858

Illumina, Inc. + Illumina Corporate Foundation$873,088$13,255,768$14,446,500$17,676,194

Number of causes supported5

1,021

1,034

1,345

1,747

2019

2020

2021

2022

$560,088$7,146,450$9,409,966$12,379,381

2019

2020

2021

2022

$312,000$573,728$519,831$563,664

19%

20%

26%

28%

Foundation match & volunteer rewards (Dollars for Doers)$208,000$721,111$546,884$606,597

Public Corporation

Revenue$4.55 billion

Illumina, Inc. Giving

Total capitalization (stockholder’s equity) market value as of 12/31/2021$6.6 billion

In-kind product donations + cash grants

5Y CAGR

11%

10Y CAGR

15%

Illumina Corporate Foundation Giving

R&D % revenue investment

22%

Employee giving

R&D spend
Building footprint1$1.1 billion
2,649,068 square feet

Employee participation (giving)

Facility additions2

7

Charitable grants$105,000$5,388,207$4,489,650$4,887,885

Facility closures3

2

Total Foundation giving (not including employees)$313,000$6,109,318$5,036,534$5,860,477

2019

2020

2021

2022

Volunteer Hours

Expand Access to Genomics

13,980

4,236

8,772

20,142

Access to Genomics

2022

Employee volunteering

29%

5%

10%

39%

Cost per genome4~$200

Intern hours

140

1,237

800

Employee hours

520

Employee Participation

2019

2020

2021

2022

Total employee participation (giving + volunteering)

40%

24%

31%

50%

Summary of International Giving (Outside US)

2019

2020

2021

2022

Illumina, Inc.

NA

$2,894,129$7,044,842$5,994,599

Illumina Corporate Foundation

NA$635,126$1,089,892$1,980,646

Number of countries

24

29

44

46

iHope™ patients supported in 2021

439

Total iHope™ patients supported since program inception

1,704

Clinical iHope™ network sites
Professional healthcare learners
Illumina Accelerator companies funded through December 2021
NGS coverage outlook: total insured lives

28>30,00074
1.2 billion

Footnotes:
Average square feet during reporting year.
Added lab support facilities in UK, commercial locations in Milan, Dubai, and Israel, and new manufacturing locations inShanghai and Singapore.
3
Moved warehouse from Eindhoven to Steenoven and moved Brazil office.
4
Announced launch in 2022 based on US list price, assuming 120 Gb/genome, compared to NovaSeqTM 6000.
5
In order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations arethen evaluated against 1,200 watch lists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that are also
excluded from matching eligibility. Illumina currently blocks charitable organizations that have been found to discriminate
against a specific race, religion, ethnicity, sexual orientation, or gender identity.
1

Total Giving

2

STEM
Number of teachers and students engaged in Illumina STEM programs

2019

2020

2021

2022

306,170

195,000

315,000

396,865

Message from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix87

Disclosures

Key Performance Indicators

Integrate Sustainability
Energy Consumption (Units: Gigajoules)

2019

2020*

2021*

2022*

Emissions (Units: Metric Tons CO2e)

247,576

390,564

403,211375,516

0

0

0

0

1,566

3,333

2,417

2,966

503,658

561,258

581,067

228,7121

1,566

3,333

9,077

375,516505,224564,591

590,144604,228

2019

2020*

2021*

2022*

Total electricity (purchased + generated)

257,648

174,028

187,297

231,678

Purchased electricity

256,082

170,694

184,882

228,711.6

1,566

3,333

2,417

2,966.4

Total fuel247,576

390,564

403,211375,516Natural gas

247,576

390,564

403,211375,516

Total steam

0

0

0

0

China

0

0

0

0

Netherlands

73

73

74

55

Total fuel consumption from non-renewable sources
Total fuel consumption from renewable sources
Generation from renewable sources consumed by the organization
Total energy consumption from non-renewable sources
Total energy consumption from renewable sources
Total energy consumption

Energy Consumption by Activity and Region (Units: Gigajoules)

Generated electricity (on-site solar)

2019

2020*

2021*

2022*

Total Scope 1 & 2 (market-based) GHG emissions

34,40436,57326,265

18,902

Total Scope 1 & 2 (location-based) GHG emissions

34,40436,57336,91439,924Gross direct GHG emissions (Scope 1)

12,48919,701

20,296

18,902Gross market-based energy indirect GHG emissions (Scope 2)

21,915

16,8725,968

0Gross location-based energy indirect GHG emissions (Scope 2)

21,915

16,872

16,61821,022

Regional Emissions Market-Based (Units: Metric Tons CO2e)

2019

2020*

2021*

2022*

Scope 1 & 2 AMR region

22,90325,20725,06018,159

Scope 1 & 2 EMEA region

3,014

2,253

864

743

Scope 1 & 2 APAC region

8,488

9,113

341

743

Country-Specific Scope 1 Emissions (Units: Metric Tons CO2e)

2019

2020*

2021*

2022*

Electricity, heating, cooling, steam sold

0

0

0

0

Total energy consumption AMR region

380,106

445,190

469,104

473,893

Singapore

0

0

0

0

1,132

801

768

688

Total energy consumption EMEA region

47,77935,07236,35836,308

United Kingdom of Great Britain and Northern Ireland

Total energy consumption APAC region

75,75280,996

84,681

94,026

United States of America

11,284

18,827

19,454

18,159Renewable Electricity Consumption

2019

2020

2021*

2022*

Country-Specific Scope 2 Market-Based Emissions (Units: Metric Tons CO2e) 2019

2020*

2021*

2022*

Percentage of global electricity consumption that is renewable

0.6%

2%

59%

100%

China

518

0

0

On-site solar generation

0.6%

2%

1%

1%

Netherlands

384

368

8

0

Renewable electricity purchased

0%

0%

3%

37%

Singapore

8,099

8,595

341

0

Covered by Renewable Energy Credits

0%

0%

55%

62%

Footnotes:
1Renewable energy credits purchased for all non-renewable electric consumption.

General Notes:* Denotes data has been assured.
• Boundary definition for energy and Scope 1 & 2 emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities.
• Boundary definition sites represent our jurisdictional control plus material locations accounting for 96% of our total 2019 baseline footprint.
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology to calculate Scope 1 and Scope 2 emissions.
• Some segments may not add up to total due to rounding.

388

United Kingdom of Great Britain and Northern Ireland

1,425

1,011

14

0

United States of America

11,619

6,380

5,605

0

Introduction

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

AccessCSR Strategy & Governance

Recognition

Key Performance Indicators

GRI Index

SASB Index

Community
TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix88

Disclosures

Key Performance Indicators

Integrate Sustainability continued
Facility-Specific Emissions1,2(Units: Metric Tons CO2e)

Scope 1

Scope 2Market-Based

Scope 2
Location-Based

2021*

2022*

2021*

2022*

2021*

2022*

Cambridge, United Kingdom

749

681

0

0

903

971

Eindhoven, Netherlands

72

04

0

04

203

04

Foster City, California

1,359

1,506

1,403

1,403

1,906

Hayward, California

634

624

592

0

592

673

Madison, Wisconsin

1,458

1,554

2,138

0

2,138

2,695

Northcoast, Singapore

N/A

05

N/A

05

05

247

15,24813,910

1,291

0

1,580

3,443

756

564

134

0

200

325

San Diego Warehouse, California

0

0

47

0

74

96

Shanghai, China

0

0

0

0

358

220

Steenoven, Netherlands

2

55

8

0

218

541

Watson, United Kingdom

19

7

14

0

23

26

Woodlands, Singapore

0

0

341

0

8,927

9,556

San Diego Headquarters, California
San Diego i3, California

Greenhouse Gas Breakdown (Units: Metric Tons CO2e)

2019

2020*

2021*

2022*

CO2 Scope 1

12,475

19,681

19,884

18,518CH4 Scope1

7

10

375

349

N20 Scope 1

6

10

37

35

Emission Intensity Ratios (Scope 1 & 2)

Scope 3 Emissions (Units: Metric Tons CO2e)

2019

2020

2021*

2022*

Purchased Goods and Services (Category 1)

72,915

100,351

138,563

131,929

Capital Goods (Category 2)3

39,94044,057

79,53083,071

Fuel- and Energy-Related Activities (Category 3)

6,956

5,785

9,048

8,590

46,32748,256

68,93485,993

236

617

1,055

1,275

Business Travel (Category 6)3

19,350

8,913

3,959

20,040

Employee Commuting (Category 7)318,012

7,567

7,616

15,027

Upstream Leased Assets (Category 8)

1,480

733

547

830

3

Upstream Transportation & Distribution (Category 4)

3

Waste Generated in Operations (Category 5)

Downstream Transportation & Distribution (Category 9)

Assessed, not relevant

Processing of Sold Products (Category 10)

Assessed, not relevant

Use of Sold Products (Category 11)

6,968End-of-Life Treatment of Sold Products (Category 12)

2,368

Downstream Leased Assets (Category 13)

9,221

11,865

2,245

5,230

31

Assessed, not relevantFranchises (Category 14)

Assessed, not relevant

Investments (Category 15)3

23,55919,03800

Total Scope 3 Emissions

238,110242,411

323,702358,651

Scope 3 Emissions: % of Total Scope 3 Emissions

2019

2020

2021*

2022*

Purchased Goods and Services (Category 1)

31%

41%

43%

37%

Capital Goods (Category 2)3

17%

18%

25%

23%

3

Fuel- and Energy-Related Activities (Category 3)

3%

2%

3%

2%

Upstream Transportation & Distribution (Category 4)3

19%

20%

21%

24%

2019

2020*

2021*

2022*

Waste Generated in Operations (Category 5)

0.1%

0.3%

0.3%

0%

GHG emission intensity per million dollars revenue

9.8

11.4

5.8

4.2

Business Travel (Category 6)3

8%

4%

1%

6%

GHG emission intensity kgCO2e/square feet

13.8

15.1

10.4

7.5

Employee Commuting (Category 7)3

8%

3%

2%

4%

GHG emission intensity per employee

4.4

4.7

2.9

1.8

Upstream Leased Assets (Category 8)

0.6%

0.3%

0.2%

0%

Emission Intensity Ratio (Scope 3)

2019

2020*

2021*

2022*

GHG emission intensity per million dollars revenue

72.6

71.3

66.1

78.8

Use of Sold Products (Category 11)

3%

2%

3%

3%

End-of-Life Treatment of Sold Products (Category 12)

1%

0.9%

2%

0%

Investments (Category 15)3

10%

8%

0%

0%

Footnotes:

General Notes:

Facilities included in Scope 1 & 2 GHG Scope Boundary.
2Energy emission factor for fuel based on 2018 Climate Registry Default Emission Factors. Metric tons
CO2e; GWP Reference: IPCC Fifth Assessment Report (AR5 – 100 year).
3Scope 3 material categories included in SBTi emission reduction and net zero targets.
4Eindhoven, Netherlands DC closed and moved to Steenoven, Netherlands.
5Northcoast, Singapore new facility opened in 2022.

* Denotes data has been assured.
• Boundary definition for energy and greenhouse gas emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities.
These sites represent our jurisdictional control plus material locations. This scope accounts for 96% of our total 2019 estimated baseline footprint.
• Refrigerant-specific data is not included.
• Some segments may not add up to total due to rounding.
• The Greenhouse Gas Protocol: A Corporate Value Chain (Scope 3) Accounting and Reporting Standard is utilized as the methodology to collect activity data andcalculate Scope 3 emissions.

1

4,850

Message from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix89

Disclosures

Key Performance Indicators

Integrate Sustainability continued
Water (Units: Megaliters)

2019

2020

2021*

2022*

Interactions with water: total water withdrawal (potable + recycled)

225

294

268

256

Non-Hazardous Waste

Water withdrawal (potable)

147

208

195

213

Non-hazardous waste total

Water withdrawal (recycled)

78

86

74

43

Reuse

63%

62%

70%

66%

Recycling

Percentage of total water withdrawal in water stressed regions1

Effluent & Waste by Type and Disposal Method (Units: Metric Tons)

2019

2020

2021

2022*

3,494

3,703

4,421

6,119

0

0

0

0

887

872

937

3,338

Water intensity (kiloliters by rentable square feet for core locations)2

0.10

0.12

0.11

0.10

Composting

149

203

259

267

% water consumption in AMR

97%

97%

97%

92%

Recovery (including energy recovery)

760

729

977

366

% water consumption in EMEA

2%

1%

1%

2%

Incineration

0

0

0

0

% water consumption in APAC

1%

2%

2%

6%

Deep well injection

0

0

0

0

1,698

1,899

2,247

2,224

Landfill

Total Waste (Units: Metric Tons)

2019

2020

2021

2022*

On-site storage

0

0

0

0

Total (hazardous + non-hazardous)

4,934

4,979

5,975

7,503

Other

0

0

0

0

51%

49%

49%

64%
1,440

1,276

1,554

1,383

Global average non-hazardous diversion from landfill

Hazardous Waste

Regional Waste Data AMR (Units: Metric Tons)

2019

2020

2021

2022*

Hazardous waste total

Non-hazardous waste total

2,619

2,869

3,326

4,802

Reuse

902

699

605

594

Recycling

39%

43%

43%

43%

Composting

0

0

0

0

850

707

1,169

943

Hazardous waste total
Madison Site % diversion3

0

0

0

489

332

65

Foster City % diversion

54%

48%

49%

66%

Recovery (including energy recovery)

Hayward % diversion3

32%

22%

22%

70%

Incineration

62

34

41

47

San Diego % diversion3

33%

36%

31%

42%

Deep well injection

0

0

0

0

Landfill

37

20

6

8

On-site storage

0

0

0

0

Other

77

26

4

12

3

Regional Waste Data EMEA (Units: Metric Tons)
Non-hazardous waste total
Hazardous waste total

2019

2020

2021

2022*

451

397

590

569

67

35

55

79

Cambridge, UK % diversion3

100%

100%

100%

100%

Netherlands % diversion3

100%

100%

100%

100%

Regional Waste Data APAC (Units: Metric Tons)

2019

2020

2021

2022*

Non-hazardous waste total

424

437

504

750

Hazardous waste total

471

542

894

710

Singapore % diversion3

100%

100%

100%

100%

Footnotes:
Water stressed regions listed on page 44.
Core locations: San Diego HQ, i3 and Warehouse, Hayward, Foster City, Madison, Netherlands, Cambridge, and Singapore.
3% Diversion calculated using non-hazardous waste and % diverted from landfill.
1

2

0
413

General Notes:* Denotes data has been assured. (Units: Metric Tons CO2e).

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix90

Disclosures

Key Performance Indicators

Nurture Our People
Workforce Data

2019

2020

2021*

2022*

Gender Data

Total employees

7,802

Full-time employees

7,749

7,828

9,191

10,257

Workforce

7,782

9,137

10,195Part-time employees

53

46

54

62

Contingent workers

1,247

1,459

1,647

1,578

Age Group
Employees under 30
Employees 30–50
Employees over 50

1,527

1,363

1,820

1,963

20%

17%

20%

19%

5,090

5,235

5,992

6,748

65%

67%

65%

66%

1,185

1,230

1,379

1,546

15%

16%

15%

15%

Total women
Full-time womenPart-time women1
Temporary women

Total employees

4,973

4,937

5,668

6,342

Full-time employees

4,954

4,918

5,650

6,324

Part-time employees

19

19

18

18

Contingent workers

971

1,182

884

726

APAC
Total employees

1,883

1,871

2,238

2,456

Full-time employees

1,882

1,871

2,238

2,456

Part-time employees

1

0

0

0

Contingent workers

164

146

588

726

EMEA

2020

2021*

2022*

3,334

3,342

4,076

4,596

43%

43%

45%

45%

3,293

3,305

4,036

4,543

43%

43%

45%

45%

41

37

40

53

79%

80%

76%

86%

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Leadership
Women in leadership2
Women in executive leadership3

AMR

2019

571

610

746

898

39%

40%

42%

41%

112

136

174

217

33%

36%

38%

38%

3

3

3

3

33%

30%

33%

33%

AMR

2,071

2,067

2,474

2,813

APAC

847

826

1,037

1,124

EMEA

416

449

565

659

Women on Board of Directors

Total Women by Region

Women in Leadership by Region
AMR

404

421

506

613

APAC

95

104

135

153

EMEA

72

85

105

132

48%

Total employees

946

1,020

1,285

1,459

Full-time employees

913

993

1,249

1,415

Part-time employees

33

27

36

44

Women in revenue-generating roles

41%

36%

48%

Contingent workers

112

131

175

186

Women in revenue-generating roles—management

35%

36%

42%

42%

Women in STEM-related roles (% of total STEM roles)

37%

37%

39%

39%

Functional Group

Footnotes:

General Notes:

Women in IT roles

24%

23%

24%

24%

Percentage of all part-time employees.
2
Leadership: Manager, equivalent, and above.
3
Executive leadership: Director and above.

* Denotes data has been assured.
• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• Some segments may not add up to total due to rounding.

Women in engineering roles

37%

36%

29%

29%

1

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix91

Disclosures

Key Performance Indicators
Learn More: Federal Employer Information EEO-1 Report

Nurture Our People continued
Percentage Female of Each EEOC Category (US)

2019

2020

2021*

2022*

EEOC Minority Summary (US)

2019

2020

2021*

2022*
3,213

White/Caucasian

41%

41%

43%

44%

Total employees identifying in minority race and ethnicity statistics1

2,429

2,422

2,830

Native Hawaiian or Other Pacific Islander

31%

27%

33%

31%

Minority of total employees1

49%

49%

50%

52%

American Indian or Native Alaskan

50%

45%

50%

50%

Non-Minority of total employees1

46%

46%

45%

44%

Asian

44%

44%

45%

46%

Decline to state of total employees

5%

5%

5%

4%

Hispanic or Latino

39%

40%

44%

43%

Black or African American

37%

41%

45%

46%

Representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more communities in workforce

17%

17%

17%

18%

2 or More

45%

46%

51%

51%

Choose not to self disclose

40%

40%

41%

37%

Representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more communities in leadership2

10%

11%

12%

13%

Minority representation in executive leadership3

21%

23%

27%

30%

EEOC Minority by Category (US)

2019

2020

2021*

2022*

2,284

2,253

2,514

2,756

46%

46%

45%

44%

62

56

67

64

1%

1%

1%

1%

10

11

13

15

<1%

<1%

<1%

0%

1,601

1,601

1,863

2,097

32%

33%

33%

34%

447

435

510

588

9%

9%

9%

9%

121

121

130

146

Percentage Male of Each EEOC Category (US)

2019

2020

2021*

2022*

White/Caucasian

59%

59%

57%

56%

Native Hawaiian or Other Pacific Islander

69%

73%

67%

69%

American Indian or Native Alaskan

50%

55%

50%

50%

Asian

56%

56%

55%

54%

Hispanic or Latino

61%

60%

56%

57%

Black or African American

63%

60%

55%

54%

2 or More

55%

54%

49%

49%

Choose not to self disclose

60%

60%

59%

63%

Percentage Gender by Level 2022*

Male 2022*

Female 2022*

Undisclosed 2022*

Support to Entry Professional

51%

49%

1%

Intermediate to Senior Professional

55%

44%

1%

Supervisor to Assoc Director

56%

44%

1%

Director and Senior Director

59%

41%

1%

VP

63%

37%

0%

SVP / C suite

64%

36%

0%

Board of Directors

67%

33%

Footnotes:
1Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those who choose not to specify a race/ethnicity.
2Leadership: Manager, equivalent, and above.
3Executive leadership: Director and above.

General Notes:* Denotes data has been assured.
• Some segments may not add up to total due to rounding.

0%White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose
VeteranDisabled

2%

2%

2%

2%

188

198

248

303

4%

4%

4%

5%

240

238

294

241

5%

5%

5%

4%

143

141

145

157

3%

3%

3%

3%

248

235

230

223

5%

5%

4%

4%

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix92

Disclosures

Key Performance Indicators
Learn More: Federal Employer Information EEO-1 Report

Nurture Our People continued
EEOC Data by Level (US)

2019

2020

2021*

2022*

261

226

264

255

24%

23%

23%

23%

29

31

34

29

3%

3%

3%

3%

3

2

3

4

<1%

<1%

<1%

<1%

Support to Entry Professional
White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

Native Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

2019

2020

2021*

2022*

Manager to Associate Director

489

452

514

485

45%

45%

45%

44%

173

160

185

191

16%

16%

16%

17%

48

38

38

36

4%

4%

3%

3%

57

56

65

83

5%

6%

6%

7%

38

34

35

26

3%

3%

3%

2%

1,403

1,389

1,555

1,721

50%

48%

48%

46%

White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

413

421

452

508

54%

56%

55%

54%

11

9

11

12

1%

1%

1%

1%

2

2

1

0

<1%

<1%

<1%

0%

182

174

214

243

24%

23%

26%

26%

65

61

70

82

9%

8%

8%

9%

17

21

22

26

2%

3%

3%

3%

22

21

23

28

3%

3%

3%

3%

46

48

51

49

6%

6%

6%

5%

Director and Above

Intermediate to Senior Professional
White/Caucasian

EEOC Data by Level (US)

22

16

21

22

1%

1%

1%

1%

4

6

7

9

<1%

<1%

<1%

<1%

895

938

1,078

1,292

32%

33%

33%

34%

199

201

243

300

7%

7%

7%

8%

51

56

63

75

2%

2%

2%

2%

105

115

150

181

4%

4%

5%

5%

143

146

191

147

5%

5%

6%

4%

General Notes: * Denotes data has been assured. • Some segments may not add up to total due to rounding.

White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

207

217

243

272

75%

75%

70%

67%

0

0

1

1

0%

0%

<1%

<1%

1

1

2

2

<1%

<1%

1%

<1%

35

37

57

77

13%

13%

16%

19%

10

13

12

15

4%

4%

3%

4%

5

6

7

9

2%

2%

2%

2%

4

6

10

11

1%

2%

3%

3%

13

10

17

19

5%

3%

5%

5%

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix93

Disclosures

Key Performance Indicators

Nurture Our People continued
New Hire Data

2019

2020

2021*

2022*

Promotion Data

2019

2020

2021*

2022*

458

380

990

860

Total number of employees promoted

1,502

1,568

2,583

2,436

30%

28%

54%

716

586

1,358

44%

Promotion Rate by EEOC (US)

2019

2020

2021*

2022*

1,320

White/Caucasian

22%

20%

34%

14%

11%

23%

20%

26%

Native Hawaiian or Other Pacific Islander

19%

10%

34%

89

88

156

140

24%

8%

7%

11%

9%

American Indian or Native Alaskan

0%

29%

33%

21%

Asian

23%

20%

37%

25%

Hispanic or Latino

19%

19%

34%

17%

Black or African American

14%

15%

33%

25%

2 or More

20%

18%

37%

38%

Choose not to self disclose

21%

22%

35%

21%

Veteran Data (US)

2019

2020

2021*

2022*

Number of US employees, regardless of whether
they have any military connection

4,908

4,866

5,561

6,210

Number of employees as defined by the federal government
as meeting the criteria for protected veteran status

87

87

90

92

143

141

145

157

New Hire by Age Group

1

Employees under 30
Employees 30–50
Employees over 50

New Hire by Gender2
New female employee hires
New male employee hires

566

490

1,185

1,049

17%

15%

29%

23%

684

560

1,262

1,240

15%

12%

25%

22%

New Hire by Region
AMR new employee hires
APAC new employee hires
EMEA new employee hires

707

629

1,479

1,315

14%

13%

26%

21%

376

249

621

621

20%

13%

28%

25%

Number of veteran and active duty employees,
regardless of protected status

180

176

404

384

19%

17%

31%

26%

Number of disabled veteran employees

2

2

3

3

Number of women veteran employees

24

20

26

27

Number of minority veteran employees—minority veterans include,
but are not limited to, people of color, women, LGBTQIA+, and (non)religious minorities

67

68

75

80

Percentage of Veterans (US)

3%

3%

3%

3%

Percentage New Hire per EEOC (US)White/CaucasianNative Hawaiian or Other Pacific Islander

44%

47%

40%

39%

1%

<1%

1%

1%

American Indian or Native Alaskan

<1%

<1%

<1%

<1%

Asian

32%

33%

34%

35%

Other Identities Self Reported (US)

2019

2020

2021*

2022*

Hispanic or Latino

10%

7%

10%

11%

LGBTQ (US)

1%

1%

2%

3%

Black or African American

2%

4%

2%

3%

Disabilities (US)

3%

5%

4%

4%

2 or More

7%

6%

7%

6%

Choose not to self disclose

5%

3%

6%

4%

Footnotes:

General Notes:

Percentage data for new hire by age represents the percentage of the total age group headcount for the reporting year.
2Represents percentage of new hires out of all female employees.

* Denotes data has been assured.
•F or all gender statistics, percentage of women is based on number of employees who identify as male or female, not total number of Illumina employees.
•S ome segments may not add up to total due to rounding.

1Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix
94

Disclosures

Key Performance Indicators

Nurture Our People continued
Employee Turnover Data

2019

2020

2021*

2022*

Total number of employee turnover

856

1,028

1,154

1,246

Rate of employee turnover

11%

14%

14%

13%

Total Turnover

644

714

1,048

1,050

Rate of voluntary turnover

9%

9%

12%

11%

Employees over 50
Voluntary employee turnover under 30
Voluntary employee turnover 30–50
Voluntary employee turnover over 50

AMR
APAC
EMEA

Turnover by Age

Employees 30–50

2019

2020

2021*

2022*

530
11%

666

763

646

13%

14%

11%

223

261

251

405

12%

14%

12%

17%

103

101

140

195

11%

10%

12%

14%

384

442

701

586

8%

9%

13%

10%

188

207

224

315

10%

11%

11%

13%

Total Turnover by Region

Total number of voluntary turnover

Employees under 30

Employee Turnover Data

229

224

246

308

15%

16%

15%

16%

489

638

749

787

10%

12%

13%

138

166

159

12%
151

12%

14%

12%

10%

Voluntary Turnover by Region
AMR
APAC

72

65

123

149

8%

7%

11%

11%

White/Caucasian

8%

10%

13%

9%

Native Hawaiian or Other Pacific Islander

11%

10%

5%

17%

American Indian or Native Alaskan

0%

0%

25%

7%

Asian

7%

8%

13%

11%

195

182

233

279

13%

13%

15%

15%

366

456

686

654

7%

9%

12%

10%

Voluntary Turnover Percentage by EEOC (US)

82

76

129

117

7%

6%

10%

8%

Turnover by Level

EMEA

Voluntary turnover support to entry professional

11%

11%

14%

16%

Hispanic or Latino

8%

7%

14%

10%

Involuntary turnover support to entry professional

3%

5%

1%

2%

Black or African American

11%

12%

16%

12%

Voluntary turnover intermediate to senior professional

8%

8%

12%

9%

2 or More

6%

11%

21%

9%

Involuntary turnover intermediate to senior professional

2%

4%

1%

2%

Choose not to self disclose

6%

8%

13%

13%

Voluntary turnover manager to associate director

6%

8%

11%

10%

Involuntary turnover manager to associate director

4%

4%

2%

1%

Voluntary turnover director and above

6%

13%

17%

9%

Involuntary turnover director and above

4%

4%

3%

2%

General Notes:* Denotes data has been assured.
• Some segments may not add up to total due to rounding.

Introduction

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Recognition

AccessCSR Strategy & Governance
Key Performance Indicators

GRI Index

SASB Index

Community
TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix95

Disclosures

Key Performance Indicators

Nurture Our People continued
Parental Leave

2019

2020

2021

2022

Total number of employees who were entitled toparental leave

4,714

4,900

5,302

5,916

Total number of employees who took parental leave,by gender

Female 116
Male 65

Female 181
Male 121
Blank 1

Female 173
Male 89

Female 236
Male 128
Blank 1

Total number of employees who returned to work in thereporting period after parental leave ended, by gender

Female 116
Male 65

Female 191
Male 138
Blank 1

Female 166
Male 123

Female 226
Male 121
Blank 1

Total number of employees who returned to work afterparental leave ended that were still employed 12 months
after their return to work, by gender

Female 100
Male 54

Female 177
Male 123
Blank 1

Female 150
Male 107

Female 192
Male 102
Blank 1Return to Work:
Female 100%
Male 98%

Return to Work:
Female 100%
Male 98%

Return to Work:
Female 98%
Male 99%

Return to Work:
Female 97%
Male 100%Return to work and retention rates of employees who
took parental leave, by gender

Benefit Plan and Other Retirement
Percentage of salary contributed by employee
or employer

Retention:
Female 86%
Male 83%

Retention:
Female 86%
Male 83%

Retention:
Female 93%
Male 89%

Retention:
Female 85%
Male 84%

2019

2020

2021

2022

US 401(k): Employee elected between 0–80%, Illumina matching contributionof 50% up to the first 6% employee election (3% of eligible salary)

Level of participation in retirement plans, such as
participation in mandatory or voluntary schemes,
regional or country-based schemes, or those withfinancial impact

US 401(k): 97% employee
voluntary participation

Employee Bonus and Stock Program2019

US 401(k): 98% employee
voluntary participation

2020

2021

Employees eligible for annual VCP bonus

All employees

Employees eligible to participate in employee stock
purchase plan

All employees

2022

Footnotes:
 ollowing the birth of a child or placement of a child for adoption or foster care, we provide 100% pay continuity to eligible US-based employees for up toF
six weeks to help ensure peace of mind during this essential time. In some cases, a mother could receive up to 28 weeks of pay continuity depending on
the combination of leaves associated with childbirth. Our parental leave policies in the other locations where we operate either meet or exceed local legal
entitlements.
2
Employee survey participation rates in 2019 are calculated using an average of two surveys per year (Q2 and Q4 of each year). For 2020, the participation
rate is based on an average of three quarterly surveys (Q2–Q4). For 2021, the participation rate is based on an average of four quarterly surveys (Q1-Q4). For
2022, one survey was completed.
1

General Notes:• For all training hour metrics, the values include only regular Illumina employees, not contingent workers.

Performance & Career Development Review

2019

2020

2021

2022

Percentage of employees receiving regularperformance and career development reviews(includes all administrative, production, technical,
middle management, and senior management)

100%

100%

100%

100%

Employee Survey2

2019

2020

2021

2022

Participation rate for employee iPulse survey

89%

79%

80%

86%

Average Compensation Ratio—Women to Men

2019

2020

2021

2022

Across all employee categories

100%

100%

100%

99%

Support to entry professional

102%

102%

101%

100%

Intermediate to senior professional

100%

100%

99%

99%

Supervisor to associate director

98%

99%

100%

99%

Director and above

101%

98%

99%

98%

Annual Compensation Ratio

2019

2020

2021

2022

Refer toProxy Filing

Refer toProxy Filing

Refer toProxy Filing

Refer toProxy Filing

2022

Ratio of annual total compensation for the organization's highest-paid
individual in each region to the median annual total compensation for
all employees

Training

2019

2020

2021

Average hours of training per employee per year

60

64

64

62

Hours of training by gender: Male

60

66

66

63

Hours of training by gender: Female

61

61

63

60

Hours of training by employee category: Individual Contributor

64

68

68

66

Hours of training by employee category: Middle Management

71

76

76

70

Hours of training by employee category: Senior Management

38

38

44

39

Hours of training by employee category: Executive Leadership

22

24

30

26

Hours of training by functional category: Commercial Operations

50

46

52

51

Hours of training by functional category: General Operations

23

25

27

25

Hours of training by functional category: Manufacturing

91

104

98

96

Hours of training by functional category: Research & Development

53

57

62

58

Total number of hours devoted to training on human rights

1,737

5,578

3,333

4,726

Applicable employees certified to Code of Conduct

99%

98%

97%

97%

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction

AccessCSR Strategy & Governance

Recognition

Key Performance Indicators

GRI Index

SASB Index

Community
TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix96

Disclosures

Key Performance Indicators

Nurture Our People continued
Health & Safety

2019

2020

2021

2022

Global recordable injury or illness incident rate (incident per
100 employees)

0.52

0.34

0.54

0.23

Lost time incident rate

0.74

0.18

0.23

Days Away Restricted Time (DART)

0.34

0.18

0.43

Environment, Health & Safety notices of violations

0

0

0

0

Environmental fines

0

0

0

0

Prevention reporting statistics

3,611

3,018

1,452

2,054

Employee Safety

2019

2020

2021

2022

Number of work-related fatalities

0

0

0

0

Rate of work-related fatalities

0

0

0

0

The number of high-consequence work-related injuries andillnesses (excluding fatalities)

49

29

51

23

0.62

0.39

0.16

0.24

The rate of high-consequence work-related injuries andillnesses (excluding fatalities)
The number of recordable work-related injuries and illnesses

2019

2020

2021

2022

Number of work-related fatalities

0

0

0

0

0.12

Rate of work-related fatalities

0

0

0

0

0.17

The number of high-consequence work-related injuries andillnesses (excluding fatalities)

0

3

2

3

The rate of high-consequence work-related injuries and illnesses(excluding fatalities)

0

0.07

0.13

0.18

The number of recordable work-related injuries and illnesses

0

3

2

3

The rate of recordable work-related injuries and illnesses

0

0.07

0.13

0.18

Ergonomics,
Strains,
Contusions,and Sprains

Ergonomics,
Strains,
Contusions,and Sprains

Fracturesand strains

Ergonomics,
strains,
contusions,and sprains

2,741,396

2,798,888

2,986,473

3,296,423

49

29

51

23

0.62

0.39

0.16

0.24

The main types of work-related injury and illness

Ergonomics,
strains,
contusions,and sprains

Ergonomics,
strains,
contusions,and sprains

Ergonomics
and strains

Ergonomics,
strains,
contusions,and sprains

The number of hours worked

15,647,395

15,344,520

15,946,780

19,462,592

The rate of recordable work-related injuries and illnesses

General Notes:• Recordable injury & illness rate calculated using total hours worked from employees + contingent workers.
• Contingent workers: workers who are not employees but whose work and/or workplace is controlled by the organization.
• Lost time incident rate calculated using total hours worked from employees—contingent workers.
• High-consequence work-related injuries are defined as all recordable injuries.
• Rates have been calculated based on 200,000 hours worked.
• DART: Days Away, Restricted, Or Transferred.
• Ergonomic injuries include repetitive stress injuries.

Safety Workers Who Are Not Employees but Whose Work
and/or Workplace is Controlled by the Organization

The main types of work-related injury and illness
The number of hours worked

Environmental, Health & Safety Training
Total hours of EHS training
Average hours per employee

26,75830,05443,06645,022

3.7

3.4

4.1

4

Message from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix97

Disclosures

Key Performance Indicators

Operate Responsibly
Governance

2019

2020

2021

2022

Non-compliance with environmental laws and regulations; Significant
fines and non-monetary sanctions for non-compliance withenvironmental laws and/or regulations

0

0

0

0

# of FDA recalls

0

0

0

0

Number of substantiated complaints concerning breaches of customer
privacy and losses of customer data

0

0

0

0

Number of public legal cases regarding corruption brought against theorganization or its employees during the reporting period

0

0

0

0

Antitrust Cases

20

See notes

See notes

Nature and total number of critical concerns communicated to highest
governance body regarding CSR topics

0

0

0

0

Total employees covered by collective bargaining agreements

0

0

0

0

See note 3

See note 3

See note 3

See note 32020 Privacy

2021 Privacy

2022 Privacy

Transparency

Transparency

Transparency

ReportReportReport

N/A

N/A

Yes

Incidents of discrimination and corrective actions taken
Transparency Reporting Law Enforcement & National Security Requests
Security personnel are trained in organization’s policies or procedures
concerning aspects of human rights that are relevant to operations.

N/A

N/A

The organization is unaware of any operations in which there is asignificant risk for incidents of child labor.

N/A

N/A

N/A

Confirmed

The organization is unaware in which there is a significant risk forincidents of forced or compulsory labor.

N/A

N/A

N/A

Confirmed

1. O
 n January 11, 2021, Complete Genomics, Inc., BGI Americas Corp., and MGI Americas, Inc. (collectively BGI) filed a complaint in the
US District Court for the Northern District of California alleging that Illumina violated federal antitrust and state unfair competition laws,
based on a patent infringement suit Illumina filed against BGI in the same court. Illumina denies the allegations, which are without merit.
In July 2022, Illumina and BGI settled all US litigation, and the case was dismissed.
2. On March 30, 2021, the United States Federal Trade Commission (FTC) filed an administrative complaint alleging that Illumina’s
acquisition of GRAIL, Inc. violates federal antitrust law. Following a full trial on the merits, in September 2022 the FTC’s Chief
Administrative Law Judge’s (ALJ) rejected the FTC’s complaint and found in favor of Illumina. On April 3, 2023, the FTC overturned the
ALJ’s rejection of the FTC complaint, and the FTC issued an opinion and order requiring Illumina to divest GRAIL. Illumina has filed apetition for expedited review with a US Court of Appeals, and the FTC’s order to unwind the acquisition will be automatically stayedpending appeal.
3. D uring the past thirteen years, neither the EEOC nor any court or administrative agency has issued a finding against Illumina in aclaim involving discrimination. There was one claim of discrimination filed during the reporting period. Illumina denies the allegation.
The matters that were pending during the last reporting period have been resolved. We do not tolerate acts of discrimination, andpromote an open culture to report concerns (including anonymously). Illumina takes all reports of misconduct seriously and has a strict
non-retaliation policy. If a report is substantiated, the company would respond as it deems appropriate or necessary, consistent withthe law, and will act swiftly to correct the problem and deter future occurrences. Depending on the circumstances, this may include
training and/or disciplinary action up to, and including, termination. Individuals may also be subject to civil or criminal prosecution forviolating the law.

ESG Governance Topics

Position

Corporate Social Responsibility / ESG
Environment, Health & Safety, Supply Chain,
Facilities, Operations

Level from CEO

Level from Board

SVP, Chief Public Affairs Officer

1

2

SVP, Chief of Global Operations

1

2

People, Employment, Diversity, Equity, and Inclusion

SVP, Chief People Officer

12Compliance, Ethics, Legal

SVP, General Counsel

1

2

Product

SVP, Chief Technology Officer

1

2

Cybersecurity

SVP, Chief Information Officer

1

2

Finance, Investor Relations, Internal Audit

SVP, Chief Financial Officer

1

2

Board of Directors (BoD)2022

BoD level oversight for CSR and ESG (including themes of sustainability and climate action; diversity, equity, andinclusion; human rights; cybersecurity; data privacy; and ethical and responsible business practices)

Yes

Clawback provision

Yes

Commitment to gender diversity on BoDYes

BoD composition by gender (% female)33%

BoD composition by racial/ethnic minority representation

33%

Number of Directors
Number of Indepenent Directors
Average Board Tenure

98
6.6 years

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

AccessCSR Strategy & Governance
Key Performance Indicators

GRI Index

SASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix98

Disclosures

Key Performance Indicators

Operate Responsibly continued
Supply Chain

2019

2020

2021

2022

Quantity of product shipped

3,118,142 units

3,297,561 units

3,862,839 units

3,752,857 units

Spend with direct suppliers$440 million$396 million$585 million$694 million

Supplier Code of Conduct in place

Yes

Countries: AE, AM, AR, AT, AU, BE, BG, BR, CA,
CH, CN, CO, CZ, DE, DK, ES, FI, FR, GB, GH,
HK, ID, IE, IL, IN, IT, JP, KR, LK, LT, LU, LV, MY,
NL, NO, NZ, PL, RO, RU, SA, SE, SG, SI, TH,
TR, TW, US, ZA

Countries: US, DE, CA, GB, SG, CH, JP, PL, FR,
AU, ZA, BE, NZ, IT, CN, NL, DK, NO, MY, IN,
ES, IS, SE, IL, PT, AR, HK, AM, KR, UA, IE, BN,
ID, BD, EC, AT, FI, TW, MO, LU, VN, TR, LK, AE,
MX, CZ, RU, RO, TH, BR, LV, CR, PH, BY, UY,
SA, HU, SI, GR, PK, CY, BG, LT, RS, BO, PY, NG,
KY, GT, PA, SV, KE, EE, PE, CL, CO

Geographic location of suppliersCountries: AE, AM, AR, AT, AU, BE, BS, CA, CH, CL,
CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, ID,
IE, IL, IN, IS, IT, JP, KR, LT, LU, MO, MX, MY, NL, NO,
NZ, PA, PE, PH, PL, PT, RO, RU, SE, SG, SI, TH, TR,
TW, UA, US, UY, VN, ZA

A description of the organization’s supply chain

Illumina’s global supply chain consists of suppliers, sub-contractors, channel partners, manufacturing sites, distribution centers, and customers

Types of suppliers

Direct, indirect, strategic, finished medical device, custom spec, off the shelf, and services

Number of suppliers engaged by organization
Estimated monetary value of payments made to suppliers
Number of active diverse suppliers (US)Countries: AE, AM, AR, AU, AU, BE, BR, BY,
CA, CH, CL, CN, CR, CZ, DE, DK, EE, ES, FI, FR,
GB, GH, HK, ID, IE, IL, IND, IS, IT, JP, KR, LT,
LU, MY, MX, NL, NO, NZ, PE, PH, PL, PT, RU,
SA, SE, SG, TH, TR, TW, UA, US,
UY, ZA

Yes

3,891

3,704

3,798

3,323

>$1 billion$935 million>$1 billion>$1 billion

>400

334

517

919

$190 million$152 million$209 million$269 million

Percentage of total PO spend with diverse suppliers (US)

19%

16%

17%

18%

Percentage of strategic suppliers that have committed to minimizing theirenvironmental footprint

N/A

75%

84%

89

% of total PO Spend with total diverse suppliers (Global)

N/A

N/A

N/A

13%

Diverse supplier spend

Message from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

Key Performance Indicators

Community

AccessCSR Strategy & Governance
GRI Index

SASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix99

Disclosures

Key Performance Indicators

Operate Responsibly continued
Political Contributions
Total monetary value of financial and in-kind political contributions
made directly and indirectly by the organization by country andrecipient/beneficiary

2019

2020

2021

2022

$50,000

$0

$0

$0

U.S. Trade Association Memberships
World 50, Inc.

$393,766$240,850

US Chamber of Commerce$150,000$160,000

Coalition for Access to Prenatal Screening (CAPS)$100,000$100,000

Access to Comprehensive Genomic Profiling Coalition$80,813$75,000

Procurement Leaders$57,000$58,710

Biocom$56,300$57,500

American Clinical Laboratory Association (ACLA)$50,000$50,000

Coalition for 21st Century Medicine$50,000$50,000

Personalized Medicine Coalition (PMC)$32,000$32,000

California Chamber of Commerce$25,000$0

San Diego Economic Development Corp. (SDEDC)$25,000$25,000

EMEA Trade Association Memberships

National Association of Manufacturers (NAM)$24,500$24,500

All.Can (ASBL)$32,204

AdvaMed$19,950$19,950

Trade Association & Memberships

2021

2022

Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of these organizations may
utilize a portion of membership fees for non-deductible state and federal lobbying and political expenditures. As part of our transparency practices, we
disclose trade memberships for which we contribute at least $5,000 annually in fees.

Trade and Industry Group Memberships Above $5,000 Threshold Annually
GlobalWorld Economic Forum$330,000$35,000$330,000EUCOPE$27,892$19,322

American Cancer Society—Cancer Action Network (ACS-CAN)*$10,000$0

US Qatar Business Council$10,000$10,000

San Diego Regional Chamber of Commerce (SD Chamber)$7,650$7,650

US Saudi Arabian Business Council$10,000$10,000

Industrial Environmental Association (IEA)$6,000$6,000

Healthcare Business Women's Association (HBA)$5,000$5,000US UAE Business Council$10,000$10,000

International Quality Network for Pathology (IQN Path)$5,000$0
For the trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under Section 162(e)(1)(B) of the Internal Revenue Code, such as payments to organizations designated as 501(c)(4) and 501(c)(6) associated with state and federal lobbying
efforts annually.

APJ and Greater China Trade Association Memberships
US India Business Council$27,500$20,000

Pathology Technology Australia$7,309$20,868

US Chamber — China$25,000$25,000

US-China Business Council (USCBC)$15,000$15,000

US-ASEAN$11,686$14,500

AmCham China$7,413$4,026

Organization†

Total Annual Membership Fee% Membership Fees Used forState or Federal Lobbying

Dollars Applied to Stateor Federal Lobbying From
Membership Fees

2021

2022

2021

2022

2021

2022

US Chamber of Commerce$161,625$160,00025%

35%$40,406$56,000

Coalition for Access toPrenatal Screening (CAPS)$100,000$100,00025%$0$25,000$0

American Clinical Laboratory
Association (ACLA)$50,000$50,000

33%

30%$16,500$29,500

Biocom$56,300$57,500

10%

10%$5,630$5,750

Coalition for 21stCentury Medicine$50,000$50,000†

30%†$15,000

Updated data to reflect most current information.

45%$22,500

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

Community

AccessSASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix
100

Disclosures

GRI Index
GRI Description

GRI Section

Illumina ReportGRI Description

GRI Section

Illumina Report

GRI 3: Material Topics

GRI 1:Foundation 2021
Statement of use

Illumina has reported in accordance with the GRI Standards forthe period 1st January 2022 to 31st December 2022

Process to determine material topics

GRI 3-1

Page: 12-17

Pages: 11-16

List of material topics

GRI 3-2

Page: 14,17

Pages: 13,16

GRI 1 reference

GRI 1

Management of material topics

GRI 3-3

Page: 12-17, 72 Pages: 11-16, 69

GRI 1: Foundation
GRI 1: Foundation
2021
2021

GRI 2: General Disclosures 2021

GRI 201: Economic Performance 2016

Organizational details

GRI 2-1

Pages: 8, 9, 89 Pages: 8, 9, 86

Management of material topics

GRI 3-3

Page: 12-17

Pages: 11-16

Entities included in the organization, sustainability reporting

GRI 2-2

Page: 86

Page: 83

Direct economic value generated and distributed

GRI 201-1

Page: Proxy

Proxy

Reporting period, frequency and contact pointGRI 2-3

Page: 86

Page: 83

GRI 201-2

Page: 44-45,
Pages:
51,41-42,
53-54,48,
10750-51, 104

Restatements of information

GRI 2-4

Page: 86

Page: 83

Financial implications and other risks and opportunities due toclimate change

External assurance

GRI 2-5

Page: 108

Page: 105

Defined benefit plan obligations and other retirement plans

GRI 201-3

Page: 67, 98

Pages: 64, 95

Activities, value chain and other business relationships

GRI 2-6

Pages: 8-9, 13-15,
12-14, 21-21,
22-22,26-30,
27-31, 48-49,
51-52, 80-83,
77-80,
89, 10186, 98

Management approach: Market Presence

GRI 3-3

Page: 12-17

Pages: 11-16

Ratios of standard entry level wage by gender compared to local
minimum wage

GRI 202-1

Page: 62, 98

Pages: 59, 95

Proportion of senior management hired from the local community

GRI 202-2

Page: 63

GRI 202: Market Presence 2016

Employees

GRI 2-7

Pages: 57-68,
Pages:
93-9954-65, 90-96

Workers who are not employees

GRI 2-8

Page: 93

Governance structure and composition

GRI 2-9

Pages: 12-17, Pages:
72, 10011-16, 69, 97

Nomination and selection of the highest governance body

GRI 2-10

Pages: 16, 72, 100
Pages: 15, 69, 97

Management approach: Indirect Economic Impacts

GRI 3-3

Page: 12-17,
Pages:
19, 36,
11-16,
57, 71
18, 33, 54, 68

Chair of the highest governance body

GRI 2-11

Pages: 16, 72, 100
Pages: 15, 69, 97

Infrastructure investments and services supported

GRI 203-1

Page:
Pages:
19,18,
22-23,
21-22,25,
24,26,
25,30,
29,37,
34,
40-41,
37-38,
54-55
51-52

Role of the highest governance body in overseeing the managementof impacts

GRI 2-12

Pages: 16, 72, 100
Pages: 15, 69, 97

Significant indirect economic impacts

GRI 203-2

Page:
Pages:
19,18,
22-23,
21-22,25,
24,26,
25,30,
29,37,
34,
40-41,
37-38,
54-55
51-52

Delegation of responsibility for managing impacts

GRI 2-13

Page: 16

Role of the highest governance body in sustainability reporting

GRI 2-14

Pages: 16, 72, 100
Pages: 15, 69, 97

Management approach: Procurement PracticeGRI 3-3

Page: 12-17,Pages:
71, 80-81
11-16, 68, 77-78

Conflicts of interest

GRI 2-15

Page: 72-76

Pages: 69-73

Proportion of spending on local suppliers

GRI 204-1

Page: 82, 101

Communication of critical concerns

GRI 2-16

Page: 100

Page: 97

Collective knowledge of the highest governance body

GRI 2-17

Page: 16, 72-76,
Pages:
100 15, 69-73, 97

Management approach: Anti-corruption

GRI 3-3

Page: 12-17, 71 Pages: 11-16, 68

Evaluation of the performance of the highest governance body

GRI 2-18

Page: 72

Operations assessed for risks related to corruption

GRI 205-1

Page: 71-76,Pages:
80-81,68-73,
100 77-78, 97

Remuneration policies

GRI 2-19

Page: 72, ProxyPage: 69, Proxy

Communication and training about anti-corruption policies
and procedures

GRI 205-2

Page: 73-74,
Pages:
80, 81,70-71,
100 77, 78, 97

Process to determine remuneration

GRI 2-20

Page: 72

Page: 69

Confirmed incidents of corruption and actions taken

GRI 205-3

Page: 100

Pages: 97

Annual total compensation ratio

GRI 2-21

Page: 72

Page: 69

GRI 206: Anti-competitive Behavior 2016

Statement on sustainable development strategy

GRI 2-22

Page: 2-3, 12-16Page: 2-3, 11-15

Management approach: Anti-competitive

GRI 3-3

Page: 12-17

Pages: 11-16

Policy commitments

GRI 2-23

Page:
Pages:13-17,
12-16,
44,
41,52,
49,62,
59,68,
65,72,
69,73,
70,74,
71,77,
74,78,
75,
79-84
76-81

Legal actions for anti-competitive behavior, anti-trust, andmonopoly practices

GRI 206-1

Page: 100

Pages: 97

Embedding policy commitments

GRI 2-24

Page:
Pages:13-17,
12-16,
44,
41,52,
49,62,
59,68,
65,72,
69,73,
70,74,
71,77,
74,78,
75,
79-84
76-81

Processes to remediate negative impacts

GRI 2-25

Page: 71-84, Page:
100, 106
68-81, 97, 103

Mechanisms for seeking advice and raising concerns

GRI 2-26

Page: 71-84, 106
Page: 68-81, 103

Compliance with laws and regulations

GRI 2-27

Page: 68, 71-84,
Page:
100
65, 69-83, 97

Membership associations

GRI 2-28

Page: 17,Page:
22, 29,16,31,
21,41,
28,44,
30,86
38, 41, 83

Approach to stakeholder engagement

GRI 2-29

Page: 17

Page: 16

Collective bargaining agreements

GRI 2-30

Page: 100

Page: 97

Page: 90

Page: 15

Page: 69

Page: 60

GRI 203: Indirect Economic Impacts

GRI 204: Procurement Practices
Pages: 79, 98

GRI 205: Anti-corruptionMessage from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

Community

AccessSASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix
101

Disclosures

GRI Index continued
GRI Description

GRI Section

Illumina ReportGRI Description

GRI Section

Illumina Report

GRI 306: Waste

GRI 301: Materials
Management approach: Materials

GRI 3-3

Pages: 12-17, Pages:
43, 49 11-16, 40, 46

Management approach: Waste

GRI 3-3

Pages: 12-17, Pages:
43, 48 11-16, 40, 45

Reclaimed products and their packaging materials

GRI 301-3

Page: 49

Waste generation and significant waste-related impacts

GRI 306-1

Pages: 43, 48-50,
Pages:92
40, 45-47, 89

Management of significant waste-related impacts

GRI 306-2

Pages: 43, 48-50
Pages: 40, 45-47

Page: 46

GRI 302: Energy
Management approach: Energy

GRI 3-3

Pages: 12-17,
Pages:
43-45,
11-16,
46 40-42, 43

Waste generated

GRI 306-3

Pages: 48, 92

Pages: 45, 89

Energy consumption within the organization

GRI 302-1

Pages:Pages:
43-44,40-41,
46, 51,43,
90,48,
91,87,
10788, 104

Waste diverted from disposal

GRI 306-4

Pages: 48, 92

Pages: 45, 89

Energy consumption outside of the organization

GRI 302-2

Pages:Pages:
43-44,40-41,
49, 51,43,
52,48,
91,10787, 88, 104

Waste directed to disposal

GRI 306-5

Pages: 48, 92

Pages: 45, 89

GRI 308: Supplier Environmental Assessment

Energy intensity

GRI 302-3

Pages: 46, 91

Reduction of energy consumption

GRI 302-4

Pages:
Pages:
43-44,
40-41,
46, 50-51,
43, 47-48,
55, 90-91
52, 87-88

Pages: 43, 88

Management approach: Supplier Environmental Assessment

GRI 3-3

Pages:
11-16,
Pages: 12-17,
43, 52,71 40, 49, 68

Reductions in energy requirements of products and services

GRI 302-5

Pages: 49-50,
Pages:
53-5546-47, 50-52

New suppliers that were screened using environmental criteria

GRI 308-1

Pages: 81, 89

Pages: 78, 86

GRI 303: Water and Effluents

Negative environmental impacts in the supply chain and actions taken

GRI 308-2

Pages: 50-51

Pages: 47-48

Management approach: Water and EffluentsGRI 3-3

Pages: 12-17, Pages:
43, 47 11-16, 40, 44

GRI 401: Employment

Interactions with water as a shared resource

GRI 303-1

Pages: 47, 92

Pages: 44, 89

Management approach: Employment

GRI 3-3

Pages: 12-17, 57Pages: 11-16, 54

Management of water discharge-related impacts

GRI 303-2

Pages: 47, 92

Pages: 44, 89

New employee hires and employee turnover

GRI 401-1

Page: 96

Water withdrawal

GRI 303-3

Pages: 47, 92

Pages: 44, 89

GRI 401-2

Pages: 67, 98

Water discharge

GRI 303-4

Pages: 47, 92

Pages: 44, 89

Benefits provided to full-time employees that are not provided totemporary or part-time employees

Water consumption

GRI 303-5

Pages: 47, 92

Pages: 44, 89

Parental leave

GRI 401-3

Page: 98

GRI 3-3

Page: 12-17, 43-45
Page: 11-16, 40-42

Management approach: Health and Safety

GRI 3-3

Pages: 12-17, 57Pages: 11-16, 54

Occupational health and safety management system

GRI 403-1

Pages: 68, 99

Pages: 65, 96

Hazard identification, risk assessment, and incident investigation

GRI 403-2

Pages: 68, 99

Pages: 65, 96

Occupational health services

GRI 403-3

64-65, 96
Pages: 67-68, Pages:
99

Worker participation, consultation, and communication on
occupational health and safety

GRI 403-4

Page: 68

Worker training on occupational health and safety

GRI 403-5

Pages: 68, 99

Pages: 65, 96

Promotion of worker health

GRI 403-6

Pages: 67-68

Pages: 64-65

Prevention and mitigation of occupational health and safety impacts
directly linked by business relationships

GRI 403-7

Pages: 68- 69 Pages: 65-66

Workers covered by an occupational health and safety
management system

GRI 403-8

Pages: 68, 99

Pages: 65, 96

Work-related injuries

GRI 403-9

Pages: 68, 99

Pages: 65, 96

Work-related ill health

GRI 403-10

Pages: 68, 99

Pages: 65, 96

GRI 304: Biodiversity
Management approach: Biodiversity
Operational sites owned, leased, managed in, or adjacent to,protected areas and areas of high biodiversity value outside
protected areas

GRI 304-1

Significant impacts of activities, products and services on biodiversity

GRI 304-2

Page: 45

Habitats protected or restored

GRI 304-3

Page: 45-46, Page:
53-5542-43, 50-52

IUCN Red List species and national conservation list species with
habitats in areas affected by operations

GRI 304-4

Page: 45, 46

Management approach: Emissions

GRI 3-3

Page: 12-17, 43-45
Page: 11-16, 40-42

Direct (Scope 1) GHG emissions

GRI 305-1

Page: 43-44,
Page:46, 90-91
40-41, 43, 87-88

Energy indirect (Scope 2) GHG emissions

GRI 305-2

Page: 43-44,
Page:46, 90-91
40-41, 43, 87-88

Other indirect (Scope 3) GHG emissions

GRI 305-3

Page: 43-44,Page:
51, 91 40-41, 48, 88

GHG emissions intensity

GRI 305-4

Page: 46, 91

Reduction of GHG emissions

GRI 305-5

Page: Page:
43-44,40-41,
46, 50-51,
43, 47-48,
55, 90-91
52, 87-88

Emissions of ozone-depleting substances (ODS)

GRI 305-6

Page: 91

Page: 88

Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant
air emissions

GRI 305-7

Page: 91

Page: 88

Page: 45-46

Page: 42-43
Page: 42

Page: 42-43

GRI 305: Emissions

Page: 43, 88

Page: 93
Pages: 64, 95
Page: 95

GRI 403: Occupational Health and Safety

Page: 65

Message from the CEO
CY’22 CSR Report

About This Report

Introduction

2030 Targets

Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

Community

AccessSASB Index

TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix102

Disclosures

GRI Index continued
GRI Description

GRI Section

Illumina ReportGRI Description

GRI Section

Illumina Report

GRI 414: Supplier Social Assessment

GRI 404: Training and Education
Management approach: Training and Education

GRI 3-3

Pages: 12-17, 57Pages: 11-16, 54

Management approach: Supplier Social Assessment

GRI 3-3

Pages: 12-17,
Pages:
52, 71,11-16,
80 49, 68, 77

Average hours of training per year per employee

GRI 404-1

Pages: 6, 63, 98
Pages: 6, 60, 95

New suppliers that were screened using social criteria

GRI 414-1

Page: 101

Management approach: Public Policy

GRI 3-3

Pages: 12-17, 71,
Pages:
84 11-16, 68, 81

Political contributions

GRI 415-1

Pages: 84, 102

Management approach: Marketing and Labeling

GRI 3-3

Pages: 12-17, 71,
Pages:
76 11-16, 68, 73

Requirements for product and service information and labeling

GRI 417-1

Pages: 76, 106 Pages: 73, 103

Incidents of non-compliance concerning product and service
information and labeling

GRI 417-2

Page: 106

Page: 103

Incidents of non-compliance concerning marketing communications

GRI 417-3

Page: 106

Page: 103

Management approach: Customer Privacy

GRI 3-3

Pages: 12-17,
Pages:
71, 75,
11-16,
78-79
68, 72, 75-76

Substantiated complaints concerning breaches of customer privacy
and losses of customer data

GRI 418-1

Page: 100Programs for upgrading employee skills and transition
assistance programs

GRI 404-2

Pages: 61, 63-66
Pages: 58, 60-63

Percentage of employees receiving regular performance and careerdevelopment reviews

GRI 404-3

Pages: 64, 98

Pages: 61, 95

Page: 98

GRI 415: Public Policy
Pages: 81, 99

GRI 417: Marketing and Labeling

GRI 405: Diversity and Equal Opportunity
Management approach: Diversity and Equal Opportunity

GRI 3-3

Pages: 12-17, Pages:
57, 60 11-16, 54, 57

Diversity of governance bodies and employees

GRI 405-1

Pages: 57-59,
Pages:
93-97,
54-56,
72,69,
100
90-94, 97

Ratio of basic salary and remuneration of women to men

GRI 405-2

Pages: 98

Management approach:GRI 3-3

Pages: 12-17, Pages:
57, 62 11-16, 54, 59

Incidents of discrimination and corrective actions taken

GRI 406-2

Pages: 100

Page: 95

GRI 406: Non-discrimination
Page: 97

GRI 407: Freedom of Association and Collective Bargaining
Management approach: Freedom of Association andCollective Bargaining

GRI 3-3

Pages: 12-17, 57Pages: 11-16, 54

Operations and suppliers in which the right to freedom of associationand collective bargaining may be at risk

GRI 407-1

Page: 106Management approach: Child LaborGRI 3-3

Pages: 12-17, Pages:
71, 77 11-16, 68, 74

Operations and suppliers at significant risk for incidents of child labor

GRI 408-1

Page: 77

Management approach: Forced and Compulsory LaborGRI 3-3

Pages: 12-17,
Pages:
71,11-16,
77, 80,68,81,
74,10077, 78, 97

Operations and suppliers at significant risk for incidents of forced orcompulsory labor

GRI 409-1

Pages: 77, 81, 100
Pages: 74, 78, 97

Management approach: Security PracticeGRI 3-3

Pages: 12-17

Pages: 11-16

Security personnel trained in human rights policies or procedures

GRI 410-1

Page: 100

Page: 97

Management approach: Local Communities

GRI 3-3

Pages: 12-17, 36
Pages: 11-16, 33

Operations with local community engagement, impact assessments,
and development programs

GRI 412-1

Pages: 36-41

Page: 103

GRI 408: Child Labor
Page: 74

GRI 409: Forced or Compulsory LaborGRI 410: Security Practices

GRI 413: Local Communities

Pages: 33-38

GRI 418: Customer Privacy

Page: 97

Introduction

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

PeopleSustainability
Assurance Statements

Operate Responsibly

Appendix103

Disclosures

SASB Index
The Sustainability Accounting Standards Board (SASB) is an independent standards-setting organization that promotes disclosure of material sustainability information to meet investor needs. Illumina is classified officially in
the Health Care Sector and Medical Equipment & Supply Industry. We have also chosen to add relevant sections from the industry categories of Biotechnology & Pharmaceuticals as well as Software & IT Services.

Dimension

General Issue Category

Disclosure Topic

Code

Accounting MetricResponse

PRIMARY SICS SECTOR: HEALTHCARE | Primary SICS Industry: Medical Equipment & Supplies
Access & Affordability

SocialCapitalProduct Quality & Safety

Selling Practices &Product Labeling

Product Design &Lifecycle Management
Business
Model &
Innovation
Supply Chain Management

Leadership &GovernanceBusiness Ethics

Other

Activity Metrics

Affordability and Pricing

HC-MS-240a.1

Ratio of weighted average rate of net price increases to the annual increase in the U.S. Consumer Price Index

76

Affordability and Pricing

HC-MS-240a.2

Description of how price information for each product is disclosed to customers or to their agents76

Product Safety

HC-MS-250a.1

Number of FDA recalls issued, total units recalled0

Product Safety

HC-MS-250a.2

List of products listed in the FDA’s MedWatch safety alerts for human medical products database0

Product Safety

HC-MS-250a.3

Number of fatalities related to products as reported in FDA Manufacturer and User Facility Device Experience

0

Product Safety

HC-MS-250a.4

Number of FDA enforcement actions taken in response to violations of Current Good Manufacturing Practices (cGMP)

0

Ethical Marketing

HC-MS-270a.1

Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

0

Ethical Marketing

HC-MS-270a.2

Description of code of ethics governing promotion of off-label use of products

Product Design &Lifecycle Management

HC-MS-410a.1

Discussion of process to assess and manage environmental and human health considerations associated with chemicals
in products, and meet demand for sustainable products

43, 49Product Design &Lifecycle Management

HC-MS-410a.2

Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipmentand (2) supplies

48, 92

Supply Chain Management

HC-MS-430a.1

Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing
and product quality

71, 83

Supply Chain Management

HC-MS-430a.2

Description of efforts to maintain traceability within the distribution chain

Supply Chain Management

HC-MS-430a.3

Description of the management of risks associated with the use of critical materials

Business Ethics

HC-MS-510a.1

Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption

Business Ethics

HC-MS-510a.2

Description of code of ethics governing interactions with health care professionals

Activity Metrics

HC-MS-000.A

Number of units sold by product category

Employee Recruitment,
Development & Retention

HC-BP-330a.1

Discussion of talent recruitment and retention efforts for scientists and R&D personnel

Employee Recruitment,
Development & Retention

HC-BP-330a.2

1) Voluntary and 2) involuntary turnover rate for a) executive/senior managers b) mid-level managers c) professionals d) all others

TC-SI-330a.3

Percentage of gender and racial/ethnic group representation for 1) management 2) technical staff 3) all other employees

76, Illumina Code of Conduct83
80-81, 83
073-74, Interactions with HCP Policy
101

Supplemental SICS Industry: Biotech & Pharma
Human
Capital

Employee Engagement,
Diversity & Inclusion

63-66
97

Supplemental SICS Industry: Software & IT Services
Human Capital

Employee Engagement,
Diversity & Inclusion

Recruiting & Managing
a Global, Diverse &Skilled Workforce

58-59, 94-95

Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix

Disclosures

Task Force on Climate-related Financial Disclosures (TCFD) Index
TCFD voluntary climate-related disclosure recommendations have been used to guide our reporting. We believe addressing climate change is key to achieving a sustainable, just, and resilient future for all. We are committed totransparency and will continue to share progress in our annual CSR Report and CDP submissions.
TCFD Disclosure Element

Topic

Description

Illumina CSR Report Section/CDP Questionnaire Response

Governance

Board oversight

Describe Board’s oversight of climate-related risks and opportunities.

CSR Report 15-16, 41, 69, 7
CDP C1.1, C1.1a., C1.1b

Management role

Describe management’s role in assessing and managing risks and opportunities.

CSR Report 15-16, 41, 71
CDP C1.2, C1.2a

Climate risk and opportunities timeline

Describe the climate-related risks and opportunities the organization has identified
over the short, medium, and long term.

CSR Report 40-52
CDP C2.1a, C2.1b, C2.2, C2.2a, C2.3, C2.3b, C2.4, C2.4b

Climate risk and opportunities impact

Describe the impact of climate-related risks and opportunities on the organization’s
businesses, strategy, and financial planning.

CSR Report 11, 16, 40-52, 71
CDP 2.2, C2.2a, C2.3b, C2.4b, C3.1, C3.2, C3.2a, C3.2b, C3.3, C3.4, C3.5

Targets to manage climate risk
and opportunities

Describe the resilience of the organization’s strategy, taking into considerationdifferent climate-related scenarios, including a 2°C or lower scenario.

CSR Report 40-52, 69, 71, 77-78, 87-89
CDP 2.2, C3.1, C3.2, C3.2a, C3.2b, C3.3

Process to identify climate risk

Describe the organization’s processes for identifying and assessing climate-related risks.

CSR Report 12-14, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Process to manage climate risk

Describe the organization’s processes for managing climate-related risks.

CSR Report 12-14, 33-34, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Process to integrate climate risk inoverall risk management

Describe how processes for identifying, assessing, and managing climate-related risks
are integrated into the organization’s overall risk management.

CSR Report 12-16, 33-34, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Climate-related metrics

Disclose the metrics used by the organization to assess climate-related risks andopportunities in line with its strategy and risk management process.

CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

GHG emission data

Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions,and the related risks.

CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

Targets to manage climate risk andperformance to targets

Describe the targets used by the organization to manage climate-related risks andopportunities and performance against targets.

CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

Describe organization’s governance around climate-relatedrisks and opportunities.

Strategy
Describe the actual and potential impacts of climatechange risks and opportunities on the organization’s
business, strategy, and financial planning where suchinformation is material.

Risk Management
Disclose how the organization identifies, assesses, andmanages climate-related risks.

Metrics & Targets
Disclose the metrics and targets used to assess andmanage relevant climate-related risks and opportunities
where such information is material.

104Message from the CEO
CY’22 CSR Report

About This Report

2030 Targets

Introduction
Recognition

CSR Strategy & Governance
Key Performance Indicators

GRI Index

AccessSASB Index

Community
TCFD Index

Sustainability
Assurance Statements

PeopleOperate Responsibly

Appendix
105

Disclosures

Independent Limited Assurance Report to Illumina, Inc.
Our Responsibilities
Our responsibility is to express a limited assurance conclusion in accordance with ISAE 3000 and ISAE 3410 whether the Reported Information
has been properly prepared in accordance with the Reporting Criteria and to provide this in a report to Illumina.
Work Performed
Independent Limited Assurance Report to Illumina, Inc.

Background and Introduction
Backgroundand introduction
ISOS
Group,
Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance engagement in
ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance
accordancewith ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s 2022 Corporate Social Responsibility Report
engagement in accordance with ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s Corporate(“2022
CSR Report”)
the period
beginning
January2021,
and andendingSocial Responsibility
Report CYfor’22 (“CY22
CSR Report”)
for the period
beginning1,January
1, 2022,
ending December
December 31, 31, 2021 (“FY21”).
2022 (“CY22”).

We have performed our limited assurance engagement in accordance with the International Standard on Assurance Engagements 3000 (ISAE
We have performed
our limited
assurance
accordance ofwithHistoricalthe International
Standard Information,
on Assurance3000),
Assuranceotherthan engagement
Audits orinReviews
Financial
as well as the International Standard on Assurance Engagements
Engagements 3000 (ISAE 3000), Assurance other than Audits or Reviews of Historical Financial Information, as well as the3410(ISAE 3410) Assurance Engagements on Greenhouse Gas Statements, issued by the International Auditing and Assurance Standards Board.
International Standard on Assurance Engagements 3410 (ISAE 3410) Assurance Engagements on Greenhouse Gas Statements,
The
allAssurance
entitiesand allfacilities
under covered
the operational
Illumina.
issuedengagementby the Internationalcovered
Auditing andStandards
Board.
The engagement
all entities andcontrol
all facilitiesof
under
the operational control of Illumina.

Our review was limited to the data reported in the following Key Performance Indicator Summary sections (pages 88–95) and marked with the
Our review*was
limited to the datareported in the comprising
Key Performanceof:
Indicator Summary sections (pages 90 – 95) marked withsymbol(“Reported
Information”),
the symbol “*” (“Reported Information”), comprising of the following metrics and their respective segmentations:Integrating
Environmental Sustainability:
Integrate
Sustainability:
Nurturing Our People:
Energy Consumption
Workforce Data
EnergyConsumption
Gender Data
• Energy Consumption
Regional, Country, and Facility Emissions
EEOC Minority Summary (US)•Emission
EnergyConsumption by Activity andNew
RegionIntensity
Hire Data
1 and 2 Emissions•ScopeRenewable
Electricity Consumption Promotion Data
Scope 3 Emission
Veteran Data (US)
•WaterEmissions
Employee Turnover Data
Other Identities Self-Reported (US)• Regional Emissions

Nurturing Our People:• Workforce Data
• Gender Data
• Percentage Female and Male of Each EEOC Category (US)• EEOC Minority Summary (US)• EEOC Minority by Category (US)• Greenhouse Gas Breakdown• EEOC Data by Level (US)We have not performed any procedures with respect to other information included in the Illumina CY22 CSR Report and,• Country-Specific• New Hire Data
therefore,
no conclusion on Scope
the Report1 as a whole is expressed.
• Country• Percentage New Hire per EEOC (US)
ReportingcriteriaSpecific Scope 2 Market-BasedThe
reporting criteria are thestandards identified in the CY22 CSR Report – Reporting Overview (“Reporting
Criteria”). Data
• Facility-Specific
Emissions• Promotion•
Emission
Intensity
Ratios•Promotion
Rate by EEOC (US)
Inherent uncertainty
Thenature of3non-financial
information and the methods used to determine non-financial information,•allow
for different,• Scope
Emissions
VeteranDatabut(US)
acceptable measurement techniques which can result in materially different measurements and can impact accuracy and• Scope 3 Emissions: % of Total Scope 3 Emissions• Employee Turnover Data
comparability. Furthermore, the nature and methods used to determine such information, as well as the measurement criteria• Waterandthe precision thereof, may change over time.
The
Reported Information
ReportingCriteriahas been measured applying the Reporting Criteria which has been adopted solely for the purpose ofproviding this non-financial information. As such the Reported Information may not be suitable for another purpose. WhereThe reporting criteria are the standards identified in the 2022 CSR Report – Reporting Overview (“Reporting Criteria”).
significant assumptions or deductions are utilized, they are disclosed. Where direct data was unavailable, the company usedindustry standards as estimates. The assurance provided therefore does not guarantee or provide certainty over theInherent Uncertainty
completeness of reported data.

The nature of non-financial information and the methods used to determine non-financial information, allow for different, but acceptable• The procedures we performed were based on our professional judgment. Our work included, but was not limited to:• Assessing the appropriateness of the Reporting Criteria for the Reported Information• Carrying out interviews with key personnel to understand the systems and controls in place during the reporting period• Assessing the systems, processes, and controls to collate, aggregate, validate,and report the data
• Reviewing a selection of factors and formulae used and calculations performed over the Reported Information• Considering the appropriateness of the Reported Information provided by Illumina and any third-party data management system service providers• Testing a sample of records against underlying records, which were either individually material or where there was potential for errors to accumulate tomaterial amounts included:• Testing of energy consumption, scope 1 and 2 emissions, and water consumption at company facilities across 12 countries in scope of the reporting• Testing of scope 3 emissions across the 11 calculated scope 3 emissions categories• Testing of human capital data aggregated across three regions and 28 countries where company operates, including against EEO-1 reporting for US
operations• Reperforming a selection of calculations of the Reported Information

The relative effectiveness and significance of specific control procedures at Illumina and their effect on assessment of control risk at a facility
level are dependent on their interaction with the controls and other factors present at individual facilities. We have not performed any proceduresto evaluate the effectiveness of controls at individual facilities. We have not conducted any work outside the agreed scope and therefore restrict
our conclusion to the above-mentioned subject matter.
Restriction of Use
This assurance report is made solely to Illumina in accordance with the terms of our engagement, which include agreed arrangements fordisclosure. Our work has been undertaken so that we might state to Illumina those matters we have been engaged to state in this limited
assurance report and for no other purpose. Our limited assurance report should not be regarded as suitable to be used or relied on by any party
wishing to acquire rights against us other than Illumina for any purpose or in any context. Any party other than Illumina who obtains access to ourlimited assurance report or a copy thereof and chooses to rely on our limited assurance report (or any part thereof) will do so at its own risk. To
the fullest extent permitted by law, we accept or assume no responsibility and deny any liability to any party other than Illumina for our work, forthis independent limited assurance report, or for the conclusions we have reached.
Conclusion
Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believethat the Reported Information, noted in the Key Performance Indicator Summary (pages 88–95) for FY21 ended on December 31, 2021, has notbeen prepared, in all material respects, in accordance with Illumina’s Reporting Criteria.

Illumina’s
responsibilities
measurement
techniques, which can result in materially different measurements and can impact accuracy and comparability. Furthermore, the
The Company’s management are responsible for:nature and methods used to determine such information, as well as the measurement criteria and the precision thereof, may change over time.
•

The accuracy and completeness of the information contained in the Reported Information.

The• Reported
been measured
applying
thetoReportingwhich
has been adopted solely for the purpose of providing thisThe design, Information
implementation, hasand maintenanceof internal controls
relevant
the preparationCriteria,of the reporttoprovide reasonableassurance
that
the report
free from material
misstatement,
whetherfraud or error.
non-financial
information.
As
suchtheisReported
Informationmay
not duebetosuitable
for another purpose. Where significant assumptions or deductions
Ensuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting Criteria”) andare•utilized,
they are disclosed. Where direct data was unavailable, the company used industry standards as estimates. The assurance provided
for the content and statements contained therein.
therefore does not guarantee or provide certainty over the completeness of reported data.
Illumina’s Responsibilities
The Company’s management are responsible for:

Brian Noveck
CSAP Practitioner for, and on behalf of, ISOS Group, Inc.
31 March 2022

• The accuracy and completeness of the information contained in the Reported Information.
• The design, implementation, and maintenance of internal controls relevant to the preparation of the report to provide reasonable assurance that thereport is free from material misstatement, whether due to fraud or error.
• Ensuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting Criteria”) and for the content and statements
contained therein.

We have not performed any procedures with respect to other information included in the Illumina 2022 Corporate Responsibility Report and, therefore, no conclusion on the Report as a whole is expressed.

Learn More: CY’ 22 Assurance LetterPhoto Credit: Juraj Krivda
Illumina Employee | Distribution Planner
Singapore | Woodlands Facility

Disclosures
This release may contain forward-looking statements that involve risks
and uncertainties. Among the important factors to which our business issubject that could cause actual results to differ materially from those inany forward-looking statements are: (i) changes in the rate of growth in
the markets we serve; (ii) the volume, timing and mix of customer orders
among our products and services; (iii) our ability to adjust our operating
expenses to align with our revenue expectations; (iv) our ability to
manufacture robust instrumentation and consumables; (v) the success of
products and services competitive with our own; (vi) challenges inherent
in developing, manufacturing, and launching new products and services,
including expanding or modifying manufacturing operations and relianceon third-party suppliers for critical components; (vii) the impact of recently
launched or pre-announced products and services on existing products
and services; (viii) our ability to further develop and commercialize our
instruments, consumables, and products, including Galleri®, the cancer
screening test developed by GRAIL, to deploy new products, services, andapplications, and to expand the markets for our technology platforms; (ix)the risks and costs associated with the integration of GRAIL’s business if
we are ultimately able to integrate GRAIL, and our ability to successfully
realize the related anticipated synergies; (x) the risk of incurring fines
associated with the consummation of our acquisition of GRAIL and thepossibility that we may be required to divest all or a portion of the assets
or equity interests of GRAIL on terms that could be materially worse than
the terms on which we acquired GRAIL; (xi) the risk that disruptions fromthe consummation of our recent acquisition of GRAIL or any associatedlegal or regulatory proceedings or obligations will harm our business,
including current plans and operations; (xii) our ability to obtain approvalby third-party payors to reimburse patients for our products; (xiii) our
ability to obtain regulatory clearance for our products from government
agencies; (xiv) our ability to successfully partner with other companies
and organizations to develop new products, expand markets, and grow ourbusiness; (xv) the application of generally accepted accounting principles,
which are highly complex and involve many subjective assumptions,estimates, and judgments and (xvi) legislative, regulatory and economic
developments, together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent filings on
Forms 10-K and 10-Q, or in information disclosed in public conference calls,
the date and time of which are released beforehand. We undertake no
obligation, and do not intend, to update these forward-looking statements,
to review or confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.

Stay up to date on recent news, stories,
and more by connecting with us.

+1.800.809.4566 toll-free (US) +1.858.202.4566 tel
www.illumina.com©2023 Illumina, Inc.
All rights reserved. All other names, logos, and other trademarks are theproperty of their respective owners.